Modern Pharmaceuticals - March 2012

Als

o av

aila

ble

in S

ri La

nka,

Mal

aysi

a, S

inga

pore

, Tha

iland

, Tai

wan

, Chi

na &

Hon

g K

ong

Editorial

5March 2012 I Modern Pharmaceuticals

W

Budget 2012: Reforms on fast track?

EditorialAdvisory Board

Ajit SinghChairman, ACG Worldwide

& Head, ISPE

Dr Abraham PataniPast President, IDMA & CMD, Inga Laboratories

Dr Gopakumar G NairIPR Consultant & Advisor

Dilip G ShahChairman, IGPA &

Secretary General, IPA

Daara PatelSecretary General, IDMA

ith this year’s Union Budget around the corner, and more importantly, its

potential upshots for the near future, it will be pertinent to do a dipstick

on some of the recent developments – both global and national – that can

significantly impact the pharmaceutical sector. Also, it will be prudent to

take strategic steps for the road ahead.

First, let’s touch upon the global scenario. The macroeconomic deceleration of

recent times is primarily owing to sovereign debt issue in certain geographies rather

than industry/company-specific financial meltdown as was experienced in 2008-09.

This means there are good as well as bad news. The good part is that the extent of

the meltdown pulling down businesses may not be as globally widespread as it was the

last time; hence, there will still be some emerging growth markets, albeit with a slow

pace of progress. However, the bad news is that no one is yet clear

about how long this business dampener will draw out, and what

if this malignancy spreads to other geographies.

As far as India is concerned, the government’s policy paralysis

seems to drag on with some of the crucial misses being the deferral

in implementation of Goods and Services Tax (GST) and Direct

Tax Code (DTC). However, recently things have picked up

some pace as the government has reportedly been able to

obtain in-principle approval from all state governments

on implementation of GST.

From a sectoral perspective, it is expected on the part

of the government to undo preferably all the benefits

that were withdrawn in the last year’s Budget, in order

to ensure a level playing field in the market atleast for

a certain period. Besides, the Finance Ministry will do

well in keeping overall policies stable and by making

growth-centric tax amendments. All these should be in line with

the Pharma Vision 2020 for India wherein it is envisioned to

become one of the most attractive destinations for end-to-end

drug discovery and innovation.

That said, the forthcoming Union Budget will be an opportune

moment for the policy-makers to make a decisive beginning,

perhaps the second phase of economic liberalisation, and leave a

long-lasting impression on the economy as well as the industry.

Read on and stay tuned for more on this in the next edition.

Manas R [email protected]

Contents


5 Editorial

10 News, Views & Analysis

22 Technology & Innovation

26 Technology Transfer

69 Projects

71 Event List

75 Book Review

76 Products

86 List of Products

87 List of Advertisers

Special Focus

REGULAR SECTIONS

Details on page no.30

In Conversation With Manish Doshi President, Indian Drugs Manufacturers Association and MD, Amoli Organics Pvt Ltd

28

Tax incentives ...............................................................32R&D incentives ............................................................34Interface - Dr Rajesh Jain ...............................................36Roundtable ....................................................................38

Budget Wishlist ..............................31

Insight & Outlook

SMEs growth story ........................................................44Role of bankers and government .....................................46SMEs in South India .....................................................48SMEs in spotlight ..........................................................50Interface - Jagdeep Singh ................................................52Roundtable ....................................................................54Th yroid cancer therapeutics market .................................55Case Study - Fighting counterfeits ..................................56

Pharma SMEs ...................... 43

Facility Visit IKA India Pvt Ltd Capitalising on the India advantage

40

Automation Trends Process Analytical Technology

Th e less explored opportunities ...................................58

Energy Management Carbon neutrality

Inching closer to the green dream ..............................60

Policies & Regulations Policies governing drug counterfeiting

Rigorous implementation: Th e way forward ...............64

Strategy What’s new in pharma marketing?

Selective pampering ...................................................66Dr Rajan T D, Pharma Consultant & Practising Dermatologist

Tips & Tricks Patent prosecution tips

Factors to be considered before fi ling a patent ............68Kamakhya Srivastava, Head-Group on Research Publication and Programme, LEX ORBIS IP Practice

Note: ` stands for Indian rupee, $ stands for US dollar and £ stands for UK pound, unless mentioned otherwise

Highlights of Next Edition

Special Focus: IT in pharma

Insight & Outlook : Cleanrooms

Event Report BioAsia 2012

Targetting the vaccine and drug discovery market ......73


FOUNDER & EDITOR, NETWORK 18Raghav Bahl

PRESIDENT & EDITORIAL DIRECTOR, TV 18Senthil Chengalvarayan

SENIOR EDITORManas R Bastia

FEATURES EDITORArshia Khan

EDITORIAL TEAMChandreyee Bhaumik, Parita Dholakia, Michael Anthony, Abha Mishra,

Paskaline Sebastian, Titash Roy Choudhury (Delhi), Jasleen Kaur Batra (Bengaluru)

ASSISTANT ART DIRECTORVaruna Naik

DESIGNSachin Bhogate

CHIEF PHOTOGRAPHERMexy Xavier

PHOTOGRAPHYNeha Mithbawkar, Joshua NavalkarBUSINESS CONTROLLERS

Pukha Dhawan, Lovey Fernandes, Akshata Rane, Deepak Bhatia, Shwetha ME, Jayashree N, Sugandha Kulkarni, Shefali Mahant

PRINTINGEXECUTIVE VICE PRESIDENT

Ananth R IyerASSISTANT GENERAL MANAGER - PPC

Shekhar KhotPRODUCTION TEAM

Dnyaneshwar Goythale, Surekha Karmarkar, Ravikumar Potdar, Ravi Salian, Sanjay ShelarOVERSEAS CONTACT

Ringier Trade Media Ltd CHINA1001 Tower 3, Donghai Plaza, 1486 Nanjing Road, West, Shanghai 200040, China

Tel: +86-21 6289 – 5533 Ext. 368, Fax: +86-21 6247 – 4855 (Craig Shibinsky) Email: [email protected] Trade Media Ltd HONG KONG

9/F, Cheong Sun Tower, 118 Wing Lok Street, Sheung Wan, Hong Kong Tel: +852 2369 – 8788 Ext. 21, Fax: +852 2869 – 5919

(Octavia Au-Yeung) Email: [email protected] Trade Media Ltd TAIWAN

Room 3, Fl. 12, No. 303, Chung Ming S. Rd., Taichung, TaiwanTel: +886-4 2329 – 7318 Ext. 16, Fax: +886-4 2310 – 7167

(Sydney La) Email: [email protected] Trade Media Ltd GERMANY, AUSTRIA, SWITZERLAND

Tel: +41-44 734 0472, Fax: +41 44 734 0680Email: [email protected]

USA Tel: (513) 527-8800 Fax: (513) 527-8801

Email: [email protected]

USA Alfredo Domador, 6505 Blue Lagoon Drive, Suite 430 Miami, FL. 33126, USA

Tel: (305) 448-6875, Fax: (305) 448-9942

GROUP CEO, NETWORK 18B Sai Kumar

CEO-PUBLISHING, INFOMEDIA 18Sandeep Khosla

EVP-HUMAN RESOURCESSanjeev Kumar Singh

ASSOCIATE VICE PRESIDENTSudhanva Jategaonkar

ADVERTISING SALESShashin Bhagat (Ahmedabad)[email protected] B (Bengaluru)[email protected] Hara Subramaniam (Chennai)[email protected] N (Coimbatore)[email protected] Kalyan Chakravarthy (Hyderabad)[email protected] Gokhale (Indore)[email protected] Bidawat (Jaipur)[email protected] Abhik Ghosal (Kolkata)[email protected] Dhingra (Ludhiana)[email protected] Yadav (New Delhi)[email protected] Dass (Pune)[email protected] Pathak (Vadodara)[email protected]

MARKETING TEAMGanesh Mahale, Prachi Mutha, Varsha Nawathe, Abhay Borkar

NEWSSTAND AND SUBSCRIPTIONSDISTRIBUTION HEADSunil NairDEPUTY GENERAL MANAGERManoj PalsaySENIOR MANAGER - SUBSCRIPTIONSSheetal Kotawdekar

CO-ORDINATORSRahul Mankar, Anant Shirke, Sarita Quadros,Chaitali Parkar, Kamlesh Mathkar, Vaibhav Ghavale

SERVICESSUBSCRIPTION SERVICES For subscription queries, write [email protected] or call +91 22 30034631-34 or toll free 1800 200 1021PERMISSIONS For subscription to copy or reuse material from Modern Pharmaceuticals,Write to [email protected]

• Monthly Issue Price: ` 100 • Annual Subscription: ` 799

Views and opinions expressed in this magazine are not necessarily those of Infomedia 18 Ltd, its publisher and/or editors. We at Infomedia 18 Ltd do our best to verify the information published but do not take any responsibility for the absolute accuracy of the information. Infomedia 18 Ltd does not accept the responsibility for any investment or other decision taken by readers on the basis of information provided herein. Infomedia 18 Ltd does not take responsibility for returning unsolicited material sent without due postal stamps for return postage. No part of this magazine can be reproduced without the prior written permission of the publisher. Infomedia 18 Ltd reserves the right to use the information published herein in any manner whatsoever.

Infomedia 18 Ltd is the publishing arm of Network 18.

Printed by Mohan Gajria and published by Lakshmi Narasimhan on behalf of Infomedia 18 Ltd.Senior Editor: Manas R BastiaPrinted at Infomedia 18 Ltd, Plot no.3, Sector 7, off Sion-Panvel Road, Nerul, Navi Mumbai 400 706, and published at Infomedia 18 Ltd, ‘A’ Wing, Ruby House, J K Sawant Marg, Dadar (W), Mumbai - 400 028. Modern Pharmaceuticals is registered with the Registrar of Newspapers of India under No. MAHENG / 2008 / 27125. Infomedia 18 Ltd does not take any responsibility for loss or damage incurred or suffered by any subscriber of this magazine as a result of his/her accepting any invitation/offer published in this edition.

News,Views & Analysis

10 Modern Pharmaceuticals I March 2012

To emphasise the need for

selecting the right people

to man the innovation-

led pharma industry, the

Indian Institute of Health

Management Research

(IIHMR) conducted a

National Conclave on ‘Human

Resource Management in

Pharmaceutical Industry:

Challenges and Future

Directions’. Th e Organization

of Pharmaceutical Producers

of India (OPPI) lent active

support for this step taken

to analyse the importance

of Human Resources in a

start-up, budding or a well-

established pharma company.

S D Gupta, Director, IIHMR,

said, “By introducing courses

such as hospital and pharma

management, IIHMR strives

to resolve the issue of talent

crunch by producing well-

qualifi ed students capable of

making a real diff erence in the

fi eld of pharma, by preparing

them for the corporate roles,”

added Gupta.

Th e goals for human resources

are talent development,

employee retention and

confl ict management.

Mumbai-based Aanjaneya Lifecare Ltd, a leading manufacturer of bulk drugs, recently announced that the company has acquired Apex Drugs and Intermediates Ltd (ADIL), an integrated API and pharma intermediates manufacturing company based in Hyderabad. Th e acquisition was valued at ` 250 crore; with debt of ` 185 crore and equity dilution of ` 65 crore.

Aanjaneya Lifecare Ltd has acquired ADIL’s assets, businesses, clients, licensees, employees and has merged both the companies’ operations, becoming a fully integrated formulation company. Th e company will also leverage the strong relations of ADIL developed in Asia, Europe, UAE & Latin America for exports. Th e acquisition also gives Aanjaneya an entry in Hyderabad market.

Post acquisition, Aanjaneya Lifecare will have approximate sales of ` 700 crore with EBITDA of ` 130 crore and total long term debt in books of about ` 220 crore against net worth of ` 365 crore.

Aanjaneya Lifecare acquires Apex Drugs and IntermediatesIIHMR and OPPI organise conclave on human resource strategy in pharma sector

Indoco Remedies has recently announced a

change of leadership with the appointment

of Aditi Kare Panandikar as the Managing

Director (MD) and Sundeep Bambolkar as

joint MD of the company. Aditi took over

the coveted position from Suresh Kare who

has stepped down from the post. However

he informed that he would be retaining the

position as the Chairman of the company.

Suresh Kare has been handling the

responsibilities of the company for the last

fi ve decades and has been instrumental in

positioning the company as one of the top

pharma companies in the country today.

He informed that seeing Indoco’s growth

over the years and the swift changes that

is taking place in the industry it was high

time to hand over the responsibilities to

a younger and competitive generation.

Commenting on the changing roles,

Aditi Kare Panandikar said, “I am very

happy with this decision as it had been my

dream to take up this position, wherein I

can contribute my share in the company’s

growth and development.” She added, “Th e

company has plans to expand its business

and explore new business ventures focussed

on propelling and pushing the company

towards its growth trajectory. Bambolkar,

Joint MD, Indoco Remedies, informed

that the company aims to grow the

domestic formulations business accounting

for about 65 per cent of the revenues and

aggressively to expand its presence. “Our

vision is to grow the international business

by more than 50 per cent year on year

in the next four to fi ve years. For this the

peripheral support systems such as trained

technical manpower and manufacturing

facilities approved by the most advanced

regulatory agencies are already in place,”

informed Bambolkar.

Suresh Kare steps down as the MD, Indoco

Ranbaxy opens manufacturing facility in MoroccoRanbaxy Morocco has announced the

opening of its new manufacturing facility at

Casablanca, Morocco, paving the way for a

direct business presence in North Africa.

With the successful audit of the facility

by the Moroccan Health Authorities,

Ranbaxy Morocco is now authorised to

commence manufacturing of its products at

its Casablanca facility. Th e achievement of

this milestone positions Ranbaxy to access a

$1 billion pharmaceutical market in Morocco.

Mahendra Bhardwaj, Head, Africa,

Ranbaxy, said, “Ranbaxy has a signifi cant

presence in Africa with its own ground

operations in key markets. Morocco is

one of the important markets and this

manufacturing facility further reinforces

our commitment to the people of Morocco

and the African continent.” In addition to

servicing the Morocco market, Ranbaxy

also plans to extend the supply from this

manufacturing unit to other African

countries, in the coming years. Ranbaxy

has a strong presence in Africa.

With the addition of Morocco, the

Company now has three manufacturing

facilities in Africa; the other two located

in Nigeria and South Africa respectively.

With fi ve subsidiaries, fi ve representative

offi ces and a strong workforce of nearly

a 1,000 people, Ranbaxy’s distribution

network caters to 44 of the 54 countries in

this continent.

L-R: Bambolkar, Kare and Panandikar



Sudhir Valia, Director, Sun

Pharma, was awarded the

Best Performing CFO in the

pharma/healthcare sector in

an award ceremony hosted

by CNBC-TV18. Th e event

witnessed many prominent

names from the industry

such as Y M Deosthalee-

Chairman & Managing

Director-L&T Finance

Holdings; Keki Mistry,

Vice Chairman & Chief

Executive Offi cer, HDFC Ltd

among others.

Speaking on the occasion,

Udayan Mukherjee, Managing

Editor, CNBC-TV18 said,

“It takes intuition, leadership

and vision to guide India’s

corporates through the current

turbulent phase.”

Sun Pharma honoured at CNBC-TV18 CFO Awards 2012

Dr K Anji Reddy honoured with Lifetime Achievement awardDr K Anji Reddy, Founder and Chairman, Dr Reddy’s

Laboratories Ltd, has been honoured with the Lifetime

Achievement in Health Award in the Asian Voice

Political & Public Life Awards for 2012 at London

for his lifetime commitment to medical research and

improving the lives of others. Voted by a committee

of Members of Parliament in Britain, this award is

an annual event hosted by Th e Asian Voice, a weekly.

Th e award ceremony was hosted at the Members’

Dining Room in the House of Commons, London.

Satish Reddy, MD & COO, Dr Reddy’s

Laboratories Ltd, who collected the award on

behalf of his father, also shared a note of thanks by

Dr Reddy on the occasion. On receiving the award,

Dr Reddy said, “I thank Keith Vaz, Member of

Parliament, Britain and host and the organisers

of this event for the recognition. I consider myself

to be fortunate that my country had given me the

opportunity to participate in the advent of aff ordable

medicine in India.”

Sourabh Mishra joins Sorento Healthcare as Business Strategy Consultant

IPC holds symposium for global quality standards for biologics and SCMIndia’s role as a leading fi gure in

global pharma manufacturing brought

together regulators, manufacturers and

other stakeholders in global public

health at the 11t IPC-USP Science

& Standards Symposium on February

22–23 in Mumbai. Hosted by the Indian

Pharmacopoeia Commission (IPC) and

the US Pharmacopoeial Convention

(USP), the nearly 400 attendees explored

ways in which science and quality standards

can help ensure good quality medicines in

India and throughout the world.

Symposium co-sponsors were the

Association of Biotechnology Led

Enterprises, the Bulk Drug Manufacturers

Association, the Indian Drug

Manufacturers Association, the Indian

Pharmaceutical Association, and the

Organization of Pharmaceutical Producers

of India. “When it comes to medicines,

good quality begins with good science,” said

Dr Praveen Tyle, Executive Vice President

and Chief Science Offi cer, USP. Topics of

discussion included therapeutic proteins,

another important class of drugs for India’s

growing biologics manufacturing sector;

strategic perspectives on biotechnology

products in developing countries; the

role of bioassays in biosimilars; and the

replacement of animal studies for potency

testing of human vaccines.

Dr V Srini Srinivasan, Executive

Vice President, International Sites and

Standards, USP and moderator for

the symposium’s opening session, said,

“Increasingly sophisticated discoveries

in science are leading to dramatic

insights into health and disease, and the

pharma community plays a key role

in translating those advances into

medical solutions that will help patients

worldwide. At the same time, those in

pharma and regulatory circles in India—

and throughout the world—must look to

increasingly robust measures to protect

the quality of pharma products sourced

and developed through a complex

network of global partnerships and

supply chains.”

-Chandreyee Bhaumik

Sorento Healthcare

Communications Pvt Ltd has

brought Sourabh Mishra on

board as Business Strategy

Consultant. Mishra meanwhile

also continues as Chief

Strategy Offi cer at Saatchi &

Saatchi, India. Talking about

his new association, Mishra

said, “Th e opportunity to

enhance the value of Sorento’s

communication solutions in healthcare by better

integrating the strategic planning process is exciting.

Sorento has already moved much beyond conventional

mass media-based communications. In that context, the

task is also to see how we can better integrate the various

off erings it has, in order to provide more holistic solutions

to clients.”

Dr Reddy’s Laboratories has launched ziprasidone hydrochloride

capsules, a bioequivalent generic version of Geodon® in the US market

following the approval by the US FDA of Dr Reddy’s ANDA for

ziprasidone hydrochloride capsules. Th e Geodon® brand had US sales

of approximately $ 1.34 billion for the most recent twelve months

ending December 2011 according to IMS Health.

Dr Reddy

Mishra

Dr Reddy’s launches of ziprasidone hydrochloride capsules



Espicom Business Intelligence, has recently

announced the launch of Espicom Interactive.

For many companies the cost of business

information represents a signifi cant investment. Its

practical use in defi ning commercial strategy and

in understanding market environment is critical

to success. However, the value of such investments

is really benefi cial if the service empowers staff to

greater effi ciency in its use. Espicom Interactive is a

new service that combines Espicom’s class-leading

information services with an online delivery that is

feature rich in user benefi ts saving time and money.

Eric Wigart, Chairman, Espicom, stated, “We

understand that customers need critical information

for their practical day-to-day planning and

development work. Such information is to be used,

not just read. For 30 years Espicom has been at the

forefront of meeting the informational needs of

clients, and with the launch of Espicom Interactive

we can save them a whole lot of time and eff ort in

using it.”

TAKE Solutions Ltd has announced

the availability of PharmaReadyTM

5.0, a web-based regulatory

compliance solution suite for Life

Science organisations to ensure faster

approvals for their new products.

Th e latest version introduces new

document management features,

and delivers technology framework

upgrades to enhance scalability,

response time, and ease-of-use.

PharmaReady 5.0 supports

submissions to Swissmedic (in

addition to US FDA, Heath

Canada and EMEA). It comes

with an improved dashboard for

easier navigation and management

of documents from a centralised

location, provides more visibility and

control of e-document/e-submission

processes, and introduces new

functionalities including drag and

drop for quicker document uploads.

In addition, PharmaReady 5.0

includes an enhanced, highly scalable

technology framework allowing

the suite to run seamlessly on any

Microsoft platform.

Ram Yeleswarapu, President

and CEO, TAKE Solutions, said,

“TAKE Solutions has understood

the pulse of the life sciences market

and has worked persistently towards

achieving the goal of better value to

our customers. Having used both our

IT expertise, as well as our domain

knowledge, we are proud to release

the upgraded version PharmaReady

5.0.” He added, “PharmaReady is a

stable and growing product line that

has been consistently delivering value

to our customers across the globe.”

TAKE Solutions announces global release of PharmaReady 5.0

Prayas, the social welfare initiative of

Sanofi , launched its fi rst disease awareness

programme that focusses at empowering

doctors in rural India with the latest

developments and updates in medicine. It

engages medical experts from tier I cities

to help develop a course curriculum that

is aligned to the needs of rural doctors.

Further, these experts train a select pool

of ‘mentors’ who are expert doctors from

tier II towns who in turn then coach

rural doctors or the ‘mentees’. Dr Viraj

Rajadhyaksha, Associate Director, Medical

Aff airs and Prayas initiatives, Sanofi ,

said, “We aim at bridging the diagnosis-

treatment gap through a structured

continuing education programme for

rural doctors across India.

Th e ‘Prayas’ workshops are diff erent

from other Continuing Medical Education

(CME) programmes as the focus is not on

a molecule or brand.” He added, till now,

over 6,300 Prayas workshops have been

conducted in 14 states of India. A total

of 564 mentors guide 11,500 mentees

who are registered on the programme.

Th e programme aims to cover 1,00,000

mentees by 2015. Prayas would continue

in its mission of facilitating healthcare

to rural interiors through expansion of

mentees covered in next fi ve years.

-Chandreyee Bhaumik

Prayas launches disease awareness programmes

Espicom launches Espicom Interactive

Brenntag, the global leader in chemical

distribution, inaugurated its new head

offi ce in Mumbai. Th is new offi ce represents

Brenntag’s continued commitment to

invest in India and to ensure the company

has ample room for its planned growth

over the next few years.

At the inauguration of the new offi ce, Steve

Holland, CEO, Brenntag Group, said, “India

is a key market in Brenntag’s global strategy.

By expanding our local presence in major

cities such as Mumbai, we are supporting

our strategy of being the leading chemical

distributor in both specialty and industrial

chemicals. We already have a strong foothold

in India and we expect to take advantage

of the high growth potential in the growth

market.”

Th e new head offi ce has a space area

covering 15,000 sq ft and will have room for

more than 100 employees. At present, there

are 44 employees based at the new offi ce, In

addition, Brenntag has offi ces and distribution

facilities in Baddi, Bengaluru, Chennai,

Gurgaon, Haridwar and Hyderabad.

-Chandreyee Bhaumik

Brenntag opens new head offi ce in India

Brenntag Indian team welcomes Holland

Dr Rajadhyaksha



Life Technologies Corporation, a

California-based company announced the

launch of its new benchtop Ion ProtonTM

sequencer powered by Ion TorrentTM

semiconductor in India that is enabled to

whole genome sequencing of both human

and plants in a day at the fraction of its

current equipment and running costs. Th is

device will be able to read an entire human

gene at ` 50,000 in about two hours, as

opposed to the earlier devices that required

days to process an entire gene and at a cost

of $5,000 to 10,000. In India, this is the

only technology present that is capable of

providing this service at such a low price

and fast speed.

“Th e Indian market is a fast growing

market and much of the worldwide

pharmaceutical industry is positioning

itself here in India,” says Gregory

T Lucier, Chairman & CEO, Life

Technologies. Th e company has spent

almost $1 billion in the development of

this semiconductor sequencer. Lucier

pointed out, “Cancer is the disease of

the DNA but mostly up until now when

somebody contracts that disease we

are not reading the DNA to fi gure out

what the right therapy is. With this

technology we will be able to read

somebody’s DNA who is suff ering from

cancer and develop a holistic approach for

his/her treatment. Th is technology will

also be useful to stop spread of infectious

disease outbreaks.”

-Titash Roy Choudhury

Sanofi Pasteur, a vaccines division

of Sanofi , has announced the

formalisation of a marketing and

distribution pact with Pune’s

Emcure Pharmaceuticals for the

anti-rabies vaccine - Verorab.

Th e product will be imported

and supplied by Sanofi Pasteur

India Pvt Ltd and then it marketed

and distributed by Emcure via its

subsidiary, Zuventus Healthcare,

according to Sanofi .

Both the fi rms will be

jointly working to increase the

awareness on rabies vaccination

at the general practitioner and

physician level, which is the fi rst

point of contact for patients and

caregivers in regard to rabies

exposure risk.

Zuventus Healthcare will be

promoting Verorab across India to

more than 60,000 physicians and

general practitioners. Verorab is a

purifi ed vero cell rabies vaccine

and it has been unveiled by

Sanofi Pasteur in 1987 in India.

Since then, over 25-million doses

of Verorab have been disbursed in

India.

Sanofi Pasteur partners with Emcure Pharmaceuticals for anti-rabies vaccine ‘Verorab’

Life Technologies introduces machine capable of genome sequencing within 2 hour and at less than ` 50,000

Panacea Biotec, India’s leading vaccine

manufacturer launched POLPROTEC

(an enhanced potency, inactivated poliovirus

vaccine) in Nigeria in collaboration with Emzor

Pharma, Nigeria.

On this occasion, Panacea Biotec and Emzor

announced a joint Planet Polio-Free Mission

statement ‘To contribute towards achieving the goal of global polio

eradication and to ensure that no child will ever again be paralysed by

WPV or Vaccine-Derived Polio Virus (VDPV) by providing complete

portfolio of Oral Polio Vaccines (OPV) & Inactivated Polio Vaccine

(IPV) & IPV-based combination vaccine at an aff ordable price’.

Dr Rajesh Jain, Joint MD, Panacea Biotec, said, “Panacea Biotec

foresaw the need of IPV during the end game of polio eradication

programme long back and launched the vaccine in India in 2008. We

are now taking this vaccine to other polio endemic countries and are

pleased to launch POLPROTEC® in Nigeria.

In 2011 till week 39, 30 cases of Acute Flaccid Paralysis (AFP) has

been reported in Nigeria.

Panacea Biotec launches polio virus vaccine in Nigeria

Ranbaxy recently took on record the audited results

for the quarter and year ended December 31, 2011.

Commenting on the business results, Arun

Sawhney, CEO & Managing Director, Ranbaxy,

said, “I am delighted to share with you that

Ranbaxy is the fi rst pharma company of Indian

origin to have surpassed sales of $ 2 billion.

We successfully launched atorvastatin, generic

Lipitor® in the US. I am satisfi ed with the progress we

are making in resolving the long standing issues with

the US regulators.

Th e settlement with the US FDA and provision

for eventual penalties that the DOJ may levy,

brings greater predictability to our business in the

US, one of our largest markets.” “During the year,

we laid emphasis on strengthening our

processes, focussing R&D eff orts on our chosen

therapies, working towards improving manufacturing

effi ciencies and costs, re-evaluating our brand

marketing strategy and directing our energies at

markets of greater importance.” Indian pharma

business recorded sales of ̀ 19,513 million ($ 412 Mn),

a growth of 7 per cent for the year. Of this, Consumer

Healthcare or the OTC business recorded sales of

` 3,110 million ($ 67 million), a growth of over

20 per cent for the year.

Ranbaxy crosses $2 billion in global sales

Pfi zer recalls Prevnar 13 pneumococcal vaccineDrugmaker Pfi zer Inc is recalling one lot of its blockbuster

vaccine against pneumococcal disease, Prevnar 13.

Th e lot is being recalled from a drug wholesaler as

the active ingredient was past its expiration date. Th e

company says none was distributed to health care

providers. Prevnar 13 protects against 13 strains of

pneumococcal bacteria, which can cause meningitis,

pneumonia and ear infections.



Strides Arcolab Ltd (Strides)

had announced that it has

received US FDA approval for

its ‘Brazilian Sterile Penems’

facility, which manufactures

sterile dry powder injectables

of Penems. Th e plant has

already been approved by

other international regulatory

agencies such as MHRA

and ANVISA and with this

approval the company is in

a position to commercialise

products worldwide in the

second half of 2012.

Th e approval is also the

fi rst US FDA approval for

an international facility of

Strides. Th e approval and

commercialisation of the

products, which are already

licensed to partners worldwide

are expected in the second half

of 2012.

Commenting on the

occasion, Venkat Iyer, CEO,

Agila Specialties, said, “Th is

approval for our Brazilian

Sterile Penems manufacturing

facility in the niche domain is

another milestone in positioning

Agila as a leading global

injectable player”.

Carbapenems are a class of β-

lactam antibiotics with a broad

spectrum of antibacterial activity

and one of the last resorts for

many bacterial infections. Th e

global market size for Penems

is approximately $ 2 billion.

Glenmark Pharmaceuticals had issued a voluntary

nationwide recall in the US for seven lots of its oral

contraceptive norgestimate and ethinyl estradiol tablets due

to a packaging error.Th e recall is issued by the company’s

US arm Glenmark Generics Inc for tablets in strengths of

0.18 mg/0.035 mg, 0.215 mg/0.035 mg, 0.25 mg/0.035 mg,

Glenmark Pharma said in a statement.

“Th e recall is being implemented because of a packaging

error, where select blisters were rotated 180 degrees within

the card, reversing the weekly tablet orientation and making

the lot number and expiry date visible only on the outer

pouch,” it added.

As a result of the error the daily regimen for these oral

contraceptives could leave women consumers in US at risk

for unintended pregnancy, the company said. It, however,

did not mention the fi nancial implications of the recall

exercise.”At this time, there remains suffi cient supply of

unaff ected lots of material in the marketplace to support

demand, Glenmark said.

Glenmark recalls select lot of oral contraceptive in US

Strides Arcolab announces US FDA approval for its Brazilian facility

Drug fi rm Elder Pharmaceuticals has

launched three female personal hygiene

products in India as part of its in-licensing

pact with a US based fi rm, Combe Inc.

Th e company has introduced the

‘Vagisil’ range of feminine personal

hygiene products in India, in association

with New York-based Combe Inc, a

global brand leader in feminine care,

Elder Pharma said in a statement.

Th e Mumbai-based fi rm, which has

in-licensed the range from Combe

Inc, is introducing three key solutions,

Vagisil anti-itch creme, Vagisil intimate

feminine wash and Vagisil

intimate feminine lubricant,

it added.

Commenting on the

development, Alok Saxena,

Joint Managing Director,

Elder Pharma said, “Th e

Vagisil range of feminine

hygiene products has

been launched in India keeping in

mind growing day-to-day problems of

women, including vaginal itching, dryness,

odour, irritation, burning and discharge.

It is a new segment, something which

is new to the Indian market.

So, it presents a huge opportunity

for us.”

According to the company,

Vagisil anti-itch creme acts as an

external itch reliever and soothes

irritated skin and helps reduce

further irritation.

“It contains benzocaine, a fast-

acting itch reliever that works directly

on the nerves to stop external feminine

itching, burning and irritation,” said

Roberta Bloom, Director of Product Safety

and Scientifi c Support, Combe Inc.

Elder launches three female personal hygiene products

Novozymes Biopharma wins Technology Innovation Award for ground-breaking half-life extension platformNovozymes Biopharma, part of Novozymes A/S, world leader in

bioinnovation, received the 2012 Drug Delivery Partnerships™

(DDP) Technology Innovation Award for the company’s half-life

extension platform. Th e albumin-based technology platform off ers

the potential to enhance patient quality of life through tailoring

drug circulatory half-life to meet specifi c medical needs.

“Th e albumin-based technology is adaptable and can be used for

both genetic fusion (Albufuse® Flex) or conjugation (Recombumin®

Flex), providing a unique ability to decrease or increase a

drug’s half-life. Clearly, this will help manufacturers to develop

pharmaceuticals with enhanced pharmacokinetic properties,

off ering more favorable dosing regimes and improving patient

compliance, while reducing healthcare costs,” said Dave Mead,

Business Development Director, Novozymes Biopharma. Lack of

patient adherence to prescribed medications poses a tremendous

challenge to the global healthcare community. Th e main reasons

cited for poor compliance include patients’ forgetfulness and

factors such as the route of administration. To overcome these

issues, the technology exploits the natural interaction between

albumin and the neonatal Fc receptor (FcRn).

Th is exciting half-life extension technology enables drug

manufacturers to design new effi cacious products, or life-cycle

manage existing drugs, with longer serum half-life, reduced

toxicity and improved pharmacokinetic profi les. As a result, the

frequency of injections a patient receives or even the amount of

drug delivered can be reduced.

Saxena



AstraZeneca Plc is considering options for its Indian

unit, including buying the remaining 10 percent of

AstraZeneca Pharma India Ltd in order to secure

full ownership in a key emerging market.

International companies have until mid-2013

under Indian regulatory rules to either reduce

their stake below 75 percent or delist their Indian

operations, after buying out minority shareholders.

“We continue to consider two options, reducing

our shareholding to the new statutory maximum

of 75 percent and delisting,” said a company

spokeswoman in London.

An earlier report in a leading newspaper citing

two people familiar with the matter, said that

AstraZeneca was planning to delist and was in

talks with top investment banks lifted shares in the

Indian unit more than 5 percent.

With a market value of around $ 1.1 billion,

buying out the rest of AstraZeneca Pharma India

would be well within AstraZeneca’s reach. Th e

company had cash reserves of $ 7.6 billion at the

end of December.

Sartorius Stedim

Biotech (SSB) has

entered into a private

label agreement with

Trace Analytics.

Th is contract grants

SSB exclusive global

rights to market,

distribute and

service BioPAT Trace,

the new online analysing system.

BioPAT Trace is a glucose-lactate

analyser used for monitoring and

controlling both pilot-scale and

process-scale fermentation and cell

cultivation processes.

Th e system measures the

concentrations of the two analytes

glucose and lactate simultaneously,

in real time and online. BioPAT

Trace can be integrated into either

single-use or reusable

stainless-steel bioreactors.

Th anks to its single-use

sensors and microfl uidic

elements, it is immediately

ready to use. Th e system

enables reliably sterile,

automated sampling, by

either fi ltration or dialysis,

from the bioreactor.

Mario Becker, Director, Marketing,

PAT and Automation, Sartorius,

said, “With BioPAT Trace, we are

expanding our PAT portfolio by

an important component. Th e new

glucose-lactate analyser provides

our customers with real-time

information about their critical

process parameters, helping them

to further optimise and automate

their processes.”

Sartorius Stedim Biotech in pact with Trace Analytics

Sanofi and the Institut Pasteur recently

announced the creation of the Sanofi -

Institut Pasteur awards to encourage

scientifi c excellence in the service of health.

€480000 will support four innovative

research projects demonstrating real

progress in the life sciences and providing

answers to major healthcare problems,

more specifi cally in four fi elds: neglected

tropical diseases, vaccine innovation, drug

resistance, and therapeutic approaches to

ageing and regenerative medicine.

Th e jury comprises seven prestigious

members: Prof Peter C Agre, John

Hopkins University, Baltimore, United

States, Nobel Prize in Chemistry - 2003;

Prof Elizabeth H Blackburn, University

of California, San Francisco, Nobel Prize

in Medicine - 2009; and many others.

“With these awards, the Institut Pasteur

confi rms its commitment to the greater

interest by encouraging research, notably

in conditions aff ecting the most vulnerable

populations and diseases sharply on the rise

in the world,” said Alice Dautry, President,

Institut Pasteur.

Candidates can submit their applications

by April 20, 2012. Th e prizes will be

awarded in November 2012 at the Institute

Pasteur in Paris.

Sanofi and the Institut Pasteur create four prestigious awards to support innovative biomedical research

AstraZeneca weighs options for Indian unit

Clinical reference laboratory strengthens its position in AsiaClinical Reference Laboratory (CRL), a

global leader in the provision of central

laboratory services for the clinical

trials industry, has announced the full

integration of its long-standing laboratory

partner Phoenix Pharma Central Services

in Singapore.

Th e integration of Phoenix’s testing

platforms into CRL’s proprietary Global

LIMSystem enhances CRL’s support of

clinical trials in Asia through improved

effi ciencies, increased quality, reduced

costs and full global project oversight.

Tim Sotos, Chief Executive Offi cer, CRL,

said, “We have a trusted relationship

with Phoenix, having worked together

for over a decade supporting a large

number of clinical trials globally. “By

incorporating Phoenix’s data into our

centralised Global LIMSystem it allows

for both sites and clinical teams to access

their data throughout the world using

CRL’s proprietary web-based ‘OASIS’

systems. Th is provides drug development

companies with direct oversight on the

status of their trial and allows them to

evaluate drug safety on a real-time basis.”

Th rough CRL’s globally implemented IT

system, every clinical trial sample drawn

anywhere in the world will immediately

be entered into its LIMSystem to assure

real time global tracking of any specimen.

Dr Yan Lee, Chief Executive Offi cer,

Phoenix Pharma Central Services,

said, “Together we are well positioned

to provide support to pharmaceutical

and biotechnological industries in the

development of drugs and medical devices.

”Tim Sotos added, “Th e partnership also

means our clients will receive the utmost

local experience working with laboratories

in every continent. Importantly the

innovative execution of a sound business

model allows us to fully streamline our

global operations.”

BioPAT Trace

Technology & Innovation


Pharmspective, a specialty therapeutics

fi rm has recently launched a syndicated

research off ering and knowledge

management application. Th e

organisiation is going to launch a

number of knowledge management

applications that will allow subscribers

to view and interact with real-time

market intelligence through state-

of-the-art user interfaces on PC and

tablets. Th e company’s syndicated

research studies will examine clinical

decision-making, drug acquisition,

access and reimbursement, and

patient administration for specialty

therapeutics in autoimmune diseases

and oncology.

“We are excited to launch the

knowledge management applications

in response to dramatic changes in

new product development within the

pharmaceutical industry,” announced

Stephen Reid, Managing Partner

and Co-Founder, Pharmspective.

Adding to this Katie Derdeyn, MD,

Managing Partner and Co-Founder,

Pharmspective, said, “In designing our

knowledge management apps, we have

examined every factor that might play a

role in the decision to develop or utilise

a specialty therapeutic. Our product

off erings follow specialty therapeutics

from drug development through patient

administration, and this focus will allow

us to help our clients build a broad

understanding of the markets in which

they wish to enter and compete.”

Pharmspective launches knowledge management apps

Th e Zeta Plus Encapsulated System (EZP) from 3M features a

unique, easy-to-use pivot action. Addressing the demand for reliable,

high-quality disposable depth fi ltration, EZP raises the bar in terms

of ergonomics; capsule design and dual zone fi lter media, which is

optimal for cell culture clarifi cation and the removal of host cell derived

impurities. “EZP is the latest addition to our industry-leading Zeta Plus

product line that has been used by customers in the biotechnology and

pharmaceutical industries for more than 35 years,” commented Lynne

Deakin, Field Applications Specialist, 3M’s CUNO Filtration business.

Adding to this he said, “It has been developed in response to requirements

for a disposable depth fi ltration solution that allows loading and unloading

at waist height so operators don’t have to lift capsules above their heads and

risk exposure to fl uid spills when handling used capsules.”

Researchers at the University of Leeds

have come up with a technology that

could help the pharmaceutical industry

in controlling crystal formation during

the process of drug development. Th e

pharmaceuticals are often received in

the crystalline form and the crystal

structure can get altered due to the

undetected fl uctuation in the system.

Th is could cause changes in the

structure and pose a threat to the safety

and effi cacy of the desired product.

Also, there are chances that the drug

might get delayed in reaching the

market. As the composition of drug

molecules are growing more complex

by each passing day the real challenge is

involved in processing the components

to obtain the desired results. According

to Dr Robert Hammond, Researcher,

“Here comes into play the potential

of their technology. It makes possible

monitoring of the crystals during their

formation inside reactor, a phenomenon

that was not thought of before.

Th e technology uses powder X-ray

diff raction, which monitors the crystal

structure while the crystalline form

passes through a temperature controlled

fl ow cell.”

New technology to monitor crystal formation

3M’s fi ltration system offers a robust convenient solution for biomanufacturing customers

DisiTest 50 disintegration tester from Dr Schleuniger®

Pharmatron incorporates innovative induction heating

technology and combines it with the benefi ts of automation

to realise cost savings by signifi cantly streamlining the

disintegration testing process.

Th e DisiTest 50 automatically detects the disintegration

time of tablets and capsules in full compliance with current

Pharmacopoeia. Visual monitoring of the disintegration

process by the operator is not required. Induction heating

technology reduces heating times to only 3-5 minutes and

completely eliminates unproductive cleaning times typically

associated with conventional water bath-based systems. DisiTest 50 ensures precise

and homogeneous temperature control. Test medium temperature is monitored

continuously by a contact-free infrared sensor and recorded for reporting purposes.

Th e DisiTest 50 can be extended to a fully automatic disintegration testing system

with up to four independent testing stations and one MediaPrep station - all

controlled via the touch screen of the master station. Because individual testing

stations are connected using state-of-the-art TCP/IP technology, system layout is

fl exible and retrofi tting additional stations is possible anytime.

Realise cost savings with the new DisiTest 50

DisiTest 50

Technology & Innovation


BMG Labtech, a leading developer and manufacturer of microplate reader instrumentation for academic and pharmaceutical research, as well as high-throughput screening applications has come up with a technology called PHERAstar FS. Th is is the ultimate multi-detection microplate reader for HTS and assay development, especially where speed and sensitivity are imperative. Th e PHERAstar FS is based on the highly successful PHERAstar

Plus with all of the outstanding features that one would expect from the ultimate HTS microplate reader.

Th e technology also incorporates unique tandem technology, using an ultra-fast UV/Vis spectrometer (220 nm – 1,000 nm) for absorbance measurements and highly sensitive, fi lter-based detection in all modes including fl uorescence intensity, FRET, fl uorescence polarisation, time-resolved fl uorescence, UV/Vis absorbance and luminescence.

Next-generation HTS microplate reader

Bio-Rad Laboratories has

launched new magnetic bead–

based multiplex immunoassays for

human T-helper type 17 (Th 17)

cytokines and cancer biomarkers.

Th e Bio-Plex Pro™ immunoassays

take advantage of the magnetic

bead workfl ow to simplify assay

preparation and reduce variability.

Th e Bio-Plex Pro human Th

17 cytokine panel is designed

to detect 16 soluble proteins

involved in the Th 17 immune

response pathway. Th e Bio-Plex

Pro human cancer biomarker

panel 1 detects 16 biomarkers

commonly associated with cancer.

Th ese assays are designed to help

preclinical and clinical researchers

investigate mechanisms of disease

and therapeutic drug action.

Th e technology features

nine new targets, including IL-

17F, IL-21, and IL-22, which

are commonly requested by

researchers, as well as IL-17 A/F,

which is unique to Bio-Rad. Th e

Th 17 cytokines are believed to

play a key role in infl ammatory

conditions such as autoimmune

diseases, antimicrobial immunity,

transplant rejection, and cancer.

Bio-Rad launches multiplex immunoassays for hum T-helper

Cryo Store and Transposafe have announced the launch of the KelvinBox

T900 series the packaging solution for all your UN3373 dry ice shipments.

Th e KelvinBox T900 packaging systems series has been developed specifi cally

for dry ice shipments of UN3373 biological substance, category B specimens,

compliant with ADR/ICAO/IATA P650 packaging instructions. Standard

UN3373 P650 sealbags are well suited for road transport (ADR), but do not

meet the tight regulations of IATA for airtransportation. For this reason,

Transposafe®, a specialist in the security sealing of valuable consignments, has

developed the Transposafe AirSealbag®, the fi rst-of-its-kind that guarantees

leak-proof shipments at temperatures of -79°C (dry ice conditions).

Th e KelvinBox T900 temperature-controlled packaging line is the result

of combined know-how and years of experience within both companies.

Available in diff erent sizes, for sending a few tubes of sample material up

to several vial boxes, with clear packaging instructions and test reports, the

KelvinBox T900 series is a complete packaging solution with a well maintained

balance between regulatory compliance and costs.

Th e KelvinBox T900 series is available in diff erent sizes, for shipping

diff erent quantities of sample material.

Cryo Store and Transposafe present the KelvinBox T900 series for UN3373 dry ice shipments

A new form of microscope which can

produce results in seconds is being

developed by researchers at the University

of Strathclyde in Glasgow. Scientists

are creating a lens which will be capable

of showing three-dimensional images

within cells and tissues at the same

time as showing the whole organism.

Th e innovative Mesolens – the only

device of its kind in the world - will

be able to capture detail in organisms

which are too big to be examined

satisfactorily by existing microscopes

and will off er a deeper insight into areas

such as cancerous tissues and the cortex

of the brain. Dr Gail McConnell, a

Reader at the Strathclyde Institute of

Pharmacy and Biomedical Sciences, a

partner in research said, “Our research

fi ts with Strathclyde’s ethos of technical

innovation with universal impact. We

already have the two-dimensional

technology for the lens in place, but a

third dimension will allow us to take

the revolutionary step of presenting

images with a range and versatility

which no single imaging platform can

currently off er.”

Lens produces hours of scientifi c work in seconds

Human fl ea

Technology Transfer


As part of our endeavour to spread the technology culture, this section provides a means to promote and facilitate exchange of select technologies. We strive to bring together suppliers of such technologies with suitable users for negotiations and industrial collaboration.

A novel process Foramides

Synthesisamides synthesis

The present technology provides with an

amidation reaction of unprotected a-amino

acids in water under neutral conditions

with various aliphatic, aromatic and

heteroaromatic amines in the presence of

coupling reagent l,l’-carbonyldiimidazole

(CDI) at ambient temperature to obtain

the corresponding a-amino acid amides.

Areas of application

Medical and pharmaceutical industry

Forms of transfer

Technology licensing

Anti-ulceritic APIs

An Indian company offers anti-ulcer drugs

like omeprazole, pantaprazole, omeprazole

sodium, omeprazole magnesium and

esomeprazole magnesium for operations

in manufacturing processes.


Formulation industries

Forms of transfer

Consultancy

Clorsulon and its intermediates

An Indian company offers clorsulon, a

highly potent anthelmintic drug, which is

administered to de-worm the intestines of

sheep and cattle.


Pharmaceutical industry

Forms of transfer

Consultancy

Detection and analysis of heavy metals

in the industrial effluents

The present technology relates to a

device and method for detecting and

also measuring the concentration

of copper in an industrial effluent.

This device comprises of an ion

selective electrode (ISE) coupled to

immobilise Bacillus sphaericus strain

characterized in producing Urease on

its one end and to a voltage measuring

device which is calibrated to indicate the

concentration of the heavy metal in the

solvent at its other end.


Industrial effluents, accumulates

Forms of transfer


Filter cleaning system

An Indian company offers an automatic

filter media cleaning equipment with drying

system. It consists of air wash, water wash

and drying facilities.


Filter media cleaning

Forms of transfer

Joint venture, equipment supply

Formulation for leucoderma

It is well known that these diseases

have property of recurrence and most

of the medicines used for cure have

various side effects and also the disease

is not fully cured. The company

offers the formulation that is quite

effective in curing all the above three

diseases in short period of time. In case

of leucoderma after application of the

formulation there starts formation of

patches (natural colour of skin) within

a week.


Pharma and medical industry

Transfer terms

Joint Venture, technology licensing,

research partnerships

Herbal formulation for psoriasis and

eczema

An Indian company offers an innovative

herbal formulation that has the ability

to control & cure psoriasis and eczema

within one month of application of

the formulation.


Herbal medicine

Forms of transfer

Joint venture, technical services,

technology licensing

Natural preparation for anxiety relief

A company offers food supplement in

the form of tablets that effectively relieves

mild to moderate anxiety problems. The

ingredient is an herbal extract, which has

been scientifically proved for its efficacy.

Efficient decrease of anxiety symptoms,

quick onset of action and no side-effects

are reported to be the advantages of

this product.



Forms of transfer

Equipment supply

Process of preparation of nanoparticles for

drug delivery system

The present invention is related to a

process for the preparation of the novel

nanoparticles of apotransferrin or transferrin

which are useful for the preparation of a

pharmaceutical composition facilitating easy

delivery of the drug.


Medical and pharma industry

Forms of transfer


Pharmaceutical composition for the treat-

ment of ophthalmic disease

A company can offer technology for

manufacturing a drug useful in the

treatment of opthalmic disorders. A

composition comprising Lithium chloride

is the product which causes retinal cell

regeneration. Lithium chloride alone

helped in proliferation of retinal cells but is

associated with other effects.


Pharma and medical industry

Transfer terms

Consultancy, technical services,

technology licensing

Technology Offered

Technology Transfer


Technology Requested

Biotechnology for wastewater

treatment system

A Thailand-based company, a

wastewater service provider, is

involved in the R&D of new technology

for water, wastewater and waste treatment.

It requires new ideas related to technology

for developing its strength in the field of

wastewater.


Biotechnology, engineering

Forms of transfer

Consultancy

Calcium Gluconate

A company needs technology for manufacturing

of Calcium Gluconate



Forms of transfer

Technical services, project report, others

Extract of medicinal and aromatic plants

A company is interested in putting up a

multi-purpose herbal extraction plant for the

extraction of medicinal and aromatic plants

and herbs like artemisinin/quinine sulphate

and other alkaloids.



Forms of transfer

Others

IV fluid manufacturing as SME

An Indian company needs new and good

technology to start manufacturing of IV

fluids.


Medical technology

Forms of transfer

Technical services, others

Kite grading engineering

A company is looking for kite grading, which

is a subservient of genetic therapy research

particularly for the cardiovascular novice.


Medical research

Transfer terms

Others

Manufacture of intravenous fluids

A company requires know how and

technological requirements for the

manufacture of intravenous fluids. Know how

should include where to obtain appropriate

grade raw materials.


Pharma/medicalForms of transfer

Others

Manufacturing technology of hepatits B,

tetanus, diphtheria and pertussis vaccines

An Indian company is interested in

a complete technology for start up of

manufacturing of combination vaccines from

bulk to formulations including supply of

protocols for manufacturing and production

strains.


Human vaccines

Transfer terms

Others

Manufacturing of liquid bio fertilisers

An agro biotech company is looking for

a proven technology for manufacturing of

liquid bio fertilisers. They would like to

know the kind of technology that could be

offered (ie the product, efficacy, length of

field trial) and a procedure of buying the

technology along with the cost incurred.


Biotechnology

Transfer terms

Others

Manufacturing technologies for mon-

telucast, rosuvastatin, ursodeoxy cholic

acid, D-biotin

A company needs API/bulk

drug manufacturing technologies

for montelucast, rosuvastatin,

ursodeoxy cholic acid and

D-biotin


API/bulk drug

Forms of transfer

Others

Pharma grade mannitol know-how

A company is on the look out for a

commercially proven latest technology &

know how (turnkey) for manufacturing

pharma grade mannitol in India. The

estimated production capacity is 600

tonnes per annum.


Pharmaceuticals

Forms of transfer

Others

Pharmaceutical Lyophilisation plant

A Peru based company is looking

for a Lyophilisation plant for

pharmaceutical use. Capacity shall be

around 175 to 200 square feet, for the

lyophilisation of 20,000 vials of 10 mL

per day.


Pharma and food processing industry

Forms of transfer

Others

Share and Solicit TechnologyThe mission of Modern Pharmaceuticals is to spread the technology culture. Here is an opportunity to be a part of this endeavour by sending your technology on offer or technology

requirements. If you belong to any of these two categories, you are invited to furnish the techno-commercial details for publication. The write-up needs to be as per the format of

this section with information about the particular technology offered or requested, its areas of application and forms of transfer. Contact us: Modern Pharmaceuticals, Infomedia 18 Ltd,

‘A’ Wing, Ruby House, J K Sawant Marg, Dadar (W), Mumbai 400 028. Tel: 022-3024 5000, 3003 4695 Fax: 022-3003 4499 Email: [email protected]

Information courtesy: Dr Krishnan S Raghavan, In-Charge, Technology Transfer Services Group, United Nations - Asian and Pacific Centre for Transfer of Technology (APCTT), APCTT Building , C-2, Qutab Institutional Area, New Delhi 110 016, Tel: 011 - 2696 6509, Fax: 011 - 2685 6274, Email: [email protected], Website: www.apctt.org, For more information on technology offers and requests, please log on to www.technology4sme.net and register with your contact details. This is a free of cost platform provided by APCTT for facilitating interaction between buyers and seekers of technologies across the globe. After submitting technology offer or request to this website, you are requested to wait for at least two weeks for receiving a response from a prospective buyer / seeker through this website, before contacting APCTT for further assistance.

In Conversation With: Manish Doshi


“One should focus on growth, and on all the input factors that lead to resultant growth,”

…says Manish Doshi, President, Indian Drugs Manufacturers Association & Managing Director, Amoli Organics Pvt Ltd. Here, he reminscences his journey.

Chandreyee Bhaumik

Photo: Joshua Navalkar

Manish Doshi


Elaborate on your journey to become the President of IDMA Th e journey has been an interesting one. I had an

exciting student life. Since my family was already

into the pharma business, I was keen to join this

industry. I graduated in pharmacy and did my

post graduation in Financial Management from

Jamnanalal Bajaj Institute of Management,

Mumbai. Frankly, I was a good scorer always.

I am managing my family business since the

last 28 years. Th e Amoli Group of Companies

manufacture API and formulations. Th e group

exports to more than 80 countries. My father

has been my constant source of inspiration. He

was very active socially. Professionally, he was

in a signifi cant position. He was the President

of the Chemists and Druggists Association

and had started various businesses that I have

subsequently grown. I always believe that

starting is more challenging than taking it

further. Further, through this journey I was

privileged to interact with some of the leaders of

the pharma industry such as Dilip Shanghvi of

Sun Pharma and many other dignitaries.

With a Presidential position comes a lot of responsibilities. How does it feel?While on one side, it certainly is exciting, on

the other it is a huge responsibility. Today, the

industry is growing reasonably well by 15 per

cent and by and large the industry has been

successful in catering to the diverse needs of

the vast population. I have been associated

with IDMA for the last 15 years. I was

appointed as the Vice-President in 2007. Th us,

it has been my constant focus to create the

right environment so that the healthy growth

continues or maybe further accelerates. Th is

involves interaction with the government to

ensure a healthy environment. In this context

policies are formulated. Sometimes even at

the operational levels there are issues that

need to be brought to the attention or need

to be sorted out.

Apart from the interaction with the

government there can be other things such

as seminars, workshops that give the right

exposure to the appropriate segments of the

industry. It must be remembered that the

industry comprises diff erent enterprises ranging

from small to medium and large, and thereby

the needs also diff er. So, it is our responsibility

as an association to ensure that all needs are

attended to.

What are your views on today’s investment in R&D? Investment in the R&D of pharma industry is

much better than most other industries in India.

So by that benchmark, one cannot say that it is

less. Again, the kind of profi tability that Indian

companies can enjoy in branded generics also put

a little constraint or limitation that a company

can do. Of course, the situation is diff erent

with the global giants or innovator companies

such as Pfi zer and Glaxo. Th eir profi tabilities

are huge because of the innovation models that

they follow.

How does one live up to the legacy?Th ere are no radical new strategies as such.

One should focus on growth, and on all the

input factors that lead to the resultant growth.

Th ere should be constant seminars, workshops,

gatherings. Th ese are the aspects that empower

the members and ultimately result in the

development of industries.

Constant eff orts should be made to ensure

that the government policies are in place and

the medicines are accessible to the interiors.

When Indira Gandhi, the then Prime

Minister decided to go for Patent Act, it only

resulted in process patent protection. Product

patents were not under this purview. Th is has

resulted in so many companies introducing

products in India; developing the products,

reverse engineering the products. Th erefore, it is

always a combination of the environmental and

the inherent internal factors. Even today, if we

consider ourselves to be the emerging powers it

is important to delve deeper into the reasons.

We are fortunate to have so many effi cient

educational boards such as Delhi University,

Mumbai University and many others. Th e

leaders at that time gave importance to

education. Th is forms the strength of the nation

otherwise we would also be like any other

African country.

Th ere are few aspects that must be

remembered as far as the pharma industry

in India is concerned. In India, medicines are

most economical. Second, the industry has

been growing in 15 per cent value terms and

more in volume terms. Th ird, we are not only

catering to the vast population of this country

but India is also the exporter to more than 150

countries across the globe. So, if one looks at

these yardsticks then one can give almost 9 out

of 10 to pharma industry. Further, if one is

talking about segments such as formulations,

Active Pharmaceutical Ingredient (API) then

it is not possible to segregate the segments

on a priority basis. Th erefore, formulation

of appropriate government policies is what

deserves immediate action.

What are your views on today’s student group? Any message for them?Our industry has either pharma students

or the students from other related fi elds

such as medicinal chemistry. Th ey are

the backbone of our industry. We are a

knowledge-based industry and human

resources is the most important component.

Th ere is a large amount of talented pharma

students. Th ey enter the industry and become

major contributors. Th us, today, even if

substantial number of pharma graduates is

going abroad we are not having any shortage of

pharma professionals.

Additionally, it is true that most of the

professional courses have disconnected with

the actual job scenario. So, it would be useful

if there is six months of paid internship during

the B Pharm or M Pharm. Th ere are enough

opportunities both on the technical as well as

marketing side post graduation. On the former

side, there are scopes on production, Quality

Control, quality assurance, regulatory aff airs

and R&D is also a huge area. Patents will gain

prominence over the years. Again, over a period

of 10 years IPR will also become important.

Next 5 years?Personally our company that is in formulation

is doing quite well. We do have plans for

aggressive growth. From the overall association

(IDMA) point of view, even though my term for

President will be near completion (two years),

whatever I am supposed to contribute to I will

continue to do so.

([email protected])

Success mantra: Hard work and smart workFavourite book: Atlas Shrugged by Ayn RandQualities important in a professional: Caliber, sincerity and reliabilityInterests and passions: Travelling. I am fortunate to have travelled to more than 60 countries

Quick Takes

Special Focus


Tax incentives

Never too late for too much ...................................................32

R&D incentives

Will innovation and R&D get a boost?..................................34

Interface

Dr Rajesh Jain, Chairman

CII National Committee on Biotechnology &

Joint MD, Panacea Biotec Ltd ...................................................36

RoundtableWill the Union Budget 2012 be SME friendly? ......................38

Budget Wishlist



As we are gradually nearing the

Budget season, individuals

associated with the pharma

industry, directly or indirectly,

are tormented with the regular questions.

Will the 2012-2013 Union Budget

ultimately off er solutions to the frequently

faced questions or concerns of the

industry? Will the Budget this year help

the pharma industry in occupying the

front seat globally?

Since the Assembly polls in fi ve states

will be completed on March 6, the

Government of India recently declared

that the Budget session of Parliament

will be convened on March 12, and the

2012-13 Union Budget will be presented

on March 16. With the approaching

date, the fears and wishes of the pharma

fraternity reaches a high crescendo.

Budget expectationsTh ere are several demands and expectations

as far the tax incentives for the pharma

industry are concerned. Th e Central

Government may incentivise the pharma

industry by lowering the taxes and duties

on life-saving products such as drugs and

Active Pharmaceutical Ingredient (API)

to provide an impetus to the growth and

development of the industry.

Discussing his expectations and

demands from the Union Budget,

Kayvanna Shah, Chief Executive Offi cer,

J B SEZ Pvt Ltd, explains, “From Special

Economic Zones’ (SEZs) point of view,

we hope that the upcoming Budget

provides grandfathering provisions to

all existing and upcoming SEZs and

unit-holders for a prolonged period.

Let us not forget that SEZs have been

one of the growth drivers for exports

generated and various players have made

immense investments keeping in mind

the fi scal incentives and concessions

off ered earlier. Th ough certain benefi ts

were withdrawn in the previous Budget,

it would augur well for all if the Finance

Ministry at least provides a level playing

fi eld to current players till a specifi c

period.” Continuing in the same vein, he

elaborates, “We also expect that certain

extra SOPs and incentives would be

off ered for industrial zones coming up

in rural hinterland for industrialisation

of various states. Th is will have a

magnifying eff ect on various industries

since it would boost investments from

all corners and concerned entities would

consider developing in such areas.”

Chandreyee Bhaumik

Special Focus: Tax incentives

The pharma industry hopes that Budget 2012 will match its expectations and inject the much needed dose of tax incentives. While the wish list varies, the common dream remains getting good tax incentives.

Neverfor

too muchtoo late

Tax incentives


Talking about the expectations from

the Union Budget, Tapan J Ray, Director

General, Organisation of Pharmaceutical

Producers of India (OPPI), says, “Setting

up infrastructure involves substantial

fi nancial investment and a long gestation

period. Hence, tax benefi ts should be

provided for units engaged in the business

of R&D and contract manufacturing by

way of deduction from profi ts linked to

investments.” He continues, “If India has

to emerge as a low-cost healthcare medical

tourism destination then there is a greater

need to setup state-of-the-art healthcare

facilities in the metros, tier-I and

tier- II cities for which adequate direct tax

incentives are to be provided.”

Customs dutyTh ere are also expectations as far as

indirect taxes are concerned. Elaborating

on customs duty, Ray says, “Basic Customs

Duty (BCD) for health supplements

should be reduced to 10 per cent and

Countervailing Duty (CVD)/ central

excise duty to 1 per cent or 5 per cent to

make it at par with drugs. Th is would help

in making the said benefi cial products

aff ordable to the common man.” He adds

that all life-saving drugs (including medical

devices) should be exempted from customs

duty. All equipment meant for diagnostic

purposes and consumables thereof should

be completely exempted from the levy of

customs/central excise duty. CVD should

be charged at a lower rate of 1 per cent on

import of vaccines, specifi ed medicaments

and health supplements imported into

India. BCD rate on import of formulations

should be reduced to 5 per cent.

Central Excise Duty and VAT According to Ray, the central excise

duty rate of API (primary raw material

for pharma formulation manufacturers)

should be rationalised and made at par

with pharma goods, ie, excise duty on the

inputs should be reduced from 10 per cent

to 5 per cent. Further, he adds that an

abatement of 45-50 per cent is necessary

to enable pharma industry to cover its

costs while calculating the central excise

duty payable. Continuing in this vein, he

says, “Th is abatement should be increased

to 45-50 per cent as the current 35 per cent

abatement does not even cover the trade

margins, the value of R&D costs and other

costs associated with the pharma industry

such as distribution of many medicines

(eg, vaccines) through ‘cold chain’.”

Further, commenting on the Value-

Added Tax (VAT), Ray adds that the tax

rate of 4-5 per cent on medicines and

the list of tax-exempt goods and declared

goods should be uniform across all states.

Rectifying the lapse Th ere were several diverse reactions to the

previous Budget (2011-2012). Hopefully

this Budget will rectify the situation.

Signing off Shah says, “We were clearly

taken aback by the Union Budget last

year that imposed Minimum Alternative

Tax (MAT) and Dividend Distribution

Tax (DDT) on SEZ developers and

unit-holders. Th is meant that few of our

prospective clients had to rethink on their

expansion plans with regards to setting

up new units in SEZs. However, if the

Finance Ministry can spur the investment

climate by acting on reforms and off ering

incentives linked to investments, the

situation shall certainly improve from

here. We hope in respect of Direct Tax

Code, full applicability of the existing SEZ

scheme is enabled to all SEZs notifi ed till

a determined cut-off date.”

([email protected])

Kayvanna ShahChief Executive Offi cer, J B SEZ Pvt Ltd

Tapan J RayDirector General, Organisation of Pharmaceutical Producers of India (OPPI)

Tax benefi ts should be provided for units engaged in the business of R&D and contract manufacturing by way of deduction from profi ts linked to investments.

We also expect that certain extra SOPs and incentives would be offered for industrial zones coming up in rural hinterland for industrialisation of various states.

Pre-Budget expecta� ons

Segment

Tax incentives

in pharma

Previous Budget

Government proposed

to levy Minimum

Alternate Tax (MAT)

of 18.5 per cent on the

book profi ts of Special

Economic Zone (SEZ)

developers and units

Expectations

Provisions to all existing

and upcoming SEZs

and unit-holders for a

prolonged period


With time India has

emerged as a hub for

various collaborative

and outsourced R&D

activities. Along with this, there is a

fundamental shift in the strategies of Indian

pharma companies from ‘business-driven

research’ to ‘research-driven business.’ With

the Budget coming soon there is constant

focus whether the government will

support the pharma industry and catalyse

its growth to become global numero uno.

Needless to say, the growth chart of the

industry is dependent on extensive research

capabilities and new product development,

and major companies are looking forward

for incentives in the same.

The present scenarioLast year the Union Budget (2011-12)

did not satisfy several industry insiders,

especially pertaining to its R&D

allowances. Th ere was no extension

provided on the weighted deduction

on the in-house R&D that stands at

200 per cent and available till FY 2012.

Th is was indeed a case of disappointment

for the pharma companies that are

actively involved in R&D activities.

Weighed deduction on the in-house

R&D means an Indian pharma

company performing in-house R&D

will get tax exemption on the amount

spent. Th e exemption would be the

double of what they spend on R&D.

For example, when a company spends

` 200 crore on R&D it will have no

tax liability on a ` 400 crore income.

Th is was 150 per cent till FY 2009 and

in the last Budget it was increased to

200 per cent. Additionally, weighted

deductions for payments inter-alia made

to National Laboratory or a University

or a specifi ed person for the purpose of

approved scientifi c research programme

has increased from 175 per cent to

200 per cent. Th e Budget can provide

a new drug delivery system for such

dosage by extending weighted deduction

for R&D activity beyond 2012 and

provide incentives for the core R&D

activity players.

More importantly, there are enough

claims that India spends less on

R&D than it ought to. According to

various expert reports, in India the

spending on R&D is approximately

2 per cent of Gross Domestic Product

(GDP) compared unfavourably with

3-4 per cent in advanced countries.

Expectations for this yearIndian pharma industry aspires to

occupy the front seat with special

emphasis on innovation and R&D.

Undoubtedly, India has the potential

required to be one of the countries with

the highest levels of intelligence in its

products. Th us, there should be eff orts

to double the percentage that is spent on

R&D over the next few years. Discussing

the wish list from the Budget, Nidhi

Saxena, Founder, President & CEO,

Karmic Lifesciences, shares, “I expect

a huge thrust to be given to R&D

activities, including clinical research

and stronger promotion for scientifi c

and research infrastructure development

in this year’s Union Budget. Next, the

healthcare sector should be given an

infrastructure status with zero duty

on R&D equipment and a longer

tax-free allowance on pharma and biotech

SEZs. Additionally, R&D and clinical

research activities should be incentivised

by providing a 5-year tax holiday on all

products developed in-house, extension

of weighted deduction on R&D on all

research-related services.”

Over the past few years the pharma

industry of the country has witnessed

Chandreyee Bhaumik

Special Focus: R&D incentives

Will innovation and R&D get a boost?With the Union Budget around the corner, it is time for pharma companies to chalk out their list of expectations. R&D incentives, in different forms, top the wish list of most of the pharma companies.

R&D incentives


Nidhi SaxenaFounder, President & CEO, Karmic Lifesciences

Vikram Gupta Founder & Managing Partner, IvyCap Ventures Advisors Pvt Ltd

There are a lot of things that are required for R&D such as chemicals, raw materials and many others. So, there should be tax exemption on all the goods that are used for R&D.

R&D and clinical research activities should be incentivised by providing a 5-year tax holiday on all products developed in-house, extension of weighted deduction on R&D on all research-related services.

Pre-Budget expecta� ons

Segment

R&D in pharma

Previous Budget

Th ere was no extension

provided on the

weighted deduction

on the in-house R&D

that stands at 200 per

cent and available till

FY2012 only

Expectations

Eff orts should be made in

order to facilitate a R&D

culture and innovation

steady growth. Today, it is considered as

one of the sectors that is continuously

driving the Indian growth story.

Identifying this success story, the

Department of Pharmaceuticals has

come up with ‘Pharma Vision 2020’ in

order to make India one of the attractive

destinations for end-to-end drug

discovery and innovation.

Talking about the benefi ts that the

R&D incentives provide the pharma

industry, Saxena avers, “Currently,

life sciences companies engaged in

R&D activities do not get any tax

deductions; if the R&D lab is not

approved by Department of Scientifi c

and Industrial Research (DSIR)

even though the company spends

considerable money on such R&D

activities. Th us, there is a need to bring

in a provision of giving tax exemptions

to companies doing R&D outside

the purview of DSIR.” Continuing

in the same vein, she adds that a fl at

10 per cent income tax on gross

profi t for the fi rst fi ve years will be a

welcome step for Clinical Research

Organisations (CROs) to start-up.

She highlights, “Th e incentives

normally given to service sector

that brings in foreign exchange

need to be introduced/re-introduced

for CROs.”

Further, discussing the need of a

proper R&D culture, Vikram Gupta,

Founder & Managing Partner, IvyCap

Ventures Advisors Pvt Ltd, says,

“Eff orts should be made in order to

facilitate a R&D culture and innovation.

Further, there are a lot of things that are

required for R&D such as chemicals,

raw materials and many others. So,

there should be tax exemption on all

the goods that are used for R&D. In

this way, there can be rationalisation

of the entire R&D segment.” Further,

according to him, there are several

activities that are not falling in

DSIR and lot of rationalisation is also

required in that context. Th is is very

important for building an entrepreneurial

innovation culture in India.

Bringing a changeWith passing time, the performance of

in-house R&D centres of major Indian

institutes show that there is a defi nite

requirement for strong merges between

the in-house R&D centres and various

national laboratories and several technical

institutes in order to attain competence in

the industry. It is true that India does not

lack the scientifi c talent or the talent pool

that is required. Th erefore, it is essential

that the centre concentrates on the R&D

segment. Th is will help the country to

assume a strong position in the global

research fi eld.

With expectations comes an obvious

comparison with the last year. Th e Union

Budget 2012-2013 will hopefully fi ll the

gaps left or created in the previous Budget.

Elaborating in this vein, Saxena explains

that in Budget 2011-12, the government

made no proposals on reducing excise

duty, tax on healthcare infrastructure and

weighted deduction for expenses incurred

outside R&D facility such as overseas

trials, dossier preparation, consulting &

legal fees on healthcare and pharma sector.

Th e positives were that by considering

the need of the industry for innovation,

it enhanced the weighted deduction on

payments made to National Laboratories,

universities and institutes of technology,

for scientifi c research, from 175- 200 per

cent. She highlights, “Th is year does not

look very positive on the R&D front until

the government takes some concrete steps

to address industry requirements.”

([email protected])


Expectations from the Union Budget as far as the R&D incentives are concerned...Th e weighted tax exemption of 200

per cent on R&D expenses should be

continued for at least the next 10 years.

Th is will help R&D-oriented companies

to take long-term strategic decisions on

R&D projects. It will also act as a booster

for further investment on R&D. Short-

term fi scal incentives do not encourage

the industry to invest on long-term

R&D projects.

How will the Union Budget help in the tax benefi ts section?At present, 200 per cent tax exemption is

allowed on revenue and capital expenses

incurred by approved R&D centres on in-

house projects. Clinical trials conducted

through Clinical Research Organisations

(CROs) are not eligible for 200 per cent

weighted tax deduction, not even 100 per

cent. Since clinical trials conducted through

CROs are important and integral part of

overall R&D programmes and account for

2/3rd of R&D cost, therefore, weighted tax

exemption of 200 per cent should be allowed

on all clinical trials irrespective of whether

conducted in-house or through CROs. Th is

will ensure the goal of Government of India

to make drugs aff ordable.

How do you think the Budget can favour SMEs?Th ere should be Budget allocation

for capacity development in pharma

and biotechnology for concerned

Ministries to work with industry and

develop the following:

Sector Skill Council in Pharma (SSC):

CII has taken the initiative to form

the pharma/biopharma sector skill

council and currently working with all

prominent industry bodies on devising

the framework to bridge the gap between

the demand and supply of skilled human

resources in specialty area such as quality

assurance, sales & marketing, regulatory

aff airs, licensing, business development of

specialty products, etc.

Good Laboratory Practice (GLP):

CII is working with National GLP

Compliance Monitoring Authority

(NGCMA) to provide GLP training to

interested organisations.

Finishing school: CII Biotech fi nishing

school proposal has received encouraging

response from its members, organisations

and are willing to train 5-10 graduates

in various biotech streams depending

on organisations area of interest. Th is

initiative would further be strengthened

with active participation of Department

of Biotechnology (DBT) and interested

member organisations.

Expense reimbursement: SME exporters

incur expenses such as USFDA audit and

National Science Foundation (NSF). As

in many Asian countries, these SMEs

must be allowed to take reimbursement

from the Government for USFDA and

NSF expenses so as to become globally

competitive in quality and assurance.

What kind of Budget will benefi t the pharma/biotech SEZs? Government must create a budget

through which 50 per cent of the total

income tax paid by a company in the last

10 years can be paid back as a soft loan

to an R&D organisation for 20 years

re-payment terms at 1 per cent annual

interest. Th is will encourage investment

in R&D in an objective manner and

at the same time ensure availability of

economical, innovative new safe and

effi cacious medicines for all

Special Focus: Interface - Dr Rajesh Jain

“Government must uniformly exempt all life-saving medicines from GST”…says Dr Rajesh Jain, Chairman, CII National Committee on Biotechnology & Joint MD, Panacea Biotec Ltd. He talks about his expectations from the Union Budget 2012-13 for R&D segment, pharma SMEs, among others.

Chandreyee Bhaumik

Dr Rajesh Jain


Government should consider exempting all products from

sales tax and excise duty that are specifi cally used for paediatric

purposes (for all children up to the age of 12 years)

Investment in upgrading quality of infrastructure and

training and development of people should also be given

200 per cent weighted tax deduction for pharma and

biotech sector

Should there be a separate Budget for the pharma/biotech industry?If done, it will be very helpful to ensure cost-eff ective

availability of international quality medicines with skilled and

well-trained work force in our sector. On top my expectations

from the proposed Finance Budget are as follows:

Goods and Services Tax (GST)

Th e likely implementation of GST will be watched closely by

the pharma industry as the total tax rate might go up thereby

make medicines costlier.

To ensure continued availability of medicines, government

must uniformly exempt all life-saving medicines from GST.

Tax-free Zone

Th e benefi ts granted to units set up in tax-free zones should be

continued under GST.

Excise

Considering the long-term benefi ts of R&D to the economy

at large, all excisable goods used for R&D purposes, should be

exempted from Central Excise Duty as also import of all capital

goods, raw materials, consumables, and reference standards for

R&D purposes must be fully exempted from customs duty and

other related duties.

Grants & loans

Government should encourage research and product

development activities by off ering grants and soft loans at zero

interest in much bigger scale and liberal manner than today.

Registration expenses

A weighted deduction of twice the expenditure on

scientifi c research incurred by a company is allowed. With

increasing volume of exports all over the world, our companies

need to invest substantial amounts in registration of products

overseas. Hence, expenditure eligible for weighted deduction

should also include expenditure on product registration in

foreign countries and consultants’ fees for patent/product

registration overseas.

Land & Building

At present, weighted deduction is not available towards land

and building. However, several leading companies carry out the

research at the locations exclusively designated for the purpose.

Th is requires infusion of huge funds on purchase of land and

on construction of buildings especially designed for research.

Th erefore, it is imperative that such companies are also granted

the weighted deduction on the expenditure incurred on land

and building.

([email protected])

Special Focus: Roundtable


Will the Union Budget 2012 be SME friendly?Apart from contributing to exports and manufacturing output, pharma Small and Medium Enterprises (SMEs) provide employment opportunities in rural areas. Will this Union Budget offer positive incentives for SMEs?

SMEs form a crucial part of the pharma industry. However, even today the primary challenges that they face point towards lack of funds. In this scenario, tax incentives in any form will be a blessing for the enterprises.

Editorial take

Dr Ajit DangiPresident & CEO,

Danssen Consulting

Since pharma SMEs contribute to

over 35 per cent of the industry’s total

turnover, they play an important role not

only in nation’s economy but in making

medicines available at aff ordable prices

as well as employment generation.

While Union Budget has limitations

in resolving some of these issues, the

least Government can do is to provide

a consistent policy environment so as to

plan the business for longer term rather

than tinkering with taxes and duties

and off er SOPs to balance the budget. It

now appears almost certain that both

Goods and Services Tax (GST) and

Direct Tax Code (DTC), which were

announced, are unlikely to be made

operational in April this year, as promised

earlier. Rationalisation of the excise duty

for raw materials and fi nished product

with abatement increased to 45 per cent

will benefi t the industry. Also, the SMEs

in the bulk drug industry need special

attention as cheaper Chinese imports

have virtually brought this industry on

the brink of closure.

Chandreyee Bhaumik

Hitesh GajariaManaging Partner, KPMG

Th ere are many expectations from the

forthcoming Union Budget towards

incentivising this sector. Th e existing

provisions do not provide any benefi t

for units engaged in contract R&D.

Th e Government could provide

certain specifi c tax holidays to SMEs

engaged in contract R&D and other

manufacturing activities. Th e current

low ceiling for tax audit of ` 60 lakh

for business undertakings could be

increased to at least ̀ 1 crore. Currently,

CENVAT Credit is available where

manufacturing is undertaken by the

brand owner itself. Many SMEs are

engaged in job work arrangements

with large pharmaceuticals companies.

Th e government could extend rules

relating to CENVAT credit to such

arrangements, which will in turn reduce

the cost of the product.

It is expected that the government

should promote an encouraging

environment for growth for this sector

by keeping stable policies and by

making favourable tax amendments.

T S Jaishankar Chairman, Confederation of Indian

Pharmaceutical Industry (CIPI)

With every Budget the taxes are on

constant rise. Th us, it should be noted

that if the government is not able to

reduce the tax it should not increase

it either. Th e tax should be allowed to

be stable. One must not forget that

SMEs are important as they form the

backbone of the pharma industry. Th ey

should be given long term incentives,

investment allowance, and many such

related benefi ts. It might not have an

immediate eff ect but they will help in the

long term. Th is will help in developing

manufacturing competitiveness.

It is already a buzz that this Budget

will witness reduction in the tax of the

diesel vehicles. But the government

should not forget that this is also an

important industry. With infl ation

catching up most of the hospitals do

not have the stock of the life-saving

drugs. Th erefore, there should be

special incentives provided so that

there is fl exibility in the pricing of the

drugs. Th is will increase the supply

of drugs.


IKA, a German company by origin,

has been present in the Indian

market since 1999. Looking at the

rate at which the pharmaceutical

sector was growing in India, IKA decided

to explore the opportunities that the

Indian market has to off er. It set up its

manufacturing plant in Bengaluru, India

in 2009. “As a company we felt that

the Indian market was doing very well.

We also noticed the gradual growth of

business in India and so we decided to set

up a manufacturing plant here. We chose

to enter the Indian market also because

we wanted to provide our support as well

as services to the Indian market that was

welcoming us and our products and also

provide support to our distributors in

India,” explains Suren Dixit, Managing

Director, IKA India Pvt Ltd.

The growth storyTh e Indian market has been one of the

biggest markets along with China over

the last 10 years. Th ough IKA did not

have a facility in India its products were

being sold in the Indian market for over

a decade. “We felt that the Indian market

is growing. Th e cost factor is high in the

Asian region and so to save on capital

spent in transporting goods from one

country to another we thought that

having a manufacturing unit in India

would be a good idea. We make sure all

the quality standards are met as per the

policies of our German manufacturing

facility,” explains Dixit.

Th e facility of IKA is an assembly

line unit; all parts of the machines are

imported from their other centres and

are assembled in India, and are then

sent back to various parts of the world

according to the requirements. “We

have not done much in the machines

aspect as we do not have people and

land in India. We are hiring people

and training them as well but it would

take time to bring them to our facility

in India as the training takes place

in Germany. What we do in India is

import parts from all over the world and

assemble them. About 50 per cent of the

assembled products are sent to Germany,

US and Europe and the rest is used in

India to meet the requirements of the

industry here,” informs Dixit.

Other geographical locationsFive years prior to setting up the facility

in India, IKA set up a facility in China.

Today, there are approximately 250

people working in the unit in China,

where IKA has set up a huge laboratory

production facility. Once the China

facility was constructed, IKA set up

a facility in Malaysia to manufacture

process machinery, which today takes

care of most of the requirement of IKA.

Th e facility in India has been set up over

35, 000 sq ft of land and has an application

lab, sales team and regional managers in

each region. “We are also in the process

of setting up a calibration laboratory and

are setting our roots fi rmly in India. Out

of our complete product portfolio, few of

them are manufactured in India and few in

other countries. Overall, we are present in

eight countries - for us the manufacturing

of the machines that we assemble and sell

to our Indian clients are manufactured by

our facility in Malaysia. We have facilities

in Germany, the mother country, and a

facility in the US, Belgium, China - where

we have three units, Malaysia, India and

Japan,” says Dixit.

High quality is maintained not just in

the products that are manufactured in India

but also in all the other units of IKA. To

ensure safe and high quality products IKA

is ISO 9001 and ISO 17 027 certifi ed.

Challenges facedTh ere are cultural and commercial

IKA India Pvt Ltd, a part of 100-year-old German company, set up its fi rst assembling unit in the country in 2009. Since then it has been bringing unique technologies to the country and leveraging on the Indian advantage.

Capitalising on the India advantage

Jasleen Kaur Batra

Phot

o: S

hrik

anth

Facility Visit: IKA India Pvt Ltd

Th e assembly line Orbital shaker

IKA India Pvt Ltd


challenges that one needs to face with

every new set up. As IKA has entered the

Indian pharma industry there is one major

challenge it is facing. “Our main challenge

was brand equity. Every international

player has been in the country for the past

20 years. Th e Indian population today

is very well educated and has in depth

knowledge of the market. So having a

German product holds no value today. Th e

diff erences are reducing and one needs to

give value for money. We are enhancing

our service capabilities, our calibration

support, sales support and are investing

in marketing. We are participating in

seminars, symposiums etc as we need to

create a brand. We are also redoing our

website for IKA, as web is a growing

space today,” explains Dixit. Adding to

this he says, “Th e Indian market is price

sensitive. As of now, costumers expect a

lot and try to push as much as possible to

get the maximum in the most economical

price. So, we did have to mend our

ways to meet the demands and expectations

of the competitive Indian market.

What we do is try to sell our products

in bulk as it helps us gain our revenues

as well.”

As a company, IKA tries to provide price

reduction to its costumers and dealers. “We

want to set our foot in India; hence, we are

looking at selling more products and want

to create a population of IKA products in

India. Today, we are above the local prices

and are trying to be a little below the

international prices,” informs Dixit.

USP of the companyIKA is one of the leading companies in

pharma in the world today as it is present in

the spaces of R&D, laboratory and producing

products in pilot as well as production scale.

“We are an instrumentation company and

are known for homogenisers. We make

a wide range of homogenisers that cater

to all requirements. What we do is create

software and machines that are capable

of mixing elements such as liquid to

liquid as well as liquid to solid in all sizes.

We provide scaling up options to companies,

as we have the technology to mix quantity

as small as 50 litre to 2,000 litre or more.

Th ere can be companies who would mix

such elements in 50 litre and few in 5,000

but the numbers of companies providing

mixing technologies for scale up projects are

very rare, and that is where our expertise in

the industry comes into place,” says Dixit.

“Our USP lies in going from laboratory

to process and having total inhouse

international validated solutions right

from R&D to the production fl oor. We

are heading towards further refi ning this

with a lot of technical support, sales and

marketing support along with a strong

service support,” says Dixit.

What’s in store?IKA has plans of expansion as well as

launching new products to explore the

various options that India has to off er.

“Th e future is almost endless. In India, we

have a strong R&D team, a calibration

laboratory, various assembly units and

QA and QC labs. We plan to explore

these verticals and make the most of it.

We are also in the process of setting up

offi ces and showrooms in all the cities

in India. In the future, we would be

defi nitely focussing on brand equity,”

informs Dixit. Elaborating on the future

plans of IKA he says, “In future, setting up

a process factory is also on the cards and

so is developing new products. But there

is time for all that to happen. What we

are doing in the near future is launching a

whole new range of products, which will

give IKA a leap in terms of the products

it has. Th e products will be launched in

June. A few products with an upgradation

of the products available currently and a

few would be new according to the trends

in the pharma.”

Over the years, IKA has invested

a huge amount of capital and would

not shy away from doing the same in

future as its main motive is to provide its

products and services to as many companies

as possible.

([email protected])

41

Suren DixitManaging Director, IKA India Pvt Ltd

Our USP lies in going from laboratory to process and having total inhouse international validated solutions right from R&D to the production fl oor.

The facility in India has been

set up over 35, 000 sq ft of land and has an application lab, sales

team and regional managers in each

region.

Testing of electronic contact thermometer ETS-D5

Dear Reader,

‘Modern Pharmaceuticals’ solicits original, well-written, application-oriented, unpublished articles that

reflect your valuable experience and expertise in the pharmaceutical industry.

You can send us Technical Articles, Case Studies and Product Write-ups. The length of the article should not

exceed 1,500 words, while that of a product write-up should not exceed 100 words.

The articles should preferably reach us in soft copy (either E-mail or a CD). The text should be in

MS Word format and images in 300 DPI resolution & JPG format.

The final decision regarding the selection and publication of the articles shall rest solely with

‘Modern Pharmaceuticals’. Authors whose articles are published will be sent a complimentary copy of that

particular edition.

Published by Infomedia 18 Ltd, ‘Modern Pharmaceuticals’ is one of the leading monthly magazines

exclusively meant for producers and user fraternities of the pharmaceutical industry. Well supported

by a national readership of over 80,000 and our strong network of 26 branch offices across India, this

magazine reaches out to key decision makers among the Indian manufacturers of pharma products,

machinery and allied sectors. Brought out in association with Hong Kong-based Ringier Trade Media Ltd

(one of the world’s largest trade publishing houses with more than 200 special interest titles and offices in

every major country), it ensures that advertisers are able to promote their products and services across the

globe at no extra cost.

So get going and rush your articles, write-ups, etc…

Thanking you,

Yours sincerely,

An invite that rewards as well...

Manas BastiaSenior Editor

Infomedia 18 Limited‘A’ Wing, Ruby House,J K Sawant Marg, Dadar (W)Mumbai 400 028 India

T +91 22 3024 5000F +91 22 3003 4499E [email protected] www.infomedia18.in

D +91 22 3003 4669


SMEs growth story Withering tales! .................................................................44

Role of bankers and governmentAbout time to have a synergistic relation .............................46

SMEs in South India Need for government reforms .............................................48

SMEs in spotlightWaiting for the right push ...................................................50

Interface Jagdeep SinghSecretary-General, SME Pharma Industries Confederation, India (SPIC) ...........................................................................52

RoundtableAre the current government schemes for SMEs satisfactory? ..................................................................54

Th yroid cancer therapeutics marketVictim of weak competition ................................................55

Case Study - Fighting counterfeitsJust an SMS away! ..............................................................56

Insight & Outlook

Pharma SMEs


During the 1960s, the Indian

pharma market was heavily

dominated by multinationals,

which aff ected the price of

medicines. However, during the 1970s and

80s we saw a slow entry of Indian companies

in the market. “With encouragement from

the government Indian companies started

penetrating the market and during 70s and

80s we saw several small scale companies

and SMEs coming into the picture,”

refl ects G D Chhibber, Chairman, Mcneil

and Argus Pharmaceuticals Ltd. Over

a period of time, many SMEs of yester

years have become national companies and

by hard work and their entrepreneurial

abilities, many have grown to be large

pharma companies with manufacturing

units in India and abroad. At present, there

are around 8,000 pharma companies in

the SME sector in India. Th ese SMEs laid

stress on quality and provided medicine

at aff ordable prices. Many of the MNCs

slowly used the services of SMEs in India

to manufacture their product. “With its

low cost and high quality, pharma products

of the SMEs have made its presence felt

both in domestic and overseas market, thus

enabling them to conquer the market,” says

Daara Patel, Secretary General, IDMA.

Th ere were various factors that had

propelled the infl ux of SMEs in the pharma

market. First, the initiative was taken by

the government to give Indian companies

at that time the opportunity to enter the

market. “In the beginning government was

the biggest buyer of medicines produced

by the SMEs,” informs Chhibber. Second,

the advent of revised Schedule M around

the turn of the 21st century triggered the

modernisation of SME pharmaceutical

plants. Although the SMEs had to

undergo fi nancial hurdles, many of them

have overcome the same and have created

pharmaceutical plants of good standards.

“Also, with the maturing of SMEs into

Schedule M-compliant companies, more

and more SMEs are becoming WHO-

GMP compliant units. It is estimated that

there are over 1,000 SMEs, which will

be WHO-GMP certifi ed by the end of

2012,” believes Patel.

The present scenarioIt has been over a decade that the pharma

market has been witnessing declining

numbers of SMEs entering the market.

“Th ere are hardly any SMEs that have

entered the market since the past fi ve

years. Instead, we are seeing the closure of

existing SSI and SME units in pharma,”

says Chhibber. Patel adds, “Compared

to the scenario witnessed in the 80s and

90s, there is hardly any growth of SMEs

in the pharma industry. Although the

Titash Roy Choudhury

Insight & Outlook: SMEs growth story

The SMEs in general, and pharma SMEs in particular, are considered the ‘growth engine’ of Indian economy. But since the past few years we have not seen many SMEs coming up in the pharma sector, which makes one wonder how something once considered the backbone of the industry is degenerating. We look at the initial stages of growth and how the scenario changed so drastically.

Withering tales!

SMEs growth story


pharma SME market is very large and

has tremendous potential, it is yet to be

tapped to its full potential.” Th ere are

various reasons that have worked towards

creating an environment that was not

conducive for new SMEs to enter. For

instance, the revised GMP norms that led

to the closure of many SSIs as they refused

to modify their manufacturing practices.

One of the main reasons why the SMEs

were not able to comply with Schedule

M norms was their perennial fi nancial

problems. “Th e profi tability of many of the

surviving units is not that attractive and

the credit availability to them is restricted

as the banks and other funding agencies do

not lend them easily. Most of the SMEs

are also not getting due share of tender

business of various government agencies

and establishments, as many governmental

organisations have stringent clauses that

keep SMEs from participating in the

tendering processes and bulk supplies,”

informs Patel.

Th e Indian pharma market has also

become extremely competitive. However,

many SMEs have started looking beyond

regions to supply nationally and even to

international markets. SMEs are now

participating in contract research, clinical

trials and biologicals, which are said to

have a good scope in the future. Also, few

decisions of the government made their

survival diffi cult. “Initially any company

that got the licence for manufacturing could

supply products to the government. But

since last 10 years from when government

had put a turnover clause, we have seen a

decline in the growth of SMEs in pharma.

Th e government decided that a company

with a particular turnover, which varied in

diff erent states, can supply medicine to the

government. And this decision according

to me is an unjustifi ed action taken by the

government,” believes Chhibber.

Challenges faced and measures requiredTh e contribution of SMEs to the economy

of any country is indispensable and for a

developing country such as ours, SME plays

an even greater role. “With the coming up

of any new SME it helps in increasing the

employment of a country, not only directly

but also indirectly and employment

generation directly aff ects the economy of

the country,” remarks Chhibber. However,

this sector is facing several challenges that

needs to be addressed immediately to

mend the present situation.

Th e major challenges include

organisational costs with limited resources

and their ability to retain capable and

trained employees, and at the same time

hiring professionals. “An SME’s continued

ability to market products while facing

fi nancial and technological challenges will

determine its survival. Th e limitations and

problems in raising funds as most banks tend

to be biased with cumbersome procedures/

collaterals, lack of venture capitalists,

etc,” says Patel. While Chhibber believes

that government should provide more

incentives to the SMEs and such clauses as

the turnover of any company deciding the

supplying factor for medicines should also

be mended. “Th ere is an increasing access to

fi nances for SMEs, thanks to government

policies. Of course, more needs to be done

by the government to ensure availability of

fi nance to the SME sector without much

hassle,” believes Patel.

Various steps have been proposed,

which if followed can change the slow

growth rate. SMEs should tap the small

towns and rural market. In today’s

environment, synergy approaches are

very important and benefi cial to all

partners. Also, partnering with bigger

companies can benefi t the SMEs and

make their survival easier. “SMEs can

engage in contract manufacturing

and provide quality products to these

large enterprises. Th ey can also do

regional marketing for large enterprises.

And in turn, these large enterprises

can encourage SMEs to grow with

their expertise so that they can get

continued quality support from them,”

suggests Patel.

Another avenue for SMEs would be

co-marketing. Pharmaceutical marketing

in India is a highly resource intensive

activity and many SMEs are regionally

well established in marketing activities.

“Many large pharma companies and

even foreign companies are eager to tie-

up with SMEs to utilise their local fi eld

force for marketing activities. Th e benefi t

of obtaining high quality and well-

researched marketing aids for product

promotion from the big companies and

foreign partners will defi nitely go in

favour of the SMEs and help them in

improving the market support of their

local products,” informs Patel.

Patel further adds continuous eff orts

are also made by organisations, such

as IDMA, who have approached the

Planning Commission to seriously

consider a separate scheme for all SME

units in the Indian pharmaceutical

industry, to enable their rapid growth

and development into world-class

manufacturing units.

([email protected])

G D ChhibberChairman, Mcneil and Argus Pharmaceuticals Ltd

There are hardly any SMEs that have entered the market since the past fi ve years. Instead, we are seeing the closure of existing SSI and SME units in pharma.

Daara PatelSecretary General, IDMA

The profi tability of many of the surviving units is not that attractive and the credit availability to them is restricted as the banks and other funding agencies do not lend them easily.


Insight & Outlook: Role of bankers and government

The pharma industry is growing

exponentially. “Enormous

opportunities are provided to

the SMEs through not only

globalisation, but also by the domestic

market, which is growing at a rate of over

15 per cent,” says T S Jaishankar, Chairman,

Confederation of Indian Pharmaceutical

Industry (CIPI). Th ere have been few

schemes by the Indian government, but

almost two decades after we are seeing

how this sector is struggling to survive.

“Competition from international generic

players is increasing. MNCs are also trying

to capitalise on India’s status as one of

the fastest growing emerging markets

by formulating country-specifi c pricing

and marketing strategies. Big pharma

companies are launching drugs and vaccines

in India at substantially low prices than

their home countries. Th is trend is going

to change the scenario of SME segment.

Hence, it is time for the government to

ensure that such activities are restricted to

encourage SME. Otherwise it is going to

be a game of bigger companies and small

companies will be compelled to wind out

their workshop,” believes Bodh Raj Sikri,

Co-Chairman, Federation of Pharma

Entrepreneurs (FOPE).

Analysing the government schemesIt would be unfair to say that the government

has not introduced schemes for the SMEs.

Several schemes are developed to support

SMEs. Small companies are increasingly

facing tough business environment due

to marketing and regulatory constraints,

pressure from buyers in regards to high

eligibility barriers, and also from suppliers

as SMEs cannot negotiate prices through

bulk purchase resulting in high procurement

costs. “SMEs are increasingly looking atthe

government for support for upgrading

manufacturing technology, brand promotion

and marketing to enhance domestic sales and

exports. Given the huge business opportunity

available for contract manufacturing, SMEs

need to have capabilities that comply with

manufacturing standards such as GMP,

WHO to be able to capture this. Th is

requires liberal funding from government

along with fi nancial incentives. Lack of

support from select banks authorised by the

government to issue the incentives has also

aff ected the free fl ow of funds allotted under

this scheme to SMEs,” informs Sikri. Th us,

there are certain schemes in favour of SME

but implementation of such schemes at a

later time when actually needed has become

a futile exercise. “Moratorium should also be

for a longer period and the rate of interest

should be at par with Chinese pattern, which

is around 6 per cent. China has converted

their weakness into strength, ie population,

by giving them ample opportunities to

become small industrialists, whereas in

India common man is deprived of such an

opportunity,” avers Sikri.

Bank’s role All banks in India have a mandate by RBI

to help the SMEs with adequate funds.

“Banks are looking positively towards

funding the SME sector in India. And for

the pharma sector we have been funding

various companies in locations such as

Dehradun, Hyderabad or Ahmedabad and

helping them in setting up a new unit or

expanding their present services,” informs

Ramesh Dharmaji, Chief General Manager,

Small Industries Development Bank of

The Small and Medium Enterprises (SME) sector requires government and fi nancial support for having an impactful existence in the competitive market for any industry. The government of India has launched various schemes along with fi nancial institutions, but the lack of implementation is hindering the growth.

About time to have a


synergistic relation

Role of bankers and government


India, (SIDBI). Th e pharma sector has been

undergoing modernisation and changes

such as gaining WHO-GMP certifi cation

and upgradation under Schedule M, and for

most of these changes non-asset creating

funding is required. He adds, “Under this

scenario, SIDBI has come out with a scheme

few years back titled ‘Growth Capital

Equity Assistance’ scheme under which

intangibles such as marketing, branding,

quality improvement and R&D initiatives,

improving technical know-how and others,

are covered. Th is scheme has received good

response from the companies and will help

the pharma companies in the coming years

to meet the global requirement without

fi nancial hassles.”

“Too many guidelines are at times

creating bottlenecks in establishing

new SMEs, particularly when young

entrepreneur wants to start a unit,”

believes Sikri.

At present, there are various fi nancing

options for pharma industry such as Venture

Capital, Private Equity, Initial Public

Off ering, debt funding from fi nancial

institutions and banks public funding.

Some of the other schemes available at

present are Credit Linked Capital Subsidy

Scheme, which was launched in 2001 by the

Government of India and has been revised

in 2005. Under this fi nancing scheme,

SMEs can avail a loan of up to ` 1 crore.

It involves a subsidy rate of 15 per cent,

which is calculated on the purchase price of

plant or machinery. Th e other scheme is the

Credit Guarantee Scheme launched by the

Government of India to make bank credit

available to SMEs without any collaterals or

third party guarantees involved. Th e basic

idea of this scheme is to make the lender

give loan primarily on the basis of asset

security. Th ese are some of the government

fi nancial schemes but in India individual

banks also have their own SME schemes,

but what is required at the moment is fi rst a

pharma priority and proper implementation

of the schemes. “Private sector banks also

provide loans for SMEs but against 100

per cent collateral security. Banks consider

pharma as potential investment sector

and are liberal in fi nancing projects,”

says Jaishankar.

Calling for a changeSME is facing lack of support from the

government. “Th ere is a strong need for

these companies to be brought together on

a common platform and to facilitate co-

ordination among them,” says Sikri. Th e

tender clause of government needs to be

readdressed since the situation has changed

drastically over the years. Tender business of

government institutions should be preferably

routed through SME pharma companies

only. Th ey will be able to off er more

competitive rates than organised companies

or MNCs. “Drugs used for common

ailments should be preferably sourced only

through SME pharma industries. Banks

and fi nancial institutions normally go for

strong credit rating companies to fi nance

them, which falls in the segment of AAA

credit rating. Th ese ratings are normally

done by RBI approved agencies such as

ICRA, Crisil, etc but there is hardly 1 per

cent such companies who qualify for the

AAA rating. Th erefore, while fi nancing

the SME segment, emphasis should be on

the credit worthiness and not only AAA

category,” says Sikri.

At present, the pharma industry

is not considered as a priority sector

lending, whereas education, agriculture

and infrastructure, among others are in

the priority category. “Funding should

be available to the pharma sector at a

special or concession rate after all health

is equally important for the citizens

of our country. Time has come for the

government to include pharma industry

under this policy. Adequate amount of

fi nance through interest subvention on

term loan for technical up gradation of

the plant, including GMP compliance

and getting approvals from overseas

regulatory authorities is required,”

believes Sikri.

([email protected])

T S JaishankarChairman, Confederation of Indian Pharmaceutical Industry (CIPI)

To be considered for eligibility, a long procedure needs to be followed that includes considerable time and money, and several SMEs cannot afford to spend either.

Bodh Raj SikriCo-Chairman, Federation of Pharma Entrepreneurs (FOPE)

Too many guidelines are at times creating bottlenecks in establishing new SMEs, particularly when a young entrepreneur wants to start a unit.

Ramesh DharmajiChief General Manager, Small Industries Development Bank of India, (SIDBI)

Banks are looking positively towards funding the SME sector in India. And for the pharma sector SIDBI is funding various companies and helping them in setting up a new unit or expanding their present services.


Insight & Outlook: SMEs in South India

The Indian pharmaceutical

industry has expanded

enormously over the decade.

Today, there are about 250 large

units that control 70 per cent of the pharma

market with market leader holding nearly

7 per cent of the market share and about

8,000 small scale units. Th ese together form

the core of the pharmaceutical industry

in India. Previously, the Indian pharma

market was known for producing generic

market but today it has entered all possible

areas. Th e pharma and biotech companies

in India today produce a complete range

of products and have entered every stage

of manufacturing.

ChallengesSMEs today have challenges in various

forms - land being one of them.

“Getting a piece of land at a good location

and at an aff ordable cost is the biggest

challenge today. Th ere are a number of

pharma and biotech companies that

have come up lately. Hence, space has

become a problem. Only an MNC

or a big pharma company can aff ord

to acquire land in the city. Th e rest

need to go to the outskirts of the city,”

avers Mohideen Kamil, Managing

Director, Concern Pharma. Another

challenge that is connected with

land is the regular supply of water and

electricity. “As we are a few kilometers

away from the city there is considerabe

problem that we face in terms of light and

water. Th ere are no street lights on the road

and no water supply. Th e biggest challenge

is lack of infrastructure and adding to this

there are regular power cuts, which slow

down the process of manufacturing of

products,” informs Th ankachan Th omas,

Director, Navagen Products Pvt Ltd.

Getting the required capital to set up

a unit with high quality instruments and

a team of experts takes a huge amount of

investment, which is a challenge. “Th ere are

various MNCs entering India today and

so the market has grown drastically over a

short span of time. Th is has also increased

the level of competition within the industry.

One of the problems that SMEs face and

MNCs do not is that of capital. For an

MNC it is very easy to get a fi nancial partner

but for a SME it gets extremely

diffi cult to convince companies to invest,”

explains Th omas.

Acquiring labour at the right cost is

another problem that is faced by the

SME sector in India. “Th e shortage of

labour is an issue we face in Karnataka today.

Increasing construction work is one of the

reasons for this shortage. Th e frequency of

turnover of labour puts the SME units into

a standstill. Being in the pharma sector, we

have the disadvantage of location as most

of the pharma industry to whom we cater

to are either in Western or Northern part

of India. Th is adds up to increasing logistic

cost and many times we lose to local

competitors. SME faces lot of challenges

within and outside the industry. To set up

an SME unit and surviving thereafter, lot

of support from the big players is essential,”

remarks Th omas.

Further, gaining trust and building

a brand takes ample of time and work;

SMEs have to be patient and hang in there

amidst not too favourable conditions. “A

small set up company does not just have

to undergo all the above-mentioned

challenges but also has to struggle to make

a name for itself and assure people that the

In the early 70s, Small and Medium Enterprises (SME) were on the rise in India. But off late those falling under the biotech and the pharma industries have withered away due to lack of government support and infrastructure.

Jasleen Kaur Batra

SMEs in South India


project would meet the desired quality.

Because of a small set up, convincing

companies about the strengths that we

have as an organisation becomes a task,”

says Th omas.

Government supportTh e Indian pharma sector is growing at

a rate of 8-9 per cent and it is expected

that in the coming years this rate will

continue to increase. To accommodate

this large small scale industry and to

ensure that it is functioning in a good

manner it is important for the government

to step forward and come up with a few

policies that would ease out the burden of

the SME sector to ensure a speedy growth

and it does not saturate and die away. To

ensure this, the government needs to come

up with a few reforms as well as policies

for the SME sector in totality.

Expressing his views on the various

areas in which the

Government of

India needs to create

reforms for the SME

sector Alok Chaudhri,

Partner, Techno

Remedies, says, “Th e

government seems

to be extremely

indecisive when it

comes to taking policy

and reform decisions

for SMEs. Th ere

have been a number

of policies that the

government was in the

process of introducing

such as Credit Linked

Capital Subsidy

Scheme (CLCSS),

but even before it

could be formed it

was withdrawn saying

that the policy was

not apt for the SME

sector of biotech and

pharma industries.

Th e government

needs to stop being so

indecisive and needs to

pay attention on the various challenges that

an SME faces today and needs to provide

reforms accordingly.”

Stability provisionTh e government has recently come

up with a clause called the turnover

clause. According to this a company

needs to generate revenues of minimum

` 20 crore for one product to be

eligible to enter the tender. Th is clause

has worked against the SME sector

instead of working for it. Adding to this

Chaudhri says, “Th e government needs

to understand that SMEs do not have

a lot of capital to begin with and so are

not in the position of producing such

turnover. It is hence the responsibility of the

government to provide a few exemptions in

terms of tax and land to ensure that SMEs

grow. Th ey need to increase the excise duty

from ` 1.5 crore to ` 3 crore. Once the

government makes the necessary changes

only then will the SMEs fl ourish.”

Meanwhile, Th e Department of

Pharmaceuticals, Ministry of Chemicals

& Fertilizers of the Government of India

has been taking initiatives to support the

SMEs through various incentives/facilities

such as CLCSS to SME units - this will

help them in upgrading the facility and

identifying approximately 18 SEZs that

would off er infrastructure, market access

and exports. In the future, the government

will set up a fund to promote R&D. Today,

considering the rapid rate at which the

industry is growing, the government too

needs to be updated and provide facilities,

opportunities and policies for the industry

to grow.

([email protected])

Alok ChaudhriPartner, Techno Remedies

It is the responsibility of the government to provide a few exemptions in terms of tax and land to ensure that SMEs grow.

Th ankachan Th omasDirector, Navagen Products Pvt Ltd

The biggest challenge is the lack of infrastructure and regular power cuts, which slow down the process of manufacturing of products.

Case studiesConcern PharmaConcern Pharma is an integrated research-based pharmaceutical company and produces a wide range of quality medicines.

Th e major problem faced by Concern Pharma during its inception was getting license, experienced manpower, capital, getting all the formalities in place for setting up the unit.Investment: ` 75 lakhLocation: ChennaiYears in the industry: 4

Manan HealthcareManan healthcare manufactures oral liquids and external semi solids/liquid preparations. Th e major problem faced by Manan Healthcare was in fi nding authentic machine suppliers and infrastructural problems such as water and electricity.Investment- ` 50 lakhLocation: BengaluruYears in the industry: 2

Navagen Products Pvt LtdNavagen Products Pvt Ltd provides machines and services to pharma companies. Th e problems faced by Navagen Products were getting electricity supply to the plant and fi nding appropriate labour as well as land.Investment- ` 20 lakhLocation: BengaluruYears in the industry: 9


Insight & Outlook: SMEs in spotlight

There are around 7,000 pharma

companies in the SME sector

in India. Out of these, the

ones that have been focussed

in this article include, Fourrts (India)

Laboratories Pvt Ltd, a Chennai-

based company started in 1977 by S V

Veerramani, Chairman & Managing

Director, Fourrts (India) Laboratories

Pvt Ltd with an initial investment of

only ` 2.5 lakh. Avik Pharmaceutical

Pvt Ltd, a Mumbai-based SME started

in 1981 with an investment of ` 88

lakh. “During that time SMEs growth

was high and many new entrepreneurs

were entering the market,” reminds

Anant Th akore, Managing Director,

Avik Pharmaceuticals. Adding to this

Ramesh Arora, Managing Director,

Kwality Pharmaceuticals Pvt Ltd says,

“We started our operations in 1980 with

a meager sum of ` 2 lakh.”

The current scenarioVeerramani points out various factors

that are likely to bring up a number of

winners from this sector in the future.

“Th e advent of revised Schedule M has

triggered the modernisation of SME

pharmaceutical plants. Although the

SMEs had to undergo fi nancial hurdles,

many of them have overcome the same

and have created pharmaceutical plant of

good standards. Th ese plants are likely to

cater to outsourcing in a big way under

contract manufacturing.” He continues,

“Th e SMEs are likely to play an

increasing role in contract manufacturing

to major Indian companies and MNCs.

Compared to metro cities and major

towns in the past, in future the will come

from small towns and rural markets.

Th is is precisely where the SMEs are

operating and they are likely to be in

an advantageous position. Th ere is also

an increasing access to fi nances for

SMEs, thanks to Government policies.”

Veerrammani also adds that more needs

to be done by the Government to ensure

availability of fi nance to the SME sector

without much hassle. Both Th akore and

Arora stresses on the lack of support by

the government. “Th e government has

not been liberal in funding, especially

when it announced the mandatory

upgradation under Schedule M but could

not get the fi nancial support for the same

at that time. Th e fi nancial support of

` 1 crore was extended but at a later stage,

so proper planning and implementation

could not be done. At present, the SMEs

The pharmaceutical sector in India has witnessed a lot of changes, upheavals, trends, and progressed to put the country on a global platform. One such trend that has fuelled the growth further is the emergence of SMEs.


Waiting for theright push

SMEs in spotlight


which are already in the market will

grow though it will be a tough time for

them with increasing prices and stiff

competition from MNCs. One has to be

innovative and it will be the survival of

the fi ttest,” says Th akore.

Business model and growth trajectoryMostly SMEs are family business and

may not have any well-established

business model. “Our company is a close

linked family held company and it has

encountered steady growth over the past

few years. Th ere was some setback faced

due to the entrance of Chinese products in

the market but we have survived that and

today we are growing at a rate of 15 to 20

per cent year-on-year,” informs Th akore.

While when it came to the growth of

the company Th akore points out, “At the

time of establishment Government was

pro-active towards SME growth and

loans were available on easy terms. Every

state had fi nancial institutions and these

state government institutions supported

the industry by giving loan on capital

investment, for equipment etc.” He

elaborates, “For buying any equipment

25 per cent of the price was paid initially

and the remaining 75 per cent could

be paid over the next few years. Land

was also made available by the state

government, while working capital was

given by nationalised banks on acceptable

terms of the entrepreneur and, unlike

today, without any collateral security. All

these factors propelled the establishment

and initial growth of the company.” He

continues, “Getting schemes sanctioned

and fi nancial help was not diffi cult.

It was a smooth process, but yes every

bureaucratic process has some pre-

defi ned procedures and once I had gone

through them and applied. Asfter my

interview I got the necessary help.”

Fourrts has the vision to become

an international pharmaceutical

organisation of repute. “Fourrts’ initial

activities were towards marketing

its products in Tamil Nadu and

neighbouring states from its plant at

Perungudi, Chennai. From the initial

plant at Perungudi in 1977, we built a

GMP compliant plant at Kelambakkam

near Chennai in 1985. From a regional

marketer, we became an all India

company in 1995. Now we are exporting

formulations to more than 30 countries.

Fourrts has grabbed many awards in its

journey of excellence. To name a few,

IDMA Quality Excellence Awards 7

times, outstanding Export Performance

Awards 2 times from Pharmexcil,

Government of India among few,”

informs Veerramani. Arora talks about

how government has been a major

obstacle in the company’s growth path.

“I had taken loan from the public sector

bank. But when it came to help from

government schemes they never got

fulfi lled. Th ere is a subsidy scheme and

we had applied for it which came to us

almost 10 years later. Hence, there are

a lot of bureaucratic hazards in the way

that lengthens the process and makes it

troublesome.” Th e model that they use is

that of marketing their products in the

generics market, mainly outside India.

“At the time when I started my company

there was not much competition since

there was not much of a demand. But

today there is cut-throat demand and

competition making the situation very

challenging. Government has been

implementing new laws and policies but

not supporting them at the same time,”

beleives Arora.

Competition and challenges Th e pharmaceutical industry is under

acute competition from more than

20,000 pharma companies. Th ere

are various challenges towards their

growth. As Arora points out, “Today,

cost is the increasing for everything;

land has become so expensive. Rather

than continuing any unit selling the

land becomes more profi table.

Also, SMEs are always blaming the

government, but to make some defi nitive

changes all SMEs should come together

and collectively try to improve the

situation.” While Veerramani informs

how his company is facing growing

competition, “A major challenge for

SMEs will be from MNCs due to the

signing of WTO agreement by India.

We are planning to overcome the

same by entering in niche segments

where multinationals will not be

operating. We have planned to work

for tie-ups and collaborations with

MNCs in our core segments.” When

asked about their plans of growing

into an MNC themselves Veerramani

replies, “Fourrts has laid the foundation

of a good manufacturing plant,

has a strong national marketing team,

besides exporting to 30 countries. It is

only a question of time for Fourrts to

become an MNC.”

([email protected])

A major challenge for SMEswill be from MNCs due to the signing of WTO agreement

by India.

S V VeerramaniChairman & Managing Director, Fourrts (India) Laboratories Pvt Ltd

Although the SMEs had to undergo fi nancial hurdles, many of them have overcome the same and have created pharmaceutical plant of good standards. These plants are likely to cater to outsourcing in a big way under contract manufacturing.


You have been part of SPIC for more than 6 years now. How has been the journey? I have been the Secretary General of

SME Pharma Industries Confederation

(SPIC) since inception and the journey

has been full of struggle for survival of

industry. SPIC had come up because of

the consequences of changes in law for

pharma SMEs and it has been struggling

over the years for the growth of pharma

SMEs in India.

Elaborate on the evolution of the pharma SME segment in India. In 2005, two important events took place

that shaped the pharma SMEs sector.

Amended Schedule M of Drug Act

was implemented to upgrade pharma

SSI to international levels. Around

300 SSI Units in Maharashtra and 90

in Haryana had to close down. Others

faced major problems since government

provided no technical support

With the objective of higher revenue and

to discourage printing of higher MRP

on labels by companies, government

changed excise modality whereby excise

was levied on MRP (less 40 per cent)

abatement instead of the ex-factory

clearance value, which was the basis

earlier. Owing to anomalies in change

of modality, the burden of excise on SSI

increased manifold rendering it unviable

at a time when they were mandated

up gradation under Schedule M costing

crore of rupees for each unit. Over 70

per cent of production of medicines

migrated to Excise Free Zones (EFZ) of

Himachal and Uttarakhand in existence

since 2003. Not only they evaded the

high burden of excise but became free

to print higher and higher MRP on

labels causing an unprecedented price

rise in medicines. NIPER recorded a

price rise of 326 per cent from EFZ

in 2006. With shifting, 70 per cent

production revenue was lost instead

of a gain as envisaged while changing

the policy.

Th ese issues were taken to the government.

Th e Prime Minister then intervened and

sought recommendations of Economic

Advisory Council, which were approved

but never implemented by the Ministry

of Finance.

What are the challenges faced by the Indian pharma SMEs?Till this day, India is saddled with

unnecessary price rise and loss

of revenue, which is contrary to

stated objectives of the change

in policy.

Further, the excise duty on medicines

that was reduced in 2008 has not brought

production back to non-EFZ, which means

revenue is lost and price rise continues,

while 5,000 pharma SMEs outside EFZ

continue to struggle.

Millions of shopkeepers across the

country are sourcing their brands

from EFZ at MRP of choice and pushing

them through doctors after bribing

them. 5,000 SSI elsewhere in the country

are out of contention as excise on MRP

prevents them to print higher MRPs

as compared to EFZ and cannot bribe

doctors. Th e fact that the consumer

has become a hapless victim is of no

consequence to government because

price rise of medicines was never an

election issue.

With 70 per cent population earning

less than ` 90 per day it is a hopeless

situation. Th ere are reports of people

dying or slipping into poverty owing to

high cost of medicines. Goverment has

been unable to provide any relief even

when the problem is essentially caused by

change of policy.

Insight & Outlook: Interface - Jagdeep Singh

“Pharma SMEs are on the decline, which is a dangerous trend in a country like ours”…says Jagdeep Singh, Secretary General, SME Pharma Industries Confederation India (SPIC). Starting his career in 1979 by setting up a small scale industry unit for injectibles and eyedrops, he has been instrumental in driving the SMEs in pharma sector. He highlights the current state of pharma SMEs in India.


Jagdeep Singh


A plan to cut down prices of medicines

to less than half was submitted to the

government around two years ago. It has

been unable to criticise the plan in several

meetings but large industries/MNCs do

not allow its implementation as it is averse

to any price control. All these facts are

mentioned in the plan and we have been

following up with the same for years now.

How have the Indian pharma SMEs grown over the years?Around 5,000 pharma SMEs in

non-EFZ have not grown over the last

5 years; their sales have declined instead.

Most of those who migrated to EFZ in

2005 and created huge units have become

unviable because they face stiff competition

from each other. Central Drugs Standard

Control Organization (CDSCO) offi cials

have also confi rmed that the highest

number of spurious drugs is produced

from EFZ. Th is happens not only because

they provide 70 per cent production but

because they cut corners on quality owing

to an unhealthy competition. Pharma

SMEs whether in EFZ or outside have

suff ered over the years. And when it

comes to government support to pharma

SMEs it is only on paper despite the fact

that it is the only regulated industry under

price control. Ask any pharma SME

whether it has ever got any support from

the government?

Future of pharma SMEs in India...Pharma SMEs are on the decline, which is

a dangerous trend in a country like ours. If

you go through the Aff ordable Medicines

Plan you can see that only pharma SMEs

are ready to bring down prices. If they are

removed from the scene, which is likely if

the present trend continues, not only prices

of medicines will skyrocket but the capacity

of the country to produce aff ordable drugs

will be lost forever.

Around 25 per cent market has already

been taken over by six MNCs alone.

Government is showing worry but

is unwilling to help SMEs or even

implement consumer-friendly Aff ordable

Priced Quality Medicines Plan submitted

by us, which could be a solution

for both SMEs and consumer in times

to come.

([email protected])

SME classic growth story:One the classic growth stories is that of Torque Pharmaceuticals Pvt Ltd, a pharmaceutical company started in 1956. Th rough its product developments and advertisements the company has grown signifi cantly over the years. Today, it has a varied product portfolio and almost everyone knows about Torex cough syrup. Th is company has seen a phenomenal growth story, which has been possible due to good product development strategies and effi cient advertisement campaigns to reach the masses and make its product well-known.


Th e SME scenario has changed drastically from the time when government pushed the growth to today where

it is not the same. Present government schemes are insuffi cient to meet the demands of SMEs and more eff orts should be taken

to fuel the further growth of this sector.

Are the current government schemes for SMEs satisfactory? Government initiatives have propelled the growth of the SMEs in the pharma sector. The question is, are these schemes, though available in large numbers, satisfactory to meet the need of the SMEs in the country?

Editorial take

V S ChakravarthiManaging Director,

Hi-Tech Pharmaceuticals Pvt Ltd

Th e government schemes are mostly

pro MNCs and the government is

making eff orts to make large and

medium companies and MNCs

grow while the SMEs have taken a

backseat. Th e SMEs in the pharma

sector can easily be termed as the

neglected lot and we are afraid

that we will soon become extinct.

At one point the government in

public forum proclaims its continued

support for the SMEs, while on

the other had all the purchases by

government organisations are from

medium-large and MNCs. During

the initial growth of SMEs in 70s

and 80s government did extend

support towards their growth but

the scenario has changed in the past

few years. Th ere is an urgent need for

government attention that needs to

be paid towards the Indian pharma

SMEs, to help them become MNCs

of tomorrow.

Vinod KalaniChairman, MSME,

Sub-Committee, IDMA

Th e government is not doing what is

required for the sector. Pharmaceutical

sector in India is highly regulated

and SMEs should be given individual

attention. At present, the schemes

and policies of government are

inclined towards large companies

and MNCs. Government should

make a separate task force to look

into pharma SMEs alone and

bring out changes that are more

supportive of this sector. Many causes

are taken up by the government that

are restricting the growth of the

SMEs, like the ` 20 crore turnover

clause or no concession in pricing

for the SMEs or no separate

platform for the SMEs to apply for

any new drug. Subsidies are also

diffi cult to get since there are many

requirements to be fulfi lled. Th ere is

no co-ordination between a scheme

passed and its requirement at that

particular time.

Rohan HedeChairman, SME Pharma

Industries Confederation India

I had applied for CLSS scheme from

the government, but I was not given

the same since the scheme would only

be given to companies having profi ts

during the last 3 years. Th ere was an

overriding clause on the scheme and

even after doing the upgradation under

Schedule M and investing money I did

not get the subsidy. Th e establishment of

EFZs has also aff ected the growth of the

SMEs and especially the ones who were

involved in contract manufacturing, who

hve all shifted to EFZs. Before 2005 my

annual business was about ` 10 crore,

which today has gone down to ` 2 to 3

crore since most of my clients for contract

manufacturing turned to EFZ. In reality,

the changes in government schemes

are all done in behest of the MNCs.

Th e government has been indiff erent

to the growth of the SMEs and if there

are no SMEs the country will loose the

capability to provide aff ordable drugs and

that is a situation we should try to avoid.

Insight & Outlook: Roundtable



The report by GlobalData

provides valuable insights

on the pipeline products

within the global thyroid

cancer therapeutics sector. It is formed

using data and information sourced

from proprietary databases, primary and

secondary research and inhouse analysis

by GlobalData’s team of industry experts.

Th e report also provides insights on the

prevalent competitive landscape and the

emerging players expected to alter the

thyroid cancer market signifi cantly and

change the positioning of the current

market leaders.

Forecast: A steep growth for thyroid cancer therapeutics marketGlobalData estimates that the thyroid

cancer market was worth $ 54.8 million

in 2010. Th e major reason for the limited

market revenues in 2010 was the lack

of approved drugs for the treatment of

thyroid cancer.

However, Zactima (vandetanib) was

approved by the US Food and Drug

Administration (USFDA) on April 6,

2011 for the treatment of metastatic

Medullary Th yroid Cancer (MTC). It

is the fi rst approved drug for thyroid

cancer. It is registered in Europe as well.

Also, doxorubicin is used as an off -label

drug for treating patients with anaplastic

thyroid cancer. Th e high growth forecast

for the thyroid cancer therapeutics market

is primarily attributed to the infl uence of

recently approved drug Zactima, and the

strong pipeline.

Th e upcoming three pipeline molecules

in Phase III stage of development, and

Zactima, are expected to take a steep rise

in the market in the next seven years.

Overall, between 2010 and 2017, the

thyroid cancer market is expected to

grow at a Compounded Annual Growth

Rate (CAGR) of 27.3 per cent, to reach

$ 297.5 million by 2017.

Strong pipeline candidates: Intense future competitionGlobalData found that the pipeline of the

thyroid cancer market is strong, as there

are 26 molecules in diff erent stages of

development. Th ere are three promising

molecules in Phase III stage.

Th ese drugs are expected to get

approved in the next seven years.

Zybrestat (combretastatin A4 phosphate)

and XL184 have been granted an orphan

drug status by the FDA.

Th ese new molecules (Zybrestat and

XL-184) with novel mechanisms of

action are expected to meet the current

unmet needs and give physicians a better

choice for the treatment of thyroid

cancer. Once these molecules get

approved they are expected to intensify

competition in the market. Hence,

the global thyroid cancer therapeutics

market is heading towards a strong

competitive landscape.

Weak competitionGlobalData found that the current

competition in the thyroid cancer

market is weak, as the market has just

one drug (Zactima), which was recently

approved for the treatment of metastatic

MTC, and the rest are off -label

drugs used for other types of thyroid

cancer. Th ese off -label drugs are aimed

at managing the conditions that

contribute to thyroid cancer. Th ere is

an open space for companies to enter

into this market and take substantial

market share.

High unmet needsTh e thyroid cancer market poses high

unmet needs due to the moderate effi cacy

and safety of the available treatment for

thyroid cancer, however, the recently

approved drug Zactima satisfi es some

unmet needs. To fulfi ll the remaning

unmet needs, pipeline drugs will need to

overcome the effi cacy and safety concerns

of the current products.

Courtesy: GlobalData

The following analysis is an essential source of information and study on the global thyroid cancer therapeutics market. The report identifi es the key trends shaping and driving the global thyroid cancer therapeutics market.

Victim of weak competition

350

300

250

200

150

100

50

02005 2010 2017

CAGR (2005-2010): 6.4%

Rev

enues

($ m

illi

on

)

CAGR (2010-2017): 27.3%

Th yroid cancer therapeutics market, global, revenue and forecast ($ million), 2005-2017

Source: GlobalData, GLOBOCAN 2008,The Lancet Oncology, New England Journal of Medicine, Annals of Oncology, GlobalDataEpidemiology-based Market Forecasting Model, Primary Research Interviews, Key Opinion Leader (KOL) Interviews, ProductPrescribing Information, Company Reports

Insight & Outlook: Thyroid cancer therapeutics market


The incidences of duplication

of drugs have increased and

one might never know when

they are being cheated with a

spurious drug. According to a report by

Th e Associated Chambers of Commerce

and Industry of India (ASSOCHAM), a

staggering 20-30 per cent of drugs available

in the market are spurious. Th e impact

of selling these in the market is huge; it

aff ects not only the costumer but also the

pharma industry. “Bringing out a drug to

the market involves a lot of revenue right

from R&D, manufacturing, marketing,

branding and more. When a company

faces competition from a spurious drug,

the entire image of the company as well

as the brand suff ers. Th ere is a huge loss

in terms of revenue and brand,” explains

Rajesh Varrier, Founder & Chief Executive

Offi cer, Activecubes. Adding to this, he

says, “To try and lessen the occurrence of

counterfeit drugs we have made a product

that might not completely remove spurious

drugs from the market but the numbers

will defi nitely reduce.”

The technologyOver the years the government as well as the

pharmaceutical industry has proactively done

considerable work to check the duplication

of drugs. Th e government has appointed a

Drug Development Offi cer to check the

drugs that are being made and exported.

Pharma industry too has adopted measures

such as sophisticated packaging that would

reduce the chance of duplication of drugs

as the people who perform such acts lack

fi nance to have a large manufacturing and

packaging unit to themselves.

In the initiative to reduce counterfeit

drugs in the market Activecubes, an

analytical company, has formed an SMS

software, which will educate the costumers

and provide them the knowledge on whether

they have purchased a fake or a genuine

drug. Explaining the technology Varrier says,

“Counterfeit drugs are a serious problem in

India and other developing nations. Th is not

only presents a signifi cant health hazard but

also revenue loss; not to mention the hit the

brand takes. In order to reduce the menace

of spurious drugs, it is important to be able

to track the drug at the level of a strip or

a vial. Bar coding them at the box level is

really of little impact. Hence, we have come

up with a unique identifi cation number for

every strip or vial that is manufactured.”

Adding to this technique, he informs,

“Th e unique identifi cation number would

be printed on each strip of the drug that a

company manufactures. Th e code is generated

with an algorithm, which is proprietary to us.

So, there is an algorithm that can read the code

and decode it when required. When the drug

goes out to the market, the number goes with

the medicine. Th e customer can then send a

SMS with the code printed on the strip to us

and within three seconds the customer will

receive a message from our end stating that

the drug is genuine. How this will help stop

spurious drugs? A person can duplicate one

strip, but without his knowledge the number

will also get duplicated. A counterfeiter can

try to replicate it, but when we get a message

of an alteration of the code we can check it

and most importantly inform the costumer

that the drug is fake.”

Dual solutionTh ere are two parts to the solution:

Unique Identifi cation Number (UIN) on

strip/vial level: A unique identifi cation

number on every strip of medication is

generated and linked to their database.

Th e numbers are not simulated, hence,

when a customer buys the medication

all he/she does is SMS the code to the

number on the strip. Th e code is received

by the system and it is cross checked in the

database. If it fi nds a match it issues a reply

about the validity of the drug, if a SMS

Insight & Outlook: Case Study - Fighting counterfeits

Counterfeiting of drugs has become one of the major concerns of the pharmaceutical industry. To help reduce the production and sale of such drugs, Activecubes has come forward with a unique SMS technique to help determine the genuineness of the drug.

Just an SMS away!

Jasleen Kaur Batra

Case Study - Fighting counterfeits


with the same code is already received

then the consumer is informed that the

drug is not genuine.

QRCode/2D code: A QRCode/2D

code is also printed on every vial as an

added mechanism for validation of the

authenticity of the strip. Th e customer

needs to download the mobile app once

for free and key in the QR code post,

which the application will communicate

with the database at the backend and

revert with the authenticity of the strip

or vial. QR codes will be an additional

level of security since they are not easy

to replicate.

Growth opportunitiesAlthough there are not many analytical

companies present in India, the

industry defi nitely has a lot of potential.

“Th ere is signifi cant space to grow

and excel in the market abroad. If you

consider the US market - it is mature in

multiple ways. From an industry growth

perspective, US does not have growth

rates like that of India. For instance, if

you consider the top companies is India

one would notice that their growth rate

is anything between 10-30 per cent,

whereas in the US it might be 4-5 per

cent year on year,” says Varrier. Explaining

the analytical market further he said,

“When an industry grows at slow rate

the competition defi nitely gets stiff .

Th e companies want to understand every

bit about the costumers, the buying

pattern, what is selling and what is not.

But the Indian market does not function

in the same manner as the growth rate of

companies is tremendous high. In India,

the question is not about fi nding ways

to understand the costumer better; it is

but to fi nd ways of reaching the market

in the least possible time. Hence, India

is still a few years away from reaching a

state where pharma companies want to

analyse all their data to fi nd ways of doing

better than their competitors.”

However, there a few leaders in the

Indian pharma industry who feel the

need to analyse data to stay a step

ahead. Th e India pharma sector needs

the help of analytics for tackling

spurious drugs, and hence, this

technology has a lot of potential to

turn the industry of counterfeit drugs

upside down.

([email protected])

Rajesh VarrierFounder & Chief Executive Offi cer, Activecubes

In India, the question is not about fi nding ways to understand the costumer better; it is but to fi nd ways of reaching the market in the least possible time.


The US Food and Drug

Administration (USFDA)

defi nes Process Analytical

Technology (PAT) as a

mechanism to create, analyse and

calibrate the drug manufacturing process

through the measurement of certain

parameters called as ‘Critical Process

Parameters’ (CPP). “Th e USFDA

had approved and implemented this

technology a few years ago for production

of medicines in batches. PAT technology

analyses and measures the CPP, which

aff ects the quality of the product. Th us,

in turn this process helps to analyse the

quality of the end product,” says Sumeet

Kad, Analyst, Synovate Healthcare. Th is

process holds more prominence while

manufacturing a generic version of

any Active Pharmaceutical Ingredient

(API), since that requires modifi cations

and certain changes in the composition,

and here in PAT helps to analyse how

certain modifi cations are going to aff ect

the quality of the fi nal drug. “Th e basic

methodology for the process is to test

the critical parameters of the drug being

manufactured while in line without

disrupting the production fl ow. Th e

analyses and the calibration happen on

the line as well. Also the testing is done

subsequently on the production line as

well,” informs Dr Vikram Venkateswaran,

Healthcare and Lifesciences Professional.

“Th is technology analyses each and

every process and helps in determining

the properties of the end product,” says

Arunabha Bhaduri, General Manager

- Process Control Solutions, Rockwell.

According to ARC Research, some of the

leading suppliers of PAT are ABB, Aegis

Analytical, GE, Perkin Elmer, Rockwell

Automation, Siemens and Solvias.

Use of PAT in the pharma industryTh e pharmaceutical drug development

process is a highly regulated mechanism

starting from drug discovery to

commercialistaion. In the traditional

manufacturing line, the drug has to

be taken off the line to be tested. Th is

is a long process and delays the fi nal

manufacturing time. Under PAT, the

drug need not be taken off the line,

instead using the PAT equipment the

drug is monitored and tested for critical

process parameters. Th is is to ensure that

the manufactured drug meets the critical

quality attributes.

“Implementing PAT consists of two

broad categories. Th e fi rst step is to

design the PAT roll out framework. Th is

would depend on the nature of the drug

being manufactured and the process

that is currently running. Th ere are two

critical steps in designing the framework,

deciding what information needs to be

collected to qualify the critical quality

attributes and deciding which stage in

the manufacturing process does one need

to collect that information. Th e second

step involves selecting the right tool for

the analytical process. Th e three main

sets of tools that are an integral part of

any PAT system include: Multivariate

Data Analysis tool - some common

tools are SPSS, SAS, Spotfi re and Excel;

Process Analytical Chemistry tools

such as Bio Sensors, Near Infra Red

Spectroscopy and Raman Spectroscopy;

and Knowledge Management tools - this

can be done through standard MES tools

and Electronic Content management

tools,” informs Dr Venkateswaran.

Advantages of PATTh is technology has been used in other

industries such as petrochemicals, food

processing but in pharmaceuticals it

has received a mixed response. Th is


The

A technology that has proved its importance in other industries is still at a nascent stage in the pharmaceutical sector. Though implemented by regulatory bodies, PAT is yet to enter the pharma market full-fl edged and prove its potential.

Automation Trends: Process Analytical Technology

less exploredopportunities

Process Analytical Technology


technology has several advantages,

which if implemented in this sector,

will give better results. One of the main

advantages of this technology is that in

manufacturing of the drugs, “Th e cycle

times and the production time will be

lowered substantially. Also, the inline

testing will result in lesser changes in

the line, which will fasten turnaround

times,” informs Dr Venkateswaran.

With reduction in production time, the

drugs can also be marketed sooner. “It

reduces the production cycle which in-

turn reduces the marketing time and

gives the company a chance of getting

a drug faster to the market,” says Kad.

Th e second biggest impact area is supply

chain. “With the shortening cycles

of manufacturing, supply chains will

become a closed loop and inventory

planning would be faster and more

accurate. According to research done

in 2009, the implementation of PAT

would create a one-time release of

$ 79 billion, which otherwise is locked

up in inventory due to production

delays,” says Dr Venkateswaran. Th is

technology will also assure the quality

of the fi nal drug. “Th rough PAT, quality

assurance on manufacturing would

be met almost always - 100 per cent

- once the quality parameters are set,”

says Dr Venkateswaran and this will

prevent rejection of batches of drugs

due to quality issues. “Th ere are various

advantages of PAT like, higher through

put, faster time to market, reduction in

manufacturing cost, higher recall and

better output,” sums up Bhaduri.

Challenges in implementationTh e implementation of this technology

has been slow in Indian pharma market

since there are various challenges that

need to be overcome before the market

can fully integrate this technology.

“Th is technology is gradually coming

to India. Th e entry was so late because

Indian pharma market is not technology

driven but controlled more manually.

Th is technology requires an initial

high cost of investment so many

companies have not yet invested in

PAT, but it is going to prove immensely

important for a generic market like

India,” feels Bhaduri. Th us, the biggest

challenge to PAT implementation is cost.

“Not only is it expensive to implement

PAT, it would also require a lot of

modernisation to do the same. Th e current

manufacturing process would not allow

for PAT to be implemented so business

process re-organisation would have to

be done and the manufacturing line re-

assembled. Also, some of our processes

are still manual and paper based, and

PAT requires a relatively high degree of

automation for the best results,” informs

Dr Venkateswaran. To implement this

technology Indian market will also

require trained professionals. “Th e know-

how and technical expertise for the same

is also required and so investment has

to be done in training. Also, the return

on investment is diffi cult to measure,”

says Kad.

Attraction for manyMany global pharmaceutical companies

such as GSK have implemented PAT

at their manufacturing sites including

Ireland, US, UK and Singapore. PAT

has also been implemented by Merck

and Pfi zer. But the absence of a

compulsory mandate has resulted in

many pharma companies ignoring

this process. Th e Indian pharmaceutical

industry is no diff erent. All these

factors have resulted in companies

in India putting this issue on the

back burner.

“For a country such as India, selective

implementation is a better way of

incorporating this technology, where

instead of utilising PAT through the

entire manufacturing process it is

installed for few processes. In that

way, they will understand the nuances

of the technology while the initial

investment will also not be very high,”

suggests Kad.

It is undoubted that this technology

will be helpful for generics market

like India. “It is slated that in the

next 5-6 years PAT would become

a regulatory mandate. Till then,

PAT for the Indian pharmaceuticals

looks like a distant reality,” believes

Dr Venkateswaran.

([email protected])

With the shortening cycles of

manufacturing, supply chains will become a

closed loop and inventory planning would be faster and more

accurate.

Sumeet KadAnalyst, Synovate Healthcare

PAT reduces the production cycle, which in-turn reduces the marketing time and gives the company a chance of getting a drug faster to the market.

Dr Vikram VenkateswaranHealthcare and Lifesciences Professional

According to research done in 2009, the implementation of PAT would create a one-time release of $ 79 billion.


The term carbon neutrality is

gaining widespread recognition.

It has become more recognisable

as companies attempt to

demonstrate their environmental and carbon

management credentials.

Carbon neutrality, or having a net zero

carbon footprint, indicates achieving the

net zero carbon emissions by balancing

the measured amount of carbon released

with an equivalent amount sequestered or

off set, or buying enough carbon credits in

order to make up the diff erence. Th erefore,

it is used in the context of carbon dioxide-

releasing processes, associated with

transportation, energy production, and

industrial processes.

Th us, the carbon neutral concept may

be extended to include other Greenhouse

Gases (GHG) measured in terms of their

carbon dioxide equivalence — the impact

a GHG has on the atmosphere expressed

in the equivalent amount of

CO₂. Further, it can be clarifi ed

that the term ‘climate neutral’ is

used to refl ect the fact that it is

not just carbon dioxide (CO2)

that is driving climate change.

Even though carbon dioxide

is present in huge dimension,

there are also other greenhouse

gases regulated by the Kyoto

Protocol, namely: methane

(CH4), nitrous oxide (N

2O),

hydrofl uorocarbons (HFC),

perfl uorocarbons (PFC) and

sulphur hexafl uoride (SF6).

What is carbon neutral?According to several documents and

reports, carbon neutrality refers to the

completion of the following phases:

Measuring emissions: Measuring carbon

emissions is the essential fi rst step in

eff ecting behaviour change and managing

emissions. According to Shruti Pande,

Clinical Team Lead, Wockhardt Ltd,

“Agencies gathered accurate information

on the greenhouse gas emissions linked to

their energy and electricity use, transport

(including domestic and international air

travel), and waste was sent to landfi ll. Th e

credibility, transparency and reporting

methods used aligned with international

public and private sector carbon

neutrality eff orts.”

Reducing emissions: Reduction

planning is an essential part of the carbon

neutrality process. It involves identifying

opportunities to reduce emissions. Pande

says, “Th e six lead agencies aimed to

reduce the amount of greenhouse gases

they released by putting in place: energy-

effi ciency measures, which included

conducting energy use audits, educating

staff on using less electricity, installing

low-energy lighting systems and more

effi cient heating and cooling systems, and

buying equipment that used less electricity

travel measures, which included creating

workplace travel plans to eliminate

unnecessary journeys, buying more fuel-

effi cient vehicles, and using transport

alternatives such as videoconferencing

facilities waste reduction and

recycling systems.”

She continues, “Agencies were expected

to lower their carbon emissions, not

reduce them to zero which would have

been impractical with the available

technology. Agencies did not undertake

emission reductions that lessened their

eff ectiveness. More emphasis was put on

making procurement decisions that had the

lowest overall cost in the long term, rather

than a low initial purchase cost but high

running costs.”

Off setting residual emissions: Th e third

stage necessitates the acquisition of carbon

credits to off set any residual emissions

and achieving internal reductions. When

off setting, considerations should be given

to the type of off sets bought to ensure

that they are of sound quality and thereby

represent real emissions reduction.

Essential elementsDiscussing the important attributes

of carbon neutrality, H G Koshia,

Commissioner, Food & Drugs Control

Administration, Government of Gujarat,

says, “Controlling the existing processes

Energy Management: Carbon neutrality

Over a period of time it has become the need of the industry to maintain a net zero carbon footprint by balancing the measured amount of carbon released. We take a closer look to determine the importance of carbon neutrality.

Chandreyee Bhaumik

Inching closergreen dream

to the

Name:___________________________________________________Designation:_________________________________________

Company:_______________________________________________________________________________________________

Address:_______________________________________________________________________________________________

City:_________________________________________Pin:_______________________State:__________________________

Tel:________________________________________Mob:_______________________________Fax:_________________________

Email:__________________________________________________Web:_______________________________________________ 03/2

012

EASY STEPS TO GET PRODUCT INFO

Product Inquiry Card

FILL IN THE BOXES

WITH PRODUCT

NUMBER/S OF YOUR

CHOICE AND SEND

TIP-15

Product Sourcing Just Got Simpler

1 See the index page in this issue. Every product carries a number.2 Choose products of your choice from the list.3 Write their serial numbers (as per the index page) of your chosen product/s one-by-one in the boxes.4 Fill in your complete contact details. 5 Send it to us at the address printed overleaf.

PLEASE ENSURE

THAT YOU FILL IN

ALL THE DETAILS

REQUIRED

TIP-2

POSTAGE WILL BE PAID BY

ADDRESSEE

NO POSTAGE STAmP

NEcESSARY If POSTED IN INDIA

Business Reply InlandBR Permit No. 555

Bhavani Shankar Post Office,mumbai 400 028.

Special Projectmodern Pharmacuticals

‘A’ Wing, Ruby House, 1st floor, J K Sawant marg Dadar (W), mumbai 400 028 INDIA

InfomedIa 18 LImIted

Carbon neutrality


with appropriate technology, effi cient

maintenance and providing for renewable

energy sources to reduce the carbon

footprint is extremely important. Th is

includes re-designing the existing

processes for identifying the steps that

can be eliminated.” Further, according

to him developing newer processes

that are targeted to achieving zero

carbon emission is also signifi cant. He

highlights, “Identifying the areas of

indirect emissions which on an individual

level or at the organisational level can be

reviewed for reduction of carbon emission,

application of renewable energy resources

such as solar energy for domestic as well

as industrial usages, use of biogases for

mass canteens, etc is important. Th e basic

approach is to work on both direct and

indirect emissions, which in a planned or

co-operative manner can be attended.”

Koshia avers, “One needs to account

for the sources of emission generation,

quantify each source for its potential for

emission and draw a balance sheet against

the steps and quantities of emissions

reduced or eliminated.” Continuing this

strain of thought, he highlights, “Th e net

balance must be targeted towards off setting

the debits-emissions, completely by the

credits –elimination of emissions.”

Pharma contextTh e pharma sector broadly consists of

two segments - Active Pharmaceutical

Ingredient (API) and formulations.

According to Koshia, the direct carbon

emission control is a bigger challenge

for API facilities and this is achieved

by migration from synthetic processes

to biotechnology-based processes.

Koshia avers that carbon neutrality has

huge importance in the pharma sector

for following reasons:

Th e signifi cant investment in the

pharma facilities is towards the

creation of controlled environment for

manufacturing areas. Th is is achieved by

installation of HVAC systems. Carbon

neutrality would contribute signifi cantly

towards reduction of DELTA factor,

ie, the factor of control of ambient

parameters to desired parameters such

as dust/particle control, temperature

control, etc

Th e safety and health hazards reduction

is feasible with adoption of technology

and concepts of carbon neutrality

Pande says, “Temperature excursions are

serious because non-compliance with the

manufacturer’s storage recommendations

and the MHRA’s guidelines on general

storage can lead to expensive product

recalls, may prompt the destruction of

aff ected products and, ultimately, could

cause a health risk to patients. Issues

relating to temperature control will cost the

distributor in a number of ways, especially

since they can lead to a loss of confi dence

in the distributor by manufacturers,

the MHRA and pharmacists.” She

continues that glossing over temperature

control issues is not an option since the

MHRA’s Orange Guide makes it clear

that distributors must comply with the

regulations or face sanctions if their

facilities are found to be wanting. Adverse

inspections will trigger recommendations

for corrective action and if it is not

taken the MHRA can take regulatory

action. Th is may include suspension of a

manufacturer’s or wholesale distribution

licence, compulsory variation of licences

to exclude certain activities and sanctions

against the responsible person. She

highlights, “It is not the general conditions

that aff ect product quality, but extremes of

temperature within the operational space.

As global warming is widely accepted as

a reality, temperature control issues are

likely to become even more of a problem

in warehouses that are not equipped with

appropriate cooling.”

Maintaining carbon neutralityPande says that unlike traditional systems,

which pump more greenhouse gases into

the environment, exacerbating the problem

over the long term, to engineer systems to

maximise ‘free’ cooling so that the chiller

plant is only operational when daytime

external temperatures are exceptionally

high.” Signing off she adds, “HVAC

solutions utilise technologically advanced

‘Balanced Jet’ air induction systems. Air

fl ow and temperature throughout the

operational space is maintained at ± 1°C

of the desired level, as the systems are

purpose-designed to entrain and recycle

heat outputs from MHE; cope with tall,

densely racked aisles, mezzanine areas and

loading bays and integrate aesthetically

with ancillary systems such as lighting,

fi re curtains and sprinklers. Importantly,

engineer systems to deliver free cooling

via a night time purge, when external

air temperatures are lower, reduces the

reliance on mechanical cooling and helps

to reduce operating costs over the system’s

life cycle.” Th ese are the steps that a

pharma company should follow in order

to maintain carbon neutrality.

([email protected])

Shruti PandeClinical Team Lead, Wockhardt Ltd

Agencies were expected to lower their carbon emissions, not reduce them to zero which would have been impractical with the available technology.

H G KoshiaCommissioner, Food & Drugs Control Administration, Government of Gujarat

Controlling the existing processes with appropriate technology, effi cient maintenance and providing for renewable energy sources to reduce the carbon footprint is extremely important.


Spurious drugs have been aff ecting

the Indian pharma market for

many years now and today the

country has become a major

source of these drugs globally. Further, this

problem gains serious momentum when it

comes to healthcare as it directly aff ects the

health of the patient and at times may lead

to death. Also, the issue of economic loss to

the manufacturing companies holding the

rights for particular products pertains. Th e

Drugs and Cosmetics Act has been in force

since 56 years but the enforcement in many

states has not yet reached the desired level.

Penetration of such laws in the interior parts

of several states is lacking. It is therefore

imperative that eff orts should come from

all the stakeholders to ensure that safe and

genuine drugs reach the public. Th e law for

curtailing this menace exists and so is the

regulatory authority; the only thing missing

is the strong will from the government to

implement the same. “Th e law has been

amended and many committees have been

formed to look into the matter, but when

it comes to implementation and taking

concrete steps we see little action,” avers

Bejon Misra, Founder, Partnership for

Safe Medicines (PSM) India. Along with

an overview of the current market scenario

we need to look at the policies and what

measures need to be taken to make the

government more pro-active.

Market scenarioTh e pharmaceutical industry in India

is approximately $ 24 billion

(` 120,000 crore) while the World Health

Organization (WHO) estimates that

counterfeit drugs make up to 20-30 per

cent of the market. According to the

WHO, counterfeit drugs include medicine

with wrong ingredients, insuffi cient active

ingredients or illegitimate packaging.

Th is has a range of negative eff ects - drug

resistance, poisoning, allergic reactions,

prolongation of treatment and even death.

“India is the world’s third largest drug

producer by volume and 14th by value, and

is increasingly being identifi ed as drug

manufacturing hub for rest of the world.

Th e size and value of the industry attracts

counterfeiters to the space and low barriers to

entry make it an easy market to access. Low

barriers include weak supply chains, multi-

level distribution channels and unregulated

systems,” says Kishore Kar, Vice President-

Sales & Marketing, PharmaSecure. Other

major factors that are fuelling the spurious

drug market are lack of enforcement in

existing laws, lack of co-ordination between

various agencies among others. “Weak

penal action is also another factor that has

been reported by the Mashelkar Committee

Report. Th ey had proposed death penalty

for the culprit that has been changed to

life-imprisonment. Th e prosecution

methods for crime of drug counterfeiting

also has various technical faults,”

informs Misra.

Policies & Regulations: Policies governing drug counterfeiting

Globally, the counterfeit drug industry is estimated to be around $ 75 billion; although no exact fi gures are available for the Indian market the number of fake drugs is about 46 per 1,000. And this number will be increasing if proper measures are not taken. Although there are various policies and amendments to stop this menace their effective implementation is an issue.


Rigorous implementation:

Theway forward

Policies governing drug counterfeiting


At the helm of affairsHealth is ultimately a state aff air and the

state government is responsible for licensing

of drug manufacturing establishments and

sales premises, carrying out inspections of

licenced premises for ensuring compliance

to conditions of licences, drawing samples

for test and monitoring the quality

of drugs & cosmetics moving in the

state, taking appropriate action such as

suspension/cancellation of licences and

instituting legal action wherever needed

as provided under the Act and Rules. Th e

Drugs and Cosmetics Act 1940 is dealing

with unlicensed medicine and this law

has been amended over the years. Various

committees have been for looking into

the issue of spurious drugs such as the

Mashelkar Committee, which looked into

the spurious drugs market in India. “Th en,

there was the P N Tandon Committee that

looked into the incorporation of technology

for detecting spurious drugs, but all that

report is doing today is catching dust!

A sub-committee was also setup under

Dr VK Katoch but even that was not

focussed. More eff orts need to be

taken; the policy exists but due to lack

of implementation it is falling short”

says Misra.

As a strategic drug manufacturer and

exporter in the Asia Pacifi c region, India

plays a crucial role in fi ghting counterfeiting.

Th e growing counterfeit drug mafi a poses

a huge threat to India’s image as a reliable

exporter. “Hence, the Director General

of Foreign Trade (DGFT) in India has

mandated a step-by-step implementation

process of serialisation as the fi rst move

against counterfeit drugs. Th us, providing

the foundation for a track and trace system

that can monitor the supply chain at all

points of distribution. Serialisation is a

widely prevalent measure being used across

the globe and the DGFT notifi cations

help Indian manufacturers comply with

global standards. Th is helps pharmaceutical

companies standardise operations and

logistics for eff ective international trade.

By July 2012 all tertiary packages must

be serialised followed by secondary (boxes

typically at chemist shops) and primary

packages (blister packs and vials) by 2013,”

informs Kar.

Measures to be takenTh e reason behind widespread counterfeit

drug prevalence in India is due in part

to weak regulations, loopholes in the

distribution chain and lack of enforcement

at the ground level. “Th e entire system

requires an eff ective overhaul at the

policy and implementation level. Hence,

a collective eff ort from manufacturers,

distributors, retailers, industry bodies and

the government is needed to restrict the

growth of counterfeit drugs in India,” Kar

believes. While according to Misra the

government needs to be more pro-active

and demonstrate the seriousness of the

situation in a time-bound manner. Th ere

is a huge dearth of trained professional to

detect the crime and government should

help in building the capacity of the state

authorities. “Th ey should look into capacity

within state government adequately

supplemented, which means manpower

up gradation, and people should be given

adequate incentive among others,” says

Misra. Technology integration is also a

major hurdle to the proper implementation

of the law and nothing concrete has been

taken in that direction. India still has a

long way to go in adopting such security

measures within the system and hence

the need for authentication measures is

even higher. “Mobile authentication has

high relevance in a country such as India,

because it has leapfrogged the landline

culture and mobile usage has become

a way of life. Th e ease of use is another

advantage in popularising the concept

and its benefi ts. Appropriate measures

have been taken at the manufacturing and

packaging stage to ensure only authentic

medicines reaches the market place. Th e

logistics management at the manufacturers

end and policy regulations from the

governing bodies together construct an

adverse environment for counterfeit drug

makers,” says Kar.

Th us, what India needs right now

are more concerted eff orts towards

implementation of the suggestions made

by various committees, and strengthening

the state regulatory authorities. More than

changes or amendments in the existing

policy, the need of the hour is to look into

proper execution of the same.

([email protected])

Bejon MisraFounder, Partnership for Safe Medicines (PSM) India

The law has been amended and many committees have been formed to look into the matter, but when it comes to implementation and taking concrete steps we see little action.

Kishore KarVice President - Sales & Marketing, PharmaSecure

By July 2012 all tertiary packages must be serialised followed by secondary (boxes typically at chemist shops) and primary packages (blister packs and vials) by 2013.

The Drugs and Cosmetics

Act has been in force since 56 years but the enforcement in many

states has not yet reached the desired level.


Pharmaceutical companies are

always looking out for innovations

to rev up their sales. Traditionally,

like all other businesses, the

pharma industry too, built up its trade brick

by brick. It was well accepted that for any

product that is launched there would be

an initial sluggish phase in its sales fi gures

before it hits pay dirt.

Today, the scenario is completely

diff erent. Due to skyrocketing cost of

land, rentals and capital, investments have

gone up. Raw materials are costlier, prices

of transportation have multiplied and

therefore overheads are higher. Besides,

in a growing economy clubbed with high

infl ation, personal aspirations are much

higher than that in the past. Th erefore,

the qualifi ed executive as well as skilled

workers demand better pay. Industries are

mostly set up with funds borrowed at high

interest rates. All these factors shoot up

the cost of research, manufacturing and

trading of pharmaceutical products.

High stakesWhen drugs are researched, manufactured

and sold at a high price; when funds are

available at a premium, the obvious thing

that the manufacturer needs is quick

and huge returns. Unless the bottom-

line zooms northwards immediately, the

industry’s survival itself appears to be

under threat. Just like a $ 100-million

movie must fetch huge box-offi ce returns

in the fi rst week of its opening itself so

that the substantial amount paid to artists,

technicians, theatres, etc is recovered

immediately to fetch profi ts for the

producer; the pharmaceutical industry also

desires a quick buck.

Any delay in building up sales and

amassing profi ts becomes a drain on the

organisation because it continues to pay

high interest rates on funds borrowed

from fi nancial institutions. Th erefore, a

drug launch must immediately be followed

by a spike in sales. Moreover, the growth

in profi ts should remain sustained for a

reasonably long period so as to prevent a

close competitor from overtaking it.

Traditional strategiesIntensive training as well as greater

incentives to the sales force, off ering higher

margins to chemists, trimming avoidable

expenses, diluting the non-sales workforce,

etc are the standard operating procedures

for pharma companies to achieve their

sales target.

Appointing senior physicians and

consultants as Key Opinion Leaders

(KOL) to speak to august medical

audiences is among the modern methods

of pharmaceutical marketing. Th e senior

practitioner discusses his views and

experiences with the molecule in question

and the audience gradually gets infl uenced

by the underlying message. While this

technique was considered to be fairly

‘scientifi c,’ it has its share of detractors who

feel that the contents of most of the talks

by these KOL are ‘doctored!’

Th e latter approach was a tough

proposition, since zeroing upon a KOL is

by no means an easy task. Th e KOL had to

be an expert with over a decade and a half

in practice or who worked as a professor

at a high-profi le medical college hospital

/research institute. Some of these KOL

tend to be too demanding by insisting on

elaborate scientifi c information, greater

compensation as appearance fee or for

conducting clinical trials etc.

Modern trendsIdentifi cation of genuine KOL is a

complicated task as it not just involves

approaching people with impeccable

integrity and scientifi c knowledge. Besides,

these leaders must be those who are

popular, respectable and have an inherent

ability to infl uence the rest of their

Pharmaceutical companies resort to several tactics to meet their initial sales target in the shortest possible time. This is attempted through several time-tested techniques. Here’s providing a unique method to effectively use the industry for successful marketing.

Strategy: What’s new in pharma marketing?

Selective pampering

What’s new in pharma marketing?


fraternity. Moreover, these senior experts

are naturally available at a premium that

only large corporations can aff ord.

Moving away from the KOL ‘game plan’

is the latest modus operandi, particularly of

the smaller players in the pharmaceutical

market. Instead of focussing on a few,

major, pricey KOL, these companies

‘enlist’ a large number of Supporters Or

Loyalists (SOL). Th ese cohorts are usually

physicians across age and personality

barriers but who either have already built

up a thriving practice or show promise

in the growth of their patient load. Th e

peer-holding capacity of the physician or

his ability to address a gathering is not a

criterion for being enlisted so long as the

company can ‘deal’ with him comfortably

and their mutual needs are met! Th ese

prescribers are wooed with clinic inputs

such as textbooks, clinical equipment,

hospital supplies, stationery or may extend

up to personal utilities / gadgets, tours,

sponsorships, etc.

ComparisonsBoth methods have its pros and cons

for the company as well as the persons

benefi tted. Th e KOL system was originally

intended to be a scientifi c system wherein

astute, senior consultants were invited

by drug-research majors to provide an

insight into therapeutic approaches, both

for the benefi t of the company as well as

his subordinates in the specialty. However,

this system favoured few physicians and

most of them tended to be academicians

or retired professors from major

medical colleges.

With the gradual lowering of moral

standards of society in general and the

added suspicion about collusion of the

KOL with the company’s fi nancial needs,

the fraternity has begun to lose faith in

the system. Consequently, KOL have lost

their authority on prescribing patterns of

the rest of the members of the speciality.

Moreover, since the general members do

not gain anything other than knowledge

from KOL-led meetings, they have lost

their charm.

KOL have to be handled at all times

by senior members of the marketing

team only. On the other hand, the SOL

system works well for smaller companies

with shoe-string budgets as it does not

have to handle big guns! Th e National

Marketing Manager fi nds it easier to divest

responsibilities among the junior cadre to

identify reclusive, budding doctors. Instead

of providing intense training to the

Professional Sales Representative (PSR)

and the Area Manager on technical product

information, they are taught to handle

specifi c personal needs of the physician,

similar to the hospitality industry. In these

cases, demands from SOL are of minor

nature and the senior marketing staff need

not be involved in processing the request

so long as the prescriptions keep fl owing

thick and fast. Th e quarterly review of

the PSR will speak more about the way

the SOL is performing rather than the

PSR. Since the prescribing pattern of the

doctor can be directly monitored by the

PSR, the loss incurred in the case of ‘non-

cooperation’, if any, is minor.

Since KOL are visible across the industry

as well as the medical fraternity, they are

identifi ed as being part of a particular

company. Th erefore, should things not work

out the way a company desires, dumping

a KOL is not an easy task, In comparison,

SOL being imperceptible outside the

known group, not everyone is aware of the

nexus. If one group of SOL does not work,

the company simply switches to another

band of supporters in the next quarter.

Boomerang!Until the past decade, only a small number

of people were chosen as KOL and the rest

of the fraternity found the system working

well. Th is was because not everyone with

a busy practice could boast of the scientifi c

thinking that a senior medical teacher

or an aged consultant possessed. Except

for a few disgruntled voices, everyone

listened to the speaker with rapt attention

and went back to their clinics with the

take-home message.

Under the present system of pampering,

SOL with personal tours, excursions and

the like, many companies are alienating a

signifi cant section of sincere, conscientious

prescribers. Doctors, who are not part of

the SOL-circle and yet, have been regularly

prescribing good products of companies

may gradually begin to go for alternative

brands. Th is is a new development

that SOL-based companies have yet

to understand!

Companies who have started

mollycoddling SOL are progressively

distancing away sensitive, genuine physician

who keep their patient’s interest supreme.

Th ese quiet-prescribers are not showered

with any goodies since they have an image of

maintaining their individuality, “It is unfair

to provide incentives to others to prescribe

the same brands that we have already been

doing without any expectations,” said a senior

consultant on the condition of anonymity.

Such physicians, who feel that they have

been ignored, will form another cartel to

switch loyalties to another brand. Over a

period of time these hostile physicians

infl uence their like-minded colleagues and

they deviate from all brands introduced

by such pharmaceutical companies.

Eventually, while the SOL brings in

revenue, the original, genuine loyalists’

reluctance to prescribe could erode into the

drug company’s bottom line.

([email protected])

When drugs are researched,

manufactured and sold at a high price; when funds are available at a premium, the obvious thing that the

manufacturer needs is quick and huge

returns.

Dr Rajan T DPharma Consultant & Practising Dermatologist

Tips & Tricks: Patent prosecution tips


before fi ling

Patent prosecution is the exchange of information, between the patent examiner and the applicant, in determining as

to whether the invention is eligible and satisfies the requirements for grant of a patent. It involves writing and filing a patent application with the Patent Office

and pursuing protection for the invention as disclosed in the patent application.

The global pharmaceutical market has been encountering significant growth over the years and filing patent for drugs is a

crucial component for fuelling that growth.

But there are various factors that should be considered before filing a patent.

Co-ordinate foreign applications: Th e applicant may amend the application in view of the prosecution in

a corresponding US or EPO application. An applicant must fi le it in Form 3 either along with the application or within six months from the date of fi ling application.

8Tips&Tricks

Ask for hearing: Th e applicant may request for a hearing when possible. It can help applicants and

patent examiners quickly identify points of disagreements and correcting them and hopefully fi le for an early patent.

7Tips&Tricks

Respect deadlines:Th e Patent Offi ce’s position is that when the Act itself prescribes timelines, it must

be treated as a fundamental aspect of the process for granting patents.

9Tips&Tricks

to be

Kamakhya SrivastavaHead-Group on Research Publication and Programme, LEX ORBIS IP Practice

Checklist: An exhaustive checklist covering legal and technical points must remain at hand to

fi nalise the application and make any corrections before submitting with the Patent Offi ce.

10Tips&Tricks

Highlight limitations: During the course of prosecution, when limitations are added to

the claim to narrow down its scope, it is always better to include a brief note to that eff ect citing the location in the specifi cation or drawings from where the support is derived for that limitation.

4Tips&Tricks

Claim set from broad to narrow: Draft your claim beginning with the broadest scope to which you feel

you are entitled and concluding with the narrowest scope that merits protection. A claim set that is graduated in scope assists in performing a complete and focussed search.

2Tips&Tricks

Comprehensive reply: An applicant must ensure that thorough responses are fi led addressing the

specifi c objections set forth in the patent examiner’s offi ce action. Th is on one hand may reduce the chances of a second examination report and on the other also provide time to respond to the second examination report, if issued.

5Tips&Tricks

Number of claims: It is always better to avoid fi ling excessive numbers of claims and keep the number of

claims manageable. An optimal number of claims enable the patent examiner to enhance the quality of prosecution by focussing the search and examination eff orts at the core of the applicant’s invention.

3Tips&Tricks Early amendments/

arguments: File arguments and amendments at the earliest stage of prosecution,

and prior to a fi nal rejection if at all possible. Amendments submitted after fi nal are more diffi cult to deal with procedurally and extend prosecution.

6Tips&Tricks

considered

Claim drafting: Claims should be drafted towards the invention. Knowing what you want to protect

before fi ling the application is the primary requirement of drafting claims. A poorly drafted claim set may not capture the protection needed or desired. Misdirected claims may create diffi culties and diffi cult to anticipate what might be claimed in the future.

1Tips&Tricks

patent

Factors

a

Projects


Alembic Pharmaceuticals LtdProject type

New facility

Project news

Alembic Pharmaceuticals Ltd is planning

to set up a new pharmaceutical facility that

would involve manufacturing of diene.

Project location

Panchamahal, Gujarat

Project cost

Unknown

Implementation stage

Construction

Contact details:

Alembic Pharmaceuticals Ltd

Alembic Road

Vadodara, Gujarat- 390003

Tel: 265-2280550

Fax: 265-2281508

E-mail: [email protected]

Aries LaboratoriesProject type

New facility

Projet news

Aries Laboratories is in the process of

setting up a new facility for bulk drug

manufacturing. The project is scheduled for

completion in April 2012.

Project location

Ahmedabad, Gujarat

Project cost

Unknown


Construction

Contact details:

Aries Laboratories

18, Natraj Industrial Estate

Sanand Dist

Sanand- 382170, Ahmedabad

Tel: 079-26926689


Celestial Biologicals LtdProject type

New Facility

Project News

Celestial Biologicals Ltd is planning to set

up a new pharmaceuticals project which

would involve manufacturing of Albumin

Factor Viii Immunoglobulin.

Project Location

Ahmedaad in Gujarat

Project Cost

Unknown

Implementation Stage

Construction

Contact details:

Celestial Biologicals Ltd

Saekethej Bayla Highway

Village Matoda, Sanand

Ahmedabad, Gujarat- 382210

Tel: 2717-662103

Fax: 2717-662126


Eisai Pharmatechnology and Manufacturing Pvt LtdProject type

New facility

Project news

Eisai has announced expansion of the

existing facility to increase manufacturing

and research capabilities. Expansion of the

facility will increase annual production

capacity to 60 tonnes of formulations and

two billion tablets by 2013.

Project location

Vishakhapatnam, Andhra Pradesh

Project cost

$20 million


Construction

Contact details:

Eisai Pharmatechnology and

Manufacturing Pvt Ltd

Eisai Knowledge Centre

Ramky Pharma City (SEZ)

Andhra Pradesh

Tel: 891-3047100

Fax: 8924-282500


Epsilon PharmaceuticalsProject type

New facility

Project news

Epsilon Pharmaceuticals is implementing

a sterile injectables manufacturing unit,

which would be spread over a land of

5 acres.

Project location

Mahabubnagar, Andhra Pradesh

Project cost

Unknown


Construction

Contact details:

Epsilon Pharmaceuticals Ltd

6th Floor, Midtown Complex

Road No. 1

Banjara Hills

Hyderabad - 500 035, Andhra Pradesh

Tel: 040-44609000 / 44609020

Fax: 040 44609007


Hyacinths Pharma Pvt LtdProject type

New facility

Project news

Hyacinths Pharma Pvt Ltd is planning

to set up a new pharma project that

would involve manufacturing of

ethambutal.

Project location

Srikakulam, Andhra Pradesh

Project cost

Unknown


Construction

Contact details:

Hyacinths Pharma Pvt Ltd

H. No 8-3-678/60

Park View apartments

Yousufguda

Hyderabad- 500045, Andhra Pradesh

Fax: 040-23756566


New projects and expansion activities are the barometers of industrial growth. These also present business opportunities to service providers like consultants, contractors, plant & equipment suppliers and others down the value chain. This feature will keep you updated with vital information regarding new projects and capacity expansions being planned by companies in the pharma/lifesceinces industry.

Projects


Igen Labs Pvt LtdProject type

New facility

Project news

Igen Labs Pvt Ltd plans to set up

an active pharmaceutical ingredients

unit. The completion is targeted in

1.5 years.

Project location

Hassan, Karnataka

Project cost

` 10 crore


Construction

Contact details:

Igen Labs Pvt Ltd

Venkateshwarlu

CTO, Plot 106A

Road 7 Jubliee hills

Hyderabad- 500033

Tel: 040-40114001/02

Fax: 040-40114004


Lupin Healthcare LtdProject type

New facility

Project news

Lupin Healthcare in planning to set

up a new pharmaceutical project

that would involve manufacturing of

pharmaceutical formulations based on

pepsin 12.50.

Project location

East Sikkim

Project cost

Unknown


Construction

Contact details:

Lupin Pharmaceuticals, Inc

Harborplace Tower

111 S. Calvert Street

21st Floor

Baltimore, MD 21202

Tel: 866-587-4617

Fax: 866-587-4627

E-mail:[email protected]

Symbiotec Pharma LabProject type

New facility

Project news

Symbiotec Pharmalab is in the process

of setting up a new fermentation

facility to produce corticosterioids.

The facility is expected to be ready

in 2014.

Project location

Dhar, Madhya Pradesh

Project cost

` 450 million


Construction

Contact details:

Symbiotec Pharmalab Ltd

Off A B Road

385, Pigdamber Rau

Indore- 453331

Tel: 731-4200052

Fax: 731 4201222


Torrent Pharmaceutical LtdProject type

New facility

Project news

Torrent Pharmaceutical, which has

interests in pharma and power, is in

the process of expansion. It is going

to expand its facility at Kadi and will

be setting up a green field project at

upcoming Dahej SEZ.

Project location

Kadi, Mehsana district

Project cost

` 300 crore


Construction

Contact details:

Torrent Pharmaceutical Ltd

Off Ashram Road

Ahmedabad- 380009

Gujarat

Tel: 079-26585090

Fax: 079-26582100


Ushma Technologies Pvt LtdProject type

New facility

Project news

Ushma Technologies is in the

process of implementing an

API and formulation project in

Madhya Pradesh to develop anti-cancer

drugs.

Project location

Dhar, Madhya Pradesh

Project cost

Unknown


Construction

Contact details:

Ushma Technologies Pvt Ltd

301, Evershine Mall

Off Malad Link Road

Malad (W)

Mumbai 400064

Tel: 022- 42172222

Fax: 022 4003 8925


Zydus CadilaProject type

New facility

Project News

Zydus is setting up a new unit in SEZ

near Ahmedabad. This facility will

manufacture transdermal patches and

various injectables.

Project location

Ahmedabad

Project cost

` 1000 million


Construction

Contact details:

Zydus Cadila Ltd

Zydus Tower

Satellite Cross Road

Ahmedabad- 380015

Gujarat

Tel: 079-26868100

Fax: 079-26862365


Event List


3rd Annual BiosimilarsWith a 2-day strategic conference and

post-conference workshop on clinical

trials, Biosimilars India 2012 will bring

together key stakeholders in the

biopharmaceutical industry to learn about

the latest industry developments

and innovative commercialisation

strategies that will propel your biosimilar

strategies to the next level; March 27-29,

2012, Hyderabad

For details contact:

UBM India Pvt Ltd

Tel: +91 22 4046 1466

Fax: +91 022 4046 1477


Website: www.biosimilars-india.com

Herbal International SummitHerbal International Summit-cum-expo

on medicinal and aromatic products is a

mega event showcasing continental,

regional & local competence in this

industry & to promote worldwide

upcoming business of herbals, spices

and finished products. More than

100 prominent companies will be

participating in this event including

foreign companies. There will be

manufacturers, suppliers, exporters,

traders of medicinal plants, herbal

plants, herbal seeds and products.

Further, product development boards

and associations related to herbal plants,

products, manufacturers and traders; April

14-15, 2012, NSIC Exhibition Complex,

New Delhi


ASSOCHAM

Tel: +91 11 46550555

Fax: +91 11 46536481


Website: www.assocham.org

Lab Expo & Conferences PuneFor many years the Indian government

has been conducting this expo in

different cities of India. Exhibitors

of various lab commodities from all

over the world will come to display

their newly launched products.

Exhibitors will exhibit their products,

instruments and equipment. It will

play an immense role for broadening

their investment market and technology.

The participants will also be able to

exchange their experiences with the

viewers; April 20-22, 2012, Auto

Cluster Development & Research

Institute Ltd, Pune


Paramount Exhibitors

Tel: +91 172-2274801

Fax: +91172 2274803


Website: www.paramountexhibitors.com

Lab Expo & Conferences CoimbatoreThis is an event that focusses on

various aspects related to lab equipment

manufacturing as well as promoting

good lab practices among the fellow

professionals. The trade show will

be a two-day affair and will witness

attendance from a considerable number

of professionals who have been involved

with this profession for a long time.

This expo will also be supplemented

with informative sessions and

workshops, which will benefit the

participants in a great way. This is an

excellent platform for the lab equipment

manufacturers and distributors to

display their latest technological

innovations and creations in front of

an international audience. Moreover,

this event also takes care of a number

of important issues related to lab

automation and labware equipment;

June 15-17, 2012, Codissia Intec

Technology Centre, Coimbatore


Paramount Exhibitors

Tel: +91 172 2274801

Fax: +91 172 2274803


Website: www.paramountexhibitors.com

Automation 2012All leading companies in industry will

showcase their latest products and help

one find the solutions at the show.

The show brings latest technologies

from an interesting array of fields

such as: factory automation, process

automation and control systems,

robotics & drives, field instrumentation

& smart sensors bus technologies,

software solutions, wireless technology,

building automation, and hydraulic &

pneumatic automation in renewable

energy. From technocrats to solution

providers, vendors and tech-buffs,

the fair is all set to draw every one

alike; September 7-10, 2012, NSE

Complex, Mumbai


IED Communications Pvt Ltd

Tel: + 91 22 22079567

Fax: + 91 22 22074516


Website: www.iedcommunications.com

NATIONAL

India’s premier industrial trade fair on products and technologies related to Machine Tools, Hydraulics & Pneumatics, Process Machinery & Equipment, Automation Instrumentation,

Packaging & Auxiliaries, IT Products, Electrical & Electronics, Material Handling and Safety Equipment.

AHMEDABADGujarat,

Oct 5-8, 2012

For details

Infomedia 18 LtdRuby House, 1st Floor, J K Sawant Marg, Dadar (W), Mumbai 400 028.

• Tel: 022 3003 4651 • Fax: 022 3003 4499 • Email: [email protected]

PUNEMaharashtra,

Nov 2-5, 2012

CHENNAITamil Nadu,

Nov 22-25, 2012

LUDHIANAPunjab,

Dec 21-24, 2012

INDOREMadhya Pradesh, Jan 11-14, 2013

AURANGABADMaharashtra, Feb 1-4, 2013

RUDRAPURUttarakhand,

Feb 23-26, 2013

Event List


INTERNATIONAL

The information published in this section is as per the details furnished by the respective organiser.

In any case, it does not represent the views of Modern Pharmaceuticals

Adaptive Designs in Clinical Drug DevelopmentAdaptive Designs in Clinical Drug

Development conference will focus a

spotlight on the industry in this rapidly

advancing novel technique. There will be

discussion on case studies from leading

pharma companies on their use of adaptive

clinical trials, maximising the benefits

of an adaptive design through effective

management, tried and tested - case

studies of successful adaptive design trials

and many others; March 26-27, 2012, The

Grange Holborn Hotel, London, UK


SMi Group Ltd

Tel: +44 0 20 7827 6000

Fax: +44 0 20 7827 6001


Website: www.smi-online.co.uk

Bio IT World 2012The 2012 Expo plans to unite 2,000 life

sciences, pharmaceutical, clinical, and

IT professionals from 30+ countries.

The expo provides the perfect venue to

share information and discuss enabling

technology that are driving biomedical

research and the drug development

process. Spanning three days, the meeting

includes 12 parallel conference tracks and

16 pre-conference workshops; April 24-

26, 2012, World Trade Center, Boston,

Massachusetts, US


Cambridge Healthtech Institute

Tel: +781 972 5400

Fax: 781 972 5425


Website: www.bio-itworldexpo.com

Anti-Counterfeiting for Pharmaceuticals 2012There will be discussions on the global

threat of counterfeit medicines and

brainstorming on how to best confront

the problem and provide insights into

establishing and implementing an anti-

counterfeiting programme in the global

pharma market to ensure that one is in

a better position to secure the products

against counterfeiters and most of all

ensure consumer safety. This will be a

unique opportunity to exchanges ideas

and address anti-counterfeiting and brand

protection matters in an open forum;

April 30-May 01, 2012, Philadelphia,

USA


IQPC

Tel: +91 80 4322 4100

Fax: +91 80 4322 4103


Website: www.anticounterfeitingpharma.com

US-India BioPharma & Healthcare Summit 2012The event will witness a congregation

of biopharma, medical devices, healthcare

companies, venture capitalists, policy

makers from Europe, the US and

India. Panel discussions will cover areas

like drug discovery and collaborative

research, restructuring R&D in order o

maximise productivity and innovation,

therapeutic areas like oncology

(research areas, investor perspective,

market opportunities, challenges and

so on). Further, there will be discussion

on emerging market opportunities,

strtageies, funding innovation, cross

border investments, M&A trends in the

biopharma & healthcare and so on; May

11, 2012, Hyatt Regency Cambridge

Massachusetts, USA


USAIC

Tel: +781 586-1212


Website: www.usaindiachamber.org

Biomarkers World Europe

This event aims to discuss how to

support target identification and

eliminate dead-end candidates,

how to understand the range of

biomarker candidates, how to create

sophisticated animal models of

human disease to develop biomarkers

for proof-of pharmacology, how to

facilitate clinical trial stratification

and employ early surrogate end

points of efficacy, how to define the

correlation between biomarker and

disease/therapeutic intervention;

May 22-24, 2012, Business Design

Centre, London, UK


Health Network Communications Ltd

Tel: +44 0 207 608 7055

Fax: +44 0 207 608 7050

Email: skhamissa@

healthnetworkcommunications.com

Website: www.

healthnetworkcommunications.com

CPhI WorldwideThe event hosts over 1900 exhibitors

and is the market leader for the

global pharmaceutical ingredients

industry. CPhI Worldwide has three

co-located events: ICSE, P-MEC

Europe and InnoPack. These events

focus on specific sub-sectors of the

pharma ingredients industry and

provide visitors and exhibitors

with additional capability to network

and do business in dedicated

areas; October 9-11, 2012, Feria de

Madrid, Spain


UBM India Pvt Ltd

Tel: +91 22 6612 2600

Fax: +91 22 6612 2626-27


Website: www.ubmindia.in


With the theme ‘Optimising

Opportunities’, BioAsia

2012 was seen in a new

avatar in its 9th edition

as an advocacy and networking platform.

Th e event was held from February 09-

11, 2012 at Hyderabad International

Convention Centre. It was inaugurated by

N Kiran Kumar Reddy, Honourable Chief

Minister, Andhra Pradesh; Dr J Geeta Reddy,

Honorable Minister of Major Industries

GoAP; Tissa Vitarana, Honourable Senior

Minister - Scientifi c Aff airs, Government

of Sri Lanka; Dr Seth Berkley, CEO, GAVI

Alliance, Geneva; and Kevin Ali, President,

Merck & Co Inc, NJ, USA. Talking about

the developments made in the industry of

biotechnology and the plans for the future

Kumar Reddy said, “Biotech companies have

a crucial role in the society and will have to

keep the quality and aff ordability of medicines

in mind. To support the industry grow better

we are in the process of improving our

policies to make the industry more industry

friendly.” Highlighting on the footfall of the

event Karikal Valaven, IAS, Convener of the

event, remarked, “Th e precise number of

registered delegates for the event was 598;

in addition over 450 visitors also thronged

the three-day global bio-business event. Sri

Lanka participated as the country partner for

the event and more than 40 countries took

part in BioAsia 2012 with major delegations

from USA, Korea, Belgium, Pennsylvania,

Germany, Iran, Singapore, Nepal and Africa.

Th e international tradeshow at BioAsia

2012 attracted about 75 companies from

across the globe wherein the Biobazaar

(International Buyer Seller Meet) had over

45 sponsored international buyers from 17

countries. We are extremely grateful for the

support received from the Government of

India through Department of Biotechnology,

Department of Pharmaceuticals, Department

of Commerce, Department of Science &

Technology etc.”

A congregation of industry stakeholdersWith panel discussions instead of technical

sessions, the event was an instant hit with the

industry primarily as the panels had industry-

focussed deliberations while encompassing

the research and academia elements as well.

Th e panel discussions held at the event

included Vaccine policy: Recommendations

and challenges; Vaccines grand challenges

programme; Investing in Asia: Enabling

vaccine industry success; Supply chain

importance in the vaccine market: Impact

of cold chain logistics and more. Th e other

panel discussions held were on Vaccine

exports – will highly regulated markets

be on the radar? Rising importance of

contract research organisations, innovative

partnership models in outsourcing:

CROs, CRAMs, CMOs and research

cost eff ectiveness – long term solution to

the industry?

Furthermore, about 50 high profi le

speakers shared their thoughts at this event.

Focussing on vaccines, BioAsia 2012 was

successful in assembling the key stakeholders

of the sector both globally and from India.

Prominent participation of the Indian

vaccine manufacturers such as Bharat Biotech

International, Shantha Biotech, Biological E,

Serum Institute of India, Panacea Biotech,

Indian Immunological Ltd, etc in addition

the global vaccine majors such as GSK,

Sanofi , Pfi zer, Novartis, etc highlighted

the importance of the event. Hyderabad

companies such as Bharat Biotech Intl,

Biological E and Shantha contribute to

more than 60 per cent of the Indian vaccine

produced. It was perhaps therefore befi tting

that vaccines was one of core focus areas for

this year’s event.

On the second day of the event, a CEO

Conclave in partnership with Frost & Sullivan

was held with focus on Mega trends: Th e new

frontier. Th e objective of the conclave was to

provide focus to companies on the evolution

of the global trends and help them drive

growth and innovation in a rapidly changing

environment. A white paper from Frost &

Sullivan on the mega trends of the industry

is being prepared based on the deliberations

during BioAsia 2012 Conclave and will be

released during end of March 2012.

A platform for manyTalking about their association with BioAsia,

Manni Kantipudi, CEO, GVK Bio, said,

To further strengthen the biotech industry and the players entering the space of new drug discovery, BioAsia 2012 stepped into its 9th edition with a focus on vaccines and the potential that the Indian market holds.

Targetting the vaccine and drug discovery market

Jasleen Kaur Batra

(L-R): Dr K V Raghavan, Vice President, Federation of Asian Biotech Associations; Ali;

Dr Berkley; Prof Vitarana; N Kiran Kumar Reddy; Dr Reddy; Dr Ella; Dr Raja Sekhar Vundru,

Joint Secretary, Dept of Pharmaceuticals; Kantipudi; and N R Munjal, Chairman, Pharmexcil

Event Report: BioAsia 2012

BioAsia 2012


“BioAsia provides a platform for companies to exhibit, launch and

showcase their products and services. GVK Biosciences has been

associated with BioAsia for the past several years as it provides an

opportunity to network and forge new business relationships. BioAsia

2012 was well attended this year due to greater industry participation

(domestic and international) and better marketing by the organisers.”

Adding to this Dr Krishna Ella, Chairman and Managing Director,

Bharat Biotech said, “Over the years, BioAsia has become an industry-

oriented event while the Bangalore India Bio event has remained

research oriented. Hyderabad is the biggest manufacturer of biotech

products and vaccines in the country and this explains the focus of

BioAsia on elements such as strategy and markets, while the Bangalore

event is focussed on research.”

For the fi rst time, BioAsia also hosted one of its kind workshop on ‘

labs of the future’ workshop in addition to limited group workshops like

Bio-manufacturing and Cleaning Validation in association with Hyde

Engineering, Workshop on Bioinformatics for students in association

with NIPER and a Tech Transfer Summit in association with MSME

& ICICI Knowledge Park were also conducted which received an

overwhelming response from the industry and academicians. But the

most novel factor of BioAsia 2012 was the Power 20 Breakfast meeting

with Dr Seth Berkley, Chief Executive Offi cer, GAVI Alliance as the

guest and the Indo-German Power Breakfast meeting.

Promoting young mindsIn order to promote investigative spirit in young school children and

scientists, BioAsia instituted ‘Innovation and Young Minds’ award

in areas of Biotechnology/Life sciences including Biomedical/

Pharmaceutical technology, Bioinformatics, Biomechanics, etc. Th is

year, out of 61 proposals received from India and from 7 countries

abroad, 13 proposals were short listed.

BioAsia Innovation Award for 2012 consisting ` 1 lakh cash

and a memento was presented by Dr T Ramasami, Secretary to

Government of India, Department of Science & Technology, during

the event. Th e award was shared between Dr Shailaja Tiwari from

Dr H S Gour Central University, Sagar, MP for her project titled-

‘Recombinant protein based liposomal combination vaccine for intranasal

immunisation against Hepatitis and Infl uenza’ and Dr Nooruddin

Khan from the Dept of Biotechnology, University of Hyderabad for his

project titled- ‘Development of ELISA based approach to detect active

Tuberculosis including smear-negative pulmonary and extra-pulmonary

TB cases’. Th e BioAsia Young Minds award for 2012 was presented to

N Koushika from Th e Ashok Leyland School for her project titled -

‘Comprehensive health check up kit.’

Regarding plans for BioAsia 2013, Shakthi M Nagappan, CEO,

BioAsia 2012 said, “Our attempts to re-strategise the 2012 edition

has been successful and is evident from the overwhelming response

received so far. We are currently evaluating the areas that need

improvement and are also in discussions with various stakeholders

on their interests including the structure, theme, etc. Based on these

discussions the 2013 event will be announced. Th e event will be

designed in tune with the demands and expectations of the biotech

and bio-pharma industry.”

([email protected])

FORM IV

Statement about ownership and other particulars aboutModern Pharmaceuticals, as required to be published in the fi rst issue every year after the last day of February.

1. Place of Publication: Ruby House, ‘A’ Wing, JK Sawant Marg, Dadar (W), Mumbai-400028

2. Periodicity of Publication: Monthly 3. Printer’s Name: Mr Mohan Gajria Nationality: Indian Address: Infomedia 18 Ltd, Ruby House, ‘A’ Wing,

JK Sawant Marg, Dadar (W), Mumbai-4000284. Publisher’s Name: Mr Lakshmi Narasimhan Nationality: Indian Address: Infomedia 18 Ltd, Ruby House, ‘A’ Wing,

JK Sawant Marg, Dadar (W), Mumbai-4000285. Editor’s Name: Mr Manas Bastia Nationality: Indian Address: Infomedia 18 Ltd, Ruby House, ‘A’ Wing,

JK Sawant Marg, Dadar (W), Mumbai-400028 6. Names and addresses of Individuals who own

Modern Pharmaceuticals & partners or shareholder holding more than 1% of total capital: Infomedia 18 Limited (formerly known as Infomedia India Limited), Ruby House, ‘A’ Wing, JK Sawant Marg, Dadar (W), Mumbai-400028 is the owner of Modern Pharmaceuticals.

Details of the shareholders of Infomedia 18 Limited who are holding more than 1% of the paid up equity share capital of the company as on 20-02-2012:

1. Network18 Media & Investments Limited, 503,504 & 507, 5th Floor, Mercantile House, 15 Kasturba Gandhi Marg, New Delhi - 110001

2. Acacia Conservation Fund LP, Citibank N A, Custody Services 3rd Flr, Trent House, G Block, Plot No. 60, BKC, Bandra (East), Mumbai - 400051

3. Pramod Premchand Shah, Kalpana Pramod Shah, Agra Building, 1st Floor, 121/4 M.G.Road, Mumbai - 400023

4. Acacia Institutional Partners, LP, Citibank N A, Custody Services 3rd Flr, Trent House, G Block, Plot No. 60, BKC, Bandra (East), Mumbai - 400051

5. SPS Capital & Money Management Services Pvt Ltd, 66,Tamarind Lane, 4/5,Haji Kasam Bldg, 1st Floor, Fort, Mumbai - 400023

6. Sanjiv Dhireshbhai Shah, 201-203, Sapphire Complex, Nr. Cargo Motors, C.G. Road, Ahmedabad - 380006

7. The Oriental Insurance Company Limited, Oriental House, P B 7037, A-25/27, Asaf Ali Road, New Delhi - 110002

8. Accurate Finstock Pvt Ltd, 9th Floor, Shikhar, Adani House, Nr. Mithakhali Six Road, Navrangpura, Ahmedabad - 380009

I, Lakshmi Narasimhan, hereby declare that all particulars given above are true to the best of my knowledge and belief.

Dated: 20th February 2012

Lakshmi NarasimhanSignature of the publisher

Book Review


Reviewer: Dr Mandar Kubal Consultant - Infectious Diseases and HIV AIDS, Infectious Diseases and Pulmonary Care (IDPC)

HardKnocks For the GreenhornAuthor: Anup Soans

Price: ` 599

Supervision for the Superwiser Front-Line Manager

Author: Anup Soans

Price: ` 799

Th e Indian pharma industry has seen a phenomenal growth in recent years. Th is

has created employment opportunities in the fi eld with respect to sales, marketing,

research and management. Th is book brings forth the necessary skills required by

Pharmaceutical Sales Representatives (PSRs) in performing their daily duties.

Th e author has in a clear and lucid language tried to elucidate the application of

basic principles of marketing to the job of these PSRs. Th e book tries to focus

on bringing out the fi ner skills hidden within an individual with the help of

illustrations and examples and their importance in sales.

Th e fi rst part of the book is an introduction to the Indian healthcare delivery

system and the pharma industry in detail. Th e second part outlines the roles and

functions of PSRs and their importance in the marketing chain. Th e next parts try

to inform the PSRs on the knowledge that they should possess anytime during

the performance of their duties. Th e concepts of industry, customers, territory and

competitor’s knowledge have been put forth in a brilliant yet simple way. Th e PSR

being the next frontline manager in future, there is a section product position,

diff erentiation, branding, pricing, new product launch and public relations. Th e

book ends with a section on personal skills like presentation, dressing, attitude,

communication skills, personality, ethics, etc, which assist in holistic development

of a PSR. Overall an excellent read for aspiring pharma sales professionals,

existing PSRs, pharma trainers, and pharma management students.

Th e second book in the series for pharmaceutical sales professionals, ‘Supervision

for the Superwiser Front-Line Manager’ is dedicated to the roles, responsibilities

and skills of a front-line manager in the pharmaceutical sector. Th is makes a unique

reading as unlike management books the principles of management are illustrated

via anecdotes, stories, case studies and cartoons, etc. Th e book begins by illustrating

the importance of the front-line manager in the growing pharmaceutical industry

and the important link that they are in between the sales force and the management.

It then expands into the ideal qualities of a good front-line manager and ways to

achieve them.

Th e stress of the book is on the leadership role, managerial role, motivational

role and teaching role played by a front-line manager towards his team of sales

representatives. Th e section on how to manage customers and how to achieve

breakthrough performance uses simple life skills and management principles

applied to the job of the front-line manager. Th e concept of emotional intelligence

and its application in team management and customer management is of practical

use to existing and potential front-line managers. Th e concluding section on

progression in the chain of management beyond front-line managers and grooming

of successors serves as an inspiration to front-line managers. Overall, a unique book

dedicated specifi cally to the needs of a front-line manager and utilising all the

principles of management towards personal and professional growth.

76

Products


Industrial panel PCTo satisfy the stringent

standards required

in food, beverage,

clinical, chemical or

pharmaceutical applications, Advantech off ers the IPPC-8151S

15” XGA TFT LCD Celeron M fanless industrial panel PC

designed with 316L stainless steel, food-safe sealing materials and

an anti-corrosive and chemical resistant touchscreen. Its fanless

design and NEMA4X/IP66 waterproof and dustproof protection

ensure reliable operation in most hazardous environments. With

the optional enclosure kit and IP66 I/O connector kit, the IPPC-

8151S can provide a fully enclosed IP66 protection for all sides.

Advantech India

Bengaluru - Karnataka

Tel: 080-23374567


Website: www.advantech.in

Walk-in-cooling chamberTh e walk-in-cooling chamber has double

walled insulated PUF modular panels,

which can easily be assembled at site

without any major hassles. Interior is made

of stainless steel and exterior is either made

of mild steel fi nished with powder coating

or stainless steel. Th e unit is provided with

perforated stainless steel trays.

Newtronic Equipment Company Pvt Ltd

Mumbai - Maharashtra

Tel: 022-28679326, Mob: 09821089932


Website: www.newtronic.in

Gas fl ow adsorption analyserTh e model SGA-100 is a continuous gas fl ow

adsorption instrument specially designed for

the study of water or organic vapour isotherms

at temperatures ranging from 0°C to 80°C

(standard version), 250°C (high-temperature

version), at an ambient pressures. Th e term

symmetrical refers to a design feature where

by both the sample side and the reference side of the microbalance

is subjected to identical temperature, relative humidity and fl ow

rate. Th is provides signifi cant stability and accuracy and allowing

the possibility of performing absolute or diff erential adsorption

experiments. Th e instrument is used in industries such as catalyst,

chemicals, pharmaceuticals, foods, electronics, etc.

Smart Instruments Company

Th ane - Maharashtra

Tel: 0251-2801123, Mob: 09323509969


Website: www.smartinsrument.com

Liquid fi lling/capping and sealing machineTh e monoblock piston fi lling/ROPP-cum-

sealer is a combination of rotary multi-

heads volumetric liquid fi lling and rotary

multi-heads RO/ROPP capping and

sealing machine. Due to its compact model

it reduces space and manpower utilisation.

A single synchronised drive mechanism couples the multi-heads

fi ller and sealer on a common base. It is suitable for glass, tin and

PET bottles/containers. Th e machine is provided with no-bottle-

no-fi ll and no-bottle-no-cap mechanism and with attachments

suitable for any one size bottle and cap.

Th e Master Mechanical Works


Tel: 022-26493459


Liquid-ring vacuum pumpTh e single and double-stage

liquid-ring vacuum pump is

silent in operation. Design

of the mechanical shaft seal

ensures adequate protection

to the shaft and provides for

ease of maintenance. Th is leads

to minimal time required for

servicing thereby cutting down

time to the barest minimum. Th e pump is rugged in design, reliable

in performance and easy to maintain.

Acmevac Sales Pvt Ltd


Tel: 022-28375837, Mob: 09223388105


Website: www.acmevac.com

PelletTh e multi-unit pellet of vitamins and minerals

and medicine in capsules include those of

vitamins and minerals, pellets of cough and

cold preparations, pellets of hyperacidity, anti-

ulcer, anti-fl atulant, anti-emetic preparations,

pellets of cardiovascular drugs, pellets of anti-

microbials & adjuvants, pellets of anti-asthamatic drugs, pellet of

NSAIDS, pellets of anti-malarial drugs, etc.

Pelltech HealthCare


Tel: 022-28662980


Website: pelltech-healthcare.com

Products


Hydraulic orbit motorTh e hydraulic orbit motor is available with

maximum peak power rating of 20 kW. It

provides high-torque low-speed performance

with limited overall dimensions. Th e orbit motor

is made with a system of lobe shaped geroter/

geroller. Some of the features include well-designed compact

structure, good weight to power ratio, reversible rotation direction,

excellent effi ciency, uniform torque, standard mounting fl anges,

etc. Th e orbit motor is used in applications like road sweepers,

agricultural and forestry machines, plastic injection moulding

machines, wood working machinery, printing machines, conveyor,

mining equipments, food & textiles processing, etc.

Pioneer Transmission Solutions

Bengaluru - Karnataka

Tel: 080-51273369


Ointment manufacturing plantTh e ointment, cream, toothpaste,

shampoo, gel and lotion

manufacturing plant has all contact

parts made out of SS-316 and all

pipelines electro-polish from inside. Joints are DIN standard, with

easy openable fi ttings after cleaning. Th e plant is provided with

inline fi lters to ensure fi ltration and PLC-based control panel for

process automation. It is equipped with CIP and SIP facility and

loadcell for online weighing. All transfers are done under vacuum

to avoid any hand touch and contamination. Th e intensive mixing

by semi-contra design anchor stirrer avoiding dead zones by tefl on

scrapper and bottom entry angular homogeniser for micronising.

Arsee Engineering Works

Navi Mumbai - Maharashtra

Tel: 022-56053602


Website: www.arsee.com

Suspension centrifugeTh e four-point suspension centrifuge is

mounted on an inertia plate with anti-

vibration mounts, thus eliminating the

cost of heavy foundation. It also eases

relocation of the machine. Only a few

bolts are to be grouted to prevent lateral movement of the machine

during operation. Maintenance of suspension system associated

with pendulum suspension machine is eliminated. Th e centrifuge

is employed in medium-to-high output processes in bulk durgs,

pharmaceuticals, food, fl avours and chemical industries. It is

off ered in complete stainless steel construction and conforms to

GMP standards.

United Engineering Enterprises


Tel: 022-23083990


Website: www.united-centrifuges.com

Continuous band sealerTh e is a versatile and high-production pouch

sealing machine for plastic heat sealable

materials like PP, LDPE, HMHD, polyester,

polylaminates, etc. It is provided with nitrogen

gas fl ushing arrangement for chips, wafers,

savouries, fl our, food items, etc. Th e machine is

a tabletop model suitable for pouches up to 2 kg weight and consists

of Tefl on belt used for driving the already fi lled pouches at fi xed

speeds through heating and cooling zones. At the bottom is a height-

adjustable conveyor for up to 16” height pouches.

Ace Industries


Tel: 022-28732530, Mob: 09324481285


Website: www.aceindus.com

Insulation materialsTh ese insulation materials include fl exible

foam produced from melamine resin. Th e three

dimensional structure of the foam is made up

of a microscopic, slender skeletal structure

that delivers insulation properties. As a result of its unique design

and inherent nature of the design, it off ers properties such as high

temperature resistance, low bacterial growth, 25/50 fi re rating,

ASTM C-1410, etc.

IUS Equipments Pvt Ltd


Tel: 022-56116626, Mob: 09960110373


Website: iusequip.com

Horizontal pull-action clampTh e model PA-H horizontal pull

action clamp has holding capacity

with easy operation. Th e treated U-

bolts permit easy simple adjustment

and provide a positive connection with

the supplied latch plate. Th e clamp fi nds application in machine

tool positioners, welding fi xtures, production fi xtures, inspection/

gauging fi xtures, chemical machinery, lathes of container lids,

pharmaceutical machinery, assembly jigs and fi xtures, etc.

Chamunda Equipments

Ahmedabad - Gujarat

Tel: 079-27522437


Website: www.chamundaequip.com

78

Products


Temperature and process controllerFuji Electric’s self-tuning

temperature and process controller

has low-cost options that include

RS485 communications, digital

input, timer function, heater

burnout alarm, dual outputs,

and programmable alarms.

Th e faceplate is watertight

and corrosion-resistant. Th e

three-button keypad allows

programming and the screw-terminal on the back eliminates the

need for sockets. In addition to auto-tuning and fuzzy control, it

has self-tuning control, which automatically retunes the controller

under certain conditions, without the need to revert to auto-

tuning. It accepts temperature & process inputs and off ers two

control outputs and two programmable alarms.

Procon Technologies Pvt Ltd

Ahmedabad- Gujarat

Tel: 079-27492566, Mob: 09824310188


Website: www.procon.co.in

SpheroidiserTh e spheroidiser consists of a round disc

mounted on a vertical shaft spinning at

high-speed at the bottom of a cylindrical

chamber or drum. Th e cylindrical drum

is called the bowl and the spinning

disc is called the chequered plate. Th e

chequered plate has a grooved pattern

to increase the friction with the product

and break the extrudates to length.

When the extrudates are charged into the spheroidiser, they are

thrown on the edge of the spinning plate by centrifugal forces.

Umang Pharmatech Pvt Ltd

Dist Th ane - Maharashtra

Tel: 0250-6450835, Mob: 09764998260


Website: www.umangpharmatech.com

Digital temperature indicatorTh e digital temperature indicators is available with

features, such as auto shut-off circuit, built-in-lineariser,

open sensor indicator, low battery indicator, 3½ digital

0.5” LCD display, low power cosumption, compact

moulded ABS cabinet, etc.

Instrument Research Associates Pvt Ltd


Tel: 022-61484000


SpectrophotometerTh e spectrophotometer is designed for

versatility in various applications. It is a

portable integrating sphere spectrophotometer

incorporating numerical gloss control. It

simultaneously measures specular component

included and specular component excluded

and displays the data on the LCD in only 1.5 seconds. Th e relativity

gloss value can be displayed by using numerical gloss control.

Th e spectrophotometer fi nds applications in pharmaceuticals,

cosmetics, printing, building materials, textiles, food, etc.

Jay Instruments & Systems Pvt Ltd


Tel: 022-23526207


Website: www.jayinst.com

Pallet shrinking toolTh e pallet shrinking tool is used for

shrink wrapping. Shrink wrapping of

export pallets, giant pallets, giant articles,

big articles/machinery are used to avoid

damage during transportation. Boxes on

pallets and other products can be shrink-

packed within minutes. It provides fi ve-sided protection for any

size or shape load from small uneven pallets to large machinery

and more strength than stretch wrapping. Th e tool is compact,

portable and handy weighing 950 g.

Dharmesh Enterprises


Tel: 022-55233591


Website: hotairguns.com

Lyophiliser Th e lyophiliser is used for pharmaceuticals,

biotechnology and allied industries. Lyophilisation

is the preferred drying process, for heat labile

substances or where any physical, chemical or

enzymic changes are detrimental to the products

and its applications. Sublimation of frozen ice

directly in the form of vapour under high vacuum is the basis

of lyophilisation process. Th e system off ers optimal fl exibility in

programming the recipe to suit a wide variety of products. Th e

drying chamber is designed for full vacuum and overpressure of

2.5 bar.

Machinfabrik


Tel: 022-25555596


Website: machinfabrik.com

Products


Remote I/O system Th e RIX CANopen remote

I/O system is designed to be

mounted near fi eld elements

like junction boxes and

in push-button panels for

individual I/O connections.

RIX units are connected to

Messung’s Nexgen-5000

PLC Master using a network cable. So, there are no snaking wires

and no unnecessary loss of space and productive time. Th ese are

compact in size and easy mounting. Auto network baud rate can

be detected by RIX base units. Th ere is data transmission on I/O

status change to reduce network traffi c. Diagnostics and I/O status

LEDs are there on each module.

Messung Systems Pvt Ltd

Pune - Maharashtra

Tel: 020-27102000


Website: www.messung.com

Vibratory fi nishing systemTh e vibratory fi nishing system

incorporates a rubber or

polyurethane lined bowl of

U-cross section mounted on

precisely calculated springs.

Th is system is driven by a highly

effi cient vibratory motor. Th e

open top of the bowl can be

loaded with suitable ceramic/

plastic or steel media and parts to be processed. Vibratory fi nishers

shake parts and media at high speeds, causing the media to scrub

the surface of the parts in an action similar to lapping. Since the

parts and the media are moving at small increments on each stroke,

the parts are not subject to severe stress or damage.

Niraj Optical Machinery

Ahmedabad - Gujarat

Tel: 079-29295747, Mob: 09909904148

Email: badrakia@rediff mail.com

Website: www.nirajopticalmachinery.com

Rotary cone vacuum dryerTh e rotary cone vacuum dryer

consists of a jacketed double

conical shell rotating around

6 rpm with provision for

application of vacuum inside

the shell and circulation

of heating media in the

jackets during the rotation

of the cone. Large

heating surface area presented by the internals of the cone

ensures uniform drying of the product, as the product gently

tumbles while the cone rotates slowly. Th e diff usive action

induced by the tumbling cone constantly presents a fresh

layer to come into contact with the indirectly heated walls of

the shell.

Bhuvaneswari Pharmach Pvt Ltd

Chennai - Tamil Nadu

Tel: 044-22641267


Automatic powder fi lling machineTh e automatic powder fi lling machine is used in fi lling of

pharmaceutical powder medicine. It fi lls any type of powder/

granules and is made of stainless steel. Th e technical output of

machine is 20-60 fi lls per minute depending upon the material

characteristic and fi lling volume. Filling volume is 5 gm to

500 gm with diff erent size of auger and funnels. Th e power

consumption is 3 phase/440 V, 1 hp, with four core wire system

and the 25 ltr hopper capacity.

Virajka Machinery Mfg Co

Ahmedabad - Gujarat

Tel: 079-25894985


82

Products


High-pressure washing unitTh e high-pressure washing unit consists of a robust and sturdy

high-pressure tripled plunger pump. Th is unit is designed to

perform under extreme duty condition. Th e benefi ts of the

machine are product quality greatly increased by eff ective and

through cleaning of the system, simplicity makes the cleaning less

tedious task, where a layman can operate it easily, reduces energy,

water, manpower and time consumption, etc.

Dupoly Marketing Pvt Ltd

Ahmedabad - Gujarat

Tel: 079-26577389


Website: www.dupoly.com

Radial drilling machine Th e heavy-duty high precision all-geared drill

head radial machine comes with forged steel

gears and toughened spindle. Th is drilling

machine has automatic vertical movement of

arms. It also provides horizontal automatic

movement of man spindle head for face

milling as well as keyway milling operations.

Th e machine has arm titling at 360-degrees to

get inclined drilling. Accuracy is as per ISI chart. Th e main spindle

runout is within 0.005 mm, ie, within 5 microns. Drilling capacity

of the machines is 38 mm in steel.

Poly Kraft Machines

Ahmedabad - Gujarat

Tel: 079-22743639, Mob: 09898003625


Website: www.polykraftmachines.com

Cooling chamberTh ese cooling chamber is provided with

perforated stainless steel trays for sample

mounting. Th is unit has full-length inner

glass door and outside metal door with

magnetic gasket and lock. It has forced

air circulation for uniform temperature,

safety thermostat, hermetically sealed

compressor, with electronic time delay to

safeguard compressor.

Newtronic Equipment Company Pvt Ltd


Tel: 022-28679326, Mob: 09821089932


Website: www.newtronic.in

Fluid bed dryerTh e fl uid bed dryer includes short drying time, uniform drying,

low drying temperature, electric or steam heated, SS heater, digital

temperature controller and indicator. Th is dryer is available from

10 kg to 120 kg capacity. It comes with a digital timer. Technical

specifi cation include: for 30 kg, 60 kg and 120 kg it is 100, 220,

430 container volume (in ltr), batch capacity (in kg) is 30-40, 60-

75, 129-140, heating load (in kW) is in the range of 18, 36, 60,

electrical heating motor (hp) of the range 5, 10, 15, etc.

Sunmach Machinery

Ahmedabad - Gujarat

Tel: 079-25840230; Mob: 09825008365


FRP cooling towerTh e maintenance-free crossfl ow

FRP induced draught cooling tower

provides higher range (cooling) with

the advantages of minimum water

loss. It is suitable for any type of water

cooling application. It eliminates

maintenance of rotating sprinklers,

spray nozzles, choking of fi lls, changes

in water pressure, etc. Higher air volume aluminium fan with

lower power consumption and special design fi ll packing gives

maximum cooling effi ciency. Water distribution with non-clog

water splitting polymer nozzles work eff ectively even with gravity

pressure. Th e fi ll packing is reusable and cleanable.

Crystal India

Ahmedabad - Gujarat

Tel: 079-25833965, Mob: 09824013727


Website: www.crystalcoolingtower.com

Pusher centrifugeTh e pusher centrifuge provides

continuous fi ltration for separation of

suspended, fast draining, crystalline,

granular or fi brous solids from

the liquid. Crystalline product has

particle size of 0.1 mm to 20 mm and

feed solids from 30 to 70 per cent by

weight. Solids are washed as they are transported through the

basket. Features include: complete separation of mechanical unit

from the process area, single or multi-stage according to product,

cylindrical/cylindro-conical basket with long and short lengths,

hydraulic pusher mechanism with variable stroke & stroke length,

slurries are fed via feed pipe and non-fl owable products are conveyed

by a screw conveyor into the feed distributor, counter current wash

and wash by displacement for high washing effi ciency.

Rotofi lt Engineers Ltd

Ahmedabad - Gujarat

Tel: 079-25712861

Email: rotofi lt@rotofi lt.com

Website: www.rotofi lt.com

Products


Electronic panel timerTh e electronic panel timer is

housed in small industrial grade

plastic box. It gives 5 per cent

setting accuracy and 1 per cent

repeat accuracy. It is available

in 415 V or 230 V with one

changeover contact. Timing

range is 30 sec, 60 sec, and 120

sec. Power and delay indications

are provided on the front side

of the timer. Potentiometer is

provided to set the required

time. It measures 102 mm x 65

mm x 43 mm and weighs 250 gm approximately.

Gelco Electronics Pvt Ltd

Ahmedabad - Gujarat

Tel: 079-22200902


Website: www.gelco-world.com

Closure feeding systemTh e fully-automatic, hygienic

and sanitation-friendly closure

feeding system is used for crowns,

PP caps, aluminium rollon caps,

etc. Th is system is suitable for

high-speed bottle fi ller machines

up to 600 bpm for industries, like

beverages, breweries, distilleries,

pharmaceuticals, dairy, etc, which

ensures the fl ow of closure in gentle

and controlled manner into the

crowner/capper hopper, which nullify the damage and bending

of closures remarkably. Th e system is self-mounted and the dies

do not require any foundation. It is moved anywhere in the

bottling hall.

Alien Fabricon (India)

Ahmedabad - Gujarat


Website: www.bottlingplantconveyor.com

Electronic ballast and fi xtureAcon electronic ballast

and ultra slim fi xture

comes in diff erent

models for tubelights,

T5 complete fi xtures

and HPSV, HPMV and

MH lamps. Th ese are

reliable with minimum

rejection, watt loss and electromagnetic/radio frequency

interference (EMI/RFI). Th e ballast has maximum power factor

Jet millTh e jet mill is increasingly

used in micronisation and

is a critical process for

API manufacturers, as all

bulk actives in order to

go to the next stage of the

production processes like,

tablets, agglomeration,

capsules, creams or

aerosols have to undergo process micronisation. Th is mill has

hourly capacities ranging from 2 gm to 200 kg down to D100<5

or lesser. It accepts feed sizes from 750 microns to 3,000 microns.

It is used to increase the active surface area of pharmaceutical bulk

drugs. A three-dimensional size reduction is also possible.

GR International


Tel: 044-22641650,Mob: 09444381252


Drive and inverter Th e Teco-7300 CV inverter has

sensorless vector control, 150 per

cent starting torque, built-in PLC

function, LED/LCD keypad

display, NPN/PNP digital input,

PID function, braking transistor

built-in, copy unit, memory pack

function, PC (Windows)/PDA

(Win CE) link function, RS–485

Modbus RTU/ASCII mode,

fi eldbus communication modules,

built-in EMC fi lter. It complies

with UL, CUL and CE global standards.

Kuna Impex Pvt Ltd

Ahmedabad - Gujarat

Tel: 079-26841523

Email: kipl123@rediff mail.com

and reliability, prevailing over humidity, dust, chemical fumes,

voltage irregularities, etc. In-house standardised testing on each

and every ballast and quality control on the raw material ensure

that Acon ballast do not fail even in neutral fault condition,

where voltage can be nearly 415 V. It is tested at ERDA and

various labs as per IS:13021.

Suveg Electronics

Ahmedabad - Gujarat

Tel: 079-26583994, Mob: 09327002155


Website: www.suvegelectronics.com

84

Products


Magnetic drive centrifugal pumpLutz magnetic drive centrifugal

pump is available in two series

range AM and TMR. Th e materials

are in glass-fi lled PP or carbon-

fi lled ETFE. Unique feature of the

TMR series is that the pump can

run dry for up to 15 mins without

damage. Th e inlet/outlet for the

pump is off ered in threaded (BSP/

NPT) or fl anged (ISO/ANSI)

connections. Th e TMR series is disassembled without disturbing

the motor. Maximum fl ow rate that achieved is up to 30 m³/hr

and heads up to 25 mWc. Th e strong magnetic coupling made

up of rare earth materials and three versions of each model allow

pumping of liquids of special gravities from 1.00 to 1.85.

Shanbhag & Associates


Tel: 022-28346604


Website: www.shanbhags.com

Cartridge sealTh e UE cartridge seal is inherently

balanced, and hence is used for

maximum range of pressure. It has

multi-springs but the spring does

not come in contact with liquid.

Th is seal is used in any kind of

contaminated fl uids. Th e seal comes

with sleeve and gland plate as one

unit. It is easy to install.

Unicorn Engineers

Delhi

Tel: 011-22421640


Website: www.mechseal.com

Programmable logic controller Th e compact size programmable

logic controller (PLC) integrates

the compactness of small-sized

controllers with the modularity

of big-sized PLCs. It off ers

breadth of power (from 14

I/O to 128 I/O). It has 128 I/O capacity in free mix, 128 KB

programme memory and 32 KB data memory. It is provided

with high-speed backplane serial bus, wide range of I/O modules

and embedded intelligence in digital I/O modules. It has IEC-

61131-3 compatible Windows-based programming package.

Th e PLC has unique offl ine, online, debugging features, powerful

function library management, modem communication FBs, and

open serial ports.

Messung Systems Pvt Ltd

Pune - Maharashtra

Tel: 020-27102000


Website: www.messung.com

Ball valveTh is ball valve comes with

pneumatic rotary actuator.

Th e valve is of on/off type

with screwed, fl anged, socket

weld, tri-clover end in three-

piece design. It is available in

SS-304 and SS-316 investment

castings and is fi tted with

double-acting pneumatic rotary

actuator that operators through

90-degrees angular movements

of ball valve or butterfl y

valves. Pneumatic actuator is

mounted directly on the shaft of the valve. Th e actuator is supplied

with solenoid valve mounted on it. It is available in diff erent

sizes up to 4” to control fl uids such as steam, chemicals, oil, air,

and water.

Madho Controls Pvt Ltd

Th ane - Maharashtra

Tel: 022-25883252, Mob: 09820066046


Website: www.madhocontrols.com

Air classifi erTh e air classifi er is a screenless machine

used for grading offl ine powder into

distinct coarse and fi ne grades from

60 mesh down to 40 microns. Th is air

classifi er-type separating machine is

operated in closed circuit with existing

equipment, such as feed from the

hopper, bins pulveriser, cyclone, etc.

It is manufactured in closed tolerance and well balanced to give

trouble-free operation. Th e material is fed through the top input

pipe down on a revolving distributor plate. Th e fl uidised particles

are propelled to the sides of the inner cone by whizzer blades and

separated from the re-circulating air stream between inner and

outer ring.

Premium Vijimech Pvt Ltd

Ahmedabad - Gujarat

Tel: 079-40083450, Mob: 09712987467


Website: www.vijimech.com

Products


The information published in this section is as per the details furnished by the respective manufacturer/

distributor. In any case, it does not represent the views of Modern Pharmaceuticals

Fluid control systemsA wide range of precision

fl uid control systems, like

pneumatically operated air

pulse dispensers, and allied

accessories, such as tips barrels,

precision dispense valves (for

various applications) pressure

tanks, etc, are off ered to give a positive control for handling various

fl uids. Dotting, lining, potting, fi lling, doming, encapsulating,

spraying, coating, etc can be done with ease, effi ciency and high

degree of repeatability and accuracy. Th ese systems handle any

type of fl uids like adhesives, anaerobics, light curing, UV curing,

moisture curing (cyanoacrylates), latex based, solvent based, etc

coating fl uids (hard coating of optical lenses), lacquers, dyes, etc.

Metering & Dispensing Technologies

Dist Th ane - Maharashtra

Tel: 022-28042189, Mob: 09833783720


Temperature data logger Th is temperature data logger is used

for pharmaceutical industries. It has

measuring capacity ranging from -

35ºC to 80ºC, accuracy of ±0.5ºC and

resolution at 0.1ºC with sensor Pt-1000.

Th e measuring rate is selected from

1 min to 8 hours. It stores 4,000 value

data in memory. Th e measuring mode is automatic with loop,

start/stop or start with set measuring rate. It comes with a

battery life of three to fi ve years. Th ese data loggers are housed

in stainless steel, PEEK. It has IP68 protection class/housing for

pharmaceutical industries.

Ambetronics


Tel: 022-28371086


Website: www.ambetronics.com

Moulded parts and componentsTh e machined moulded parts and

components are manufactured

from industrial and engineering

plastics, such as nylon, UHMWPE,

delrin, polycarbonate, acrylic,

polyurethane, abs, Tefl on, PVC,

peek, PPO, PPS and Noryl. Th ese

are available in various size and

shapes in the form of sheets, rods,

tubes, pipes, blocks and profi les. Engineering plastics off ers a

variety of features like light weight, high abrasion resistant, self

lubrication, corrosion proof, noise and vibration dampening and

good dimensional stability. Th ese fi nd applications in various

industries like bottling & beverages, pharmaceuticals, paper

ceramic tiles manufacturing plants, material handling, conveyors,

steel, power, cement and chemical industries.

Arvind Anticor Ltd

Ahmedabad - Gujarat

Tel: 079-32918016, Mob: 07878883400


Website: www.picklingplant.com

Air-cooled single-stage pumpTh e oil-lubricated air-cooled single-

stage pump comes with multi-vane

built-in anti-suck back system. It is

provided with oil recirculation system

having exhaust fi lters to produce mist-

free exhaust. Th e pump is available

with capacities ranging from 15 m³/hr to 150 m³/hr. Th e pump

is used in various applications like packaging, bottle fi lling, pick

and place, leak detection, heat treatment, distillation, suction in

hospitals, oil purifi cation, degassing and drying, etc. Advantages

of the pump are less oil, less power, noise less and pollution free

compared to normal oil seal vacuum pumps.

Toshniwal Instruments (Madras) Pvt Ltd


Tel: 044-26252716


Website: www.toshniwal.net

Multi-purpose trolleyTh e specially designed multi-purpose trolley is

used for ICU/hospital/surgery. It comes with

multi-purpose aluminum extruded legs, heavy-

duty designed castor wheels, MDF monitor

top with anti-skid rubber mat, lockable MDF,

scratch-proof painted drawer box. Diff erent

boxes or trays are adjusted according to

needs due to the specially designed profi le of

tapped strip. Because of aluminium metallic structure, earthing

is affi rmative and provides safe working for electrical and

electronic appliances.

Envair Electrodyne Ltd

Pune - Maharashtra

Tel: 020-30688117


Website: www.envairelectrodyne.com

List of Products


Sl No Product Pg No

1 AC motors ...............................23

2 Acoustic enclosure .......................25

3 Agitator ........................................19

4 Air classifi er .................................84

5 Air fi lter .................................15, 17

6 Air treatment system ...............FGF

7 Air-cooled single-stage

pump ..........................................85

8 Analytical instruments........88, BIC

9 Automatic powder fi lling

machine .....................................81

10 Ball valve .................................84

11 Batch disperser .............................19

12 Bbl brake motors .........................23

13 Biological safety cabinet ........15, 17

14 Blow-fi ll-seal machine .................11

15 Booklet and leafl et label ............BC

16 Booklet .........................................81

17 Calorimeter ..............................19

18 Cartridge seal ...............................84

19 Chlorine gas cylinder/tonner ......57

20 Chromatography ..........................88

21 Clean attire ....................................6

22 Cleanroom apparel ........................6

23 Cleanroom door.....................15, 17

24 Cleanroom garment ......................6

25 Closure feeding system................83

26 COD analyser ..............................37

27 Column ........................................88

28 Columns and chemistries .........BIC

29 Continuous hand sealer ...............77

30 Cooling chamber .........................82

31 Cooling tower ..........................FGF

32 Counters and power

supplies ...................................FIC

33 DC motor ................................23

34 Digital temperature indicator ......78

35 Dispensing booth ..................15, 17

36 Disperser ......................................19

37 Drive and inverter .......................83

38 Dry vane pump............................25

39 Duo label ..................................... bc

40 Electronic ballast and fi xture ....83

41 Electronic chlorine dosing

system and chloroscope ............57

42 Electronic panel timer .................83

43 Elemental analysis .......................88

44 Empower ...................................BIC

45 Encoder .....................................FIC

46 Fan fi lter unit ..................... 15, 17

47 Flag label ....................................BC

48 Flameproof motor .......................23

49 Flange mounting motor ..............23

50 Fluid bed dryer ............................82

51 Fluid control systems ..................85

52 FRP cooling tower ......................82

53 Gas chlorinator ........................57

54 Gas conditioning and fi re

protection ...................................39

55 Gas detector .................................37

56 Gas fl ow adsorption analyser ......70

57 Geared motor ..............................23

58 General pump ..............................21

59 Hanger label.............................bc

60 Heating bath ................................19

61 Hepa fi lter terminal

housing ................................15, 17

62 High-pressure homogeniser ........19

63 High-pressure washing unit ........82

64 Horizontal pull-action clamp......77

65 Hot plate ......................................19

66 HPLC .................................88, BIC

67 Hydraulic orbit motor .................77

68 Industrial control and sensing

device ..................................FIC

69 Industrial cooler .......................FGF

70 Industrial panel PC .....................70

71 Informatics ................................BIC

72 Injectable manufacturing

line .......................................15, 17

73 Inline disperser.............................19

74 Inspection systems .......................13

75 Insulation materials .....................77

76 Integrityplus attire .........................6

77 Inverter/variable frequency

drive ........................................FIC

78 Jet mill .....................................83

79 Kneading machine ...................19

80 Laboratory reactor ....................19

81 Laboratory software.....................19

82 Laminar air fl ow

workstation ..........................15, 17

83 Level controller .........................FIC

84 Liquid fi lling/capping and

sealing machine .........................70

85 Liquid-ring vacuum pump ..........70

86 Lyophiliser ...................................78

87 Magnetic drive centrifugal

pump ......................................84

88 Magnetic stirrer ...........................19

89 Mass spectroscopy .......................88

90 Measuring and monitoring

relay .........................................FIC

91 Mills .............................................19

92 Molecular spectroscopy ...............88

93 Motion control .........................FIC

94 Motor ..........................................23

95 Moulded parts and

components ...............................85

96 Multi-purpose trolley ..................85

97 Ointment manufacturing

plant .......................................77

98 Overhead stirrer ...........................19

99 Packaging service provider .......53

100 Pallet shrinking tool ....................78

101 Pass box ..................................15, 17

102 Pellet .............................................70

103 Photoelectric sensor ..................FIC

104 Pilot plant ....................................19

105 Pre-engineered and pre-

fabricated modular panel ....15, 17

106 Programmable logic

controller ...........................FIC, 84

107 Programmable terminals ..........FIC

108 Proximity sensor .......................FIC

109 Pump ............................................25

110 Pusher centrifuge .........................82

111 Quick-change terminal

house ................................ 15, 17

112 Radial drilling machine ............82

113 Rapid endotoxin detection

system ........................................81

114 Remote I/O system .....................81

115 Return air riser .......................15, 17

116 RFID .........................................FIC

117 Roots blower ................................25

118 Rotary cone vacuum dryer ..........81

119 Rotary evaporator ........................19

120 Safe change housing ........... 15, 17

121 Safety light curtain ...................FIC

122 Sampling booth .....................15, 17

123 Shakers .........................................19

124 Slipring crane duty motors .........23

125 Solid-liquid mixer ........................19

126 Spectrophotometer ......................78

127 Spheroidiser .................................78

128 Spray analysis ...............................39

129 Spray control system ...................39

130 Spray fabrication ..........................39

131 Spray nozzles and accessories .....39

132 Sterilising/depyrogenating

tunnel ...................................15, 17

133 Suspension centrifuge ..................77

134 Switching relay .........................FIC

135 Technical garments ....................6

136 Tefzel HHS isotactic PP

material ........................................8

137 Temperature and process

controller ....................................78

138 Temperature controller .............FIC

139 Temperature data logger .............85

140 Th ermoplastic valves & piping

system ..........................................8

141 Th ermostats and vacuum dryer/

mixer ..........................................19

142 Timer ........................................FIC

143 Turnkey systems for dust

suppression ................................39

144 UHPLC ...................................88

145 UPLC .......................................BIC

146 Vacuum booster pump ..............25

147 Vacuum system ............................25

148 Vibratory fi nishing system ..........81

149 Vision sensor .............................FIC

150 Walk-in-cooling chamber .........70

BC-Back cover, BIC-Back inside cover, COC-Cover on cover, FGF-Front gate fold, FIC-Front inside cover

Sl No Product Pg No Sl No Product Pg No Sl No Product Pg No

To know more about the products featured in this magazine, fax us on 022-3003 4499 or tear and post to us the ‘Product Inquiry Card’ by following the 5 easy steps given there. Alternatively, you may also write to us at [email protected] or call us on 022-3003 4684, and we will send your inquiries to the advertisers/companies directly to help you source better.

List of Advertisers

87

Advertiser’s Name & Contact Details Pg No Advertiser’s Name & Contact Details Pg No Advertiser’s Name & Contact Details Pg No

Our consistent advertisers

March 2012 I Modern Pharmaceuticals

Aqua Services 57

T: +91-265-2331748

E: [email protected]

W: www.aquaservicesindia.com

Ask Enterprises 53

T: +91-9860921110


W: www.asktechnopack.com

Charles River 81

T: +91-80-25588175


W: www.criver.com

Dover India P Ltd-Dfm India Division 21

T: +91-44-26271020


W: www.almatec.de

Everest Blowers 25

T: +91-11-45457777


W: www.everestblowers.com

Eng Expo 30

T: +91-09819552270


W: www.engg-expo.com

Fabtech Technologies Intl Pvt Ltd 15,17

T: +91-22-61592900


W: www.fabtecheng.ae

IKA India Private Limited 19

T: +91-80-26253900


W: www.ika.in

J B Sez Pvt Ltd FGF

T: +91-422-3267800


W: www.gemindia.com

Omron Automation Pvt Ltd FIC

T: +91-80-40726400


W: www.omron-ap.com

Plus Ventilation 6

T: +91-40-23812152, 23812153


W: www.plusventilation.com

Reynders Label Printing India Pvt Ltd BC

T: +91-149-3305400


W: www.reynders.com

Salesworth India Pvt Ltd(Rommelag) 11

T: +91-80-25274495


W: www.rommelag.com

Salesworth India Pvt Ltd(Seidenader) 13

T: +91-80-25274495


W: www.seidenader.de

Spraying Systems (India) Pvt Ltd 39

T: +91-80-39853200/01


W: www.spray.com

The Indian Electric Co 23

T: +91-20-24474303


W: www.indianelectric.com

Thermo Fisher Scientific Sid Div 88

T: +91-22-67429494


W: www.thermofisher.com

Uniphos Envirotronic Pvt Ltd 37

T: +91-22-6123500


W: www.uniphos-she.com

UNP Polyvalves India Pvt Ltd 8

T: +91-265-2649248


W: www.polyvalve.com

Waters (India) Pvt Ltd BIC

T: +91-80-28371900


W: www.waters.com

BC-Back cover, BIC-Back inside cover, COC-Cover on cover, FGF-Front gate fold, FIC-Front inside cover

90

RNI No: MAHENG / 2008 / 27125Postal Regd No: G / NMD / 122 / 2011 - 13

Posted at P.C Stg. Offi ce, GPO, Mumbai 400 001 On 19th & 20th Of Every Month

Date Of Publication: 16th Of Every Month

Modern Pharm

aceuticals M

arch 2012

Supplement with Modern Pharmaceuticals - March 2012Presents

22 Modern Pharmaceuticals - Supplement I March 20122

3March 2012 I Modern Pharmaceuticals - Supplement 3


55March 2012 I Modern Pharmaceuticals - Supplement







12

RNI No: MAHENG / 2008 / 27125Postal Regd No: G / NMD / 122 / 2011 - 13

Posted at P.C Stg. Offi ce, GPO, Mumbai 400 001 On 19th & 20th Of Every Month

Date Of Publication: 16th Of Every Month

Documents

Modern Pharmaceuticals - March 2012